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Abstract 
Late normal tissue injury is dose -limiting for radiation therapy of cancer. The molecular 
mechanisms of this injury are unknown. However, almost all radiosensitive animals and 
cell lines are deficient in some aspect of DNA repair. We have derived EBV- transformed 
cell lines from five patients with late radiation injury to determine whether there was any 
evidence of reduced activity or expression of the enzymes active in non -homologous 
recombination, the major mammalian repair pathway for DNA double -strand breaks 
which cause radiation -induced cell death. Two of these cell lines exhibit post- radiation 
viability intermediate between normal controls and a cell line from an individual with 
ataxia -telangiectasia. DNA -dependent protein kinase activity in vitro was reduced 8-10 - 
fold in these two cell lines compared to normal controls. The primary tumours from one 
of these patients, and a post- radiation cervix biopsy form the second, exhibited no 
immunoreactivity with a polyclonal antibody against the catalytic subunit of the DNA - 
dependent protein kinase (DNA -PKcs). Immunoblotting showed normal levels of Ku70, 
Ku80 and XRCC4, and the presence of DNA -PKcs, in both cell lines. This suggests that 
the DNA -dependent protein kinase might be an important factor in determining the 
predisposition of radiotherapy patients to late radiation injury. 
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1.1 Radiation treatment is an integral part of cancer therapies 
Cancer is the leading cause of death in many parts of the world; in 2000, an 
estimated 6 million people died from the disease globally, with an expected increase 
in cancer deaths to 10 million per year by 2020 (World Cancer Report, World Health 
Organisation, 2001). 50 to 60% of patients with cancer are projected to require 
radiation treatment in the course of their battle against this disease (International 
Atomic Energy Agency, 2003). 
1.2 Late Radiation Injury to Normal Tissue Limits the Radiation Dose 
For individuals undergoing a curative course of radiotherapy, up to about 5% 
are estimated to experience an unexpected, severe late morbidity (Busch D, 1994). 
Severe morbidity is usually defined as grade 4 morbidity according to the late 
morbidity score defined by the Radiation Therapy Oncology Group (RTOG) and the 
European Organisation for Research and Treatment of Cancer (EORTC). Late 
morbidity is defined as morbidity arising more than 90 days after the start radiation 
treatment. Late morbidity caused by radiation is generally irreversible and has a 
potentially devastating effect on a patient's quality of life. 
By limiting tumour doses to that which results in severe late morbidity in no 
more than 5% of the patient population treated, local control in some cancers is 
achieved in only a fraction of the total number of patients treated (Kagan AR, 1988). 
Analysis of dose -response curves suggests that the injured patients are not a 
random sample of the total patient population but instead constitute a radiation - 
sensitive subset (Kagan AR, 1988). This is supported by the work of Turesson et al. 
in which it was demonstrated that as much as 80% of the variation in normal tissue 
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reactions could not be accounted for by known factors, and thus the variation was 
likely due to differences in intrinsic cellular radiosensitivity (Turesson I et al., 1996; 
Safwat A et al., 2002). 
If these sensitive individuals can be identified prior to treatment and radiation 
therapy regimes individualized to keep the normal tissue complication rate at no more 
than 5 %, the gains in tumour control have been estimated to be from less than 10% to 
as high as 40 %. The higher end of the estimates has been obtained usually with the 
assumption that any increased radiosensitivity will be shared by both normal tissue 
and cancer cells (Tucker SL et al., 1996; Bentzen SM, 1997; MacKay RI and Hendry 
JH, 1999). Indeed there have been reports where dose reductions were made to avoid 
radiation injury in patients with ataxia telangiectasia (see below) and tumour control 
has not been compromised (Abadir R and Hakami N, 1983; Hart RM et al., 1987). 
1.3 Can patients predisposed to develop severe radiation morbidity be 
identified prior to radiation treatment? 
1.3a Inherited syndromes with radiation hypersensitivity 
There are two well described and two less well known human syndromes 
which are associated with an exquisite sensitivity to ionising radiation. 
Ataxia telangiectasia (AT) is an autosomal recessive condition that is 
associated with chromosomal fragility, immune deficiency and cancer proneness. 
Individuals also have ocular telangiectasias and develop ataxia. It was recognised in 
the 1960s that these individuals responded unexpectedly severely to ionising radiation 
used to treat their malignancies, some eventually perished from the radiation injury 
(Gotoff SP et al., 1967; Morgan JL et a., 1968; McFarlin DE et al., 1972). Currently 
13 
wherever possible individuals with AT and cancer are treated with alternative cancer 
therapies. 
The clinically observed hypersensitivity in AT individuals is due to a global 
increase in cellular radiosensitivity (Taylor AMR et al., 1975) Indeed cell -lines from 
obligate heterozygotes have also demonstrated increased sensitivity to ionising 
radiation compared to normal controls (Paterson MC et al., 1979) but are less 
sensitive than those from affected individuals. Attempts have been made to identify 
ATM mutations in non -syndromic patients in the `general' cancer population who 
have experienced severe radiation morbidity and these have produced variable results. 
Five studies have found no mutations (Table 1.1). One study reported late radiation 
injury (including necrosis) in all 3 patients harbouring two mutations in the ATM 
gene, but no late injury in the 3 patients with a single mutation or the 40 with no ATM 
mutation (Ianuzzi CM et al., 2002). A second preliminary report suggested that a 
disproportionate number, but not all, of prostate cancer radiotherapy patients who 
experience severe late effects are AT heterozygotes (Hall EJ et al., 1998). 
The cloning of the gene mutated in ataxia telangiectasia (ATM) by Savitsky et 
al in 1995 has paved the way for investigators to elucidate the molecular basis for the 
pleiotropic phenotypic features of the disease. The current knowledge of the role of 
the ATM protein in the area of radiation hypersensitivity will be discussed in 1.7b. 
Nijmegen Breakage Syndrome (NBS) is also an autosomal recessive 
condition that shares many similarities with AT. Individuals also have 
immunodeficiency, cancer proneness and are hypersensitive to ionising radiation. 
However they do not have telangiestasias nor develop ataxia. Instead they are small in 
stature, have microcephaly and mental retardation (Taalman RDFM et al., 1983). 
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TABLE 1.1 
A summary of clinical studies examining the association of increased radiation 
morbidity and ATM mutations in cancer patients in the `general' population. 
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Radiation Morbidity Type of 
cancer 
lannuzi CM et al., 
2002 
46 Late subcutaneous effects, 
RTOG 3 -4 
Breast 
Hall EJ et al., 1998 17 Severe late sequelae, 
specifically proctitis or 
cystitis 
Prostate 





Radiation Morbidity Type of cancer 
Appleby JM et 
a/.,1997 
23 Mainly acute 16 breast, 7 
others 
Shayeghi M et 
x/.,1998 
41 Marked changes in breast 
appearance 
Breast 
Ramsay J et al., 1998 15 Severe late Breast 
Clarke RA et al., 
1998 
5 Severe acute 
Weissberg JB et al., 
1998 
13 Acute and long-term 11 breast and 2 
prostate 
Oppitz U et al., 1999 20 RTOG 3 -4, acute and late 11 breast, 9 
others 
Izatt L et al., 1999 16 Breast 
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Cellular features include radiosensitivity and many other similar features to 
those of AT. 2 groups cloned the gene responsible for this condition simultaneously in 
1998 (Varon R et al., 1998; Carney JP et al., 1998). Nbsl is the human homologue of 
xrs -2 and the gene product Nibrin is found to complex with hMre11 and hRad50. The 
function of the complex with regards to DNA damage response will be discussed in 
1.7c. 
In 1999, Stewart, et al ascribed the Ataxia Telangiectasia Like Disorder 
(ATLD) to a mutation in hMrell (Stewart GS et al., 1999). ATLD has been 
described in only a handful of families (Hernandez D et al., 1993). The affected 
individuals share many features of AT including progressive cerebellar degeneration, 
cellular radiosensitivity and chromosomal instability. The role of the 
hMrel1/hRad50/Nbs1 complex in radiation hypersensitivity will also be discussed in 
section 1.7c. 
Hypomorphic mutations in DNA ligase IV have now been described in 
association with extreme radiosensitivity. This was first described for a paediatric 
leukaemia patient who was radiation hypersensitive, developmentally normal and had 
no evidence of immunodeficiency (Plowman PN et al.,1990). The fibroblast cell line 
from this patient, 180BR was reported to contain a hypomorphic mutation in DNA 
ligase IV within a highly conserved motif encompassing the active site (Riballo E et 
al., 1999). Subsequently, 4 paediatric patients with features of immunodeficiency and 
developmental growth delay were found to have mutations in DNA ligase IV and cell 
lines from these patients show pronounced radiosensitivity (O'Driscoll M et al., 
2001). 
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1.3b Radiation -sensitive individuals without any pre- treatment phenotype 
Unfortunately, the vast majority of patients who develop severe radiation 
morbidity do not have any phenotypic characteristics that allow him or her to be 
identified prior to radiation treatment. It is estimated that about 5% of the population 
of radiotherapy patients receiving a conventional course of treatment will develop 
severe late morbidity (Busch D, 1994; Kagan AR, 1988). There is accumulating 
evidence to suggest that even for individuals with no pre- treatment phenotypes, 
genetic differences in normal tissue radiosensitivity contribute to the severe morbidity 
that is clinically observed (Busch D, 1994; Kagan AR, 1988; Geara FB et al., 1998; 
Brock WA and Tucker SL, 2000; Andreassen CN et al., 2002). 
Studies have shown a positive correlation between the in vitro cellular or 
chromosomal radiosensitivity of either fibroblasts or lymphocytes and the extent of 
normal tissue response (Burnet NG et al., 1992; Geara FB et al., 1993 ; Johansen J et 
al., 1994, Borgmann K et al., 2002; West CML et al., 2001; Hoeller U et al., 2003) 
although there have been negative studies as well (Russell NS et al., 1998; Peacock J 
et al., 2000). One possible reason for this discrepancy is the `signal' (inter-patient 
variability) versus `noise' (assay variability) ratio. The two negative studies both had 
less favourable signal:noise ratios for reasons that are discussed in an ESTRO 
workshop report (Bentzen SM and Hendry JH, 1999). A signal versus noise difficulty 
of another, intriguing nature is well discussed in a recent paper by E Dikomey. Here 
the `noise' is represented by the patients whose individual radiosensitivity falls within 
the normal distribution and yet develop a severe late complication of radiotherapy. 
Since any study of over reactors (defined as an individual whose normal tissue 
reaction falls outside the normal range [Burnet NG et al., 1998]) is likely to have a 
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significant number of these patients compared to the truly sensitive individuals whose 
individual sensitivity falls below 1 SD from the mean (`signal'), a negative study 
might result (Dikomey E et al., 2003). 
It has also been demonstrated that first-degree relatives of breast cancer 
patients with increased in vitro radiosensitivity exhibit increased in vitro 
radiosensitivity compared to normal controls (Burrill W et al., 2000). Rogers PB et 
al., describe 3 paediatric cancer patients who were phenotypically normal at 
presentation and whose radiation hypersensitivity has been attributed to underlying 
genetic defects. 2 were attributed to the ataxia- telangiectasia gene and 1 to DNA 
ligase IV (Rogers PB et al., 2000). 
However there are as yet no tests that are in routine clinical use for the 
identification of individuals who may have a heightened response to radiation 
treatment. In spite of the studies that have positively correlated in vitro cellular or 
chromosomal radiosensitivity with the extent of normal tissue response, there is still 
insufficient sensitivity or specificity with these tests for them to be applied as 
predictive assays. Moreover assessment of cellular radiosensitivity usually involves 
establishing cell -lines and then either a colony forming assay or a proliferation assay 
to measure the survival following ionising radiation treatment. The whole procedure 
takes at least 4 -6 weeks to perform while the patient often requires treatment to 
commence before such survival results are available. 
Due to the need for more rapid (but reliable) tests for the identification of 
patients with radiation hypersensitivity, others (Kearsley JH et al., 1998; Barber JBP 
et al., 2000) have evaluated the use of methods which measure chromosomal 
sensitivity to radiation, namely the micronucleus test, and the G2 chromosomal 
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aberration test. These are performed on peripheral blood lymphocytes and thus do not 
require the establishment of cell -lines. While promising, Barber et al have concluded 
that these tests in their present form are unlikely to result in reliable `stand- alone' 
predictive assays (Barber JBP et al., 2000). 
Yet another strategy for the development of predictive test /s is to identify 
genes implicated in radiation injury. This is likely to involve differences in the 
expression and activity of a large number of genes (Brock WA and Tucker SL, 2000; 
Andeassen CN et al., 2002). Identification of the gene and gene products involved in 
normal tissue radiation response could pave the way for the development of rapid, and 
reliable tests perhaps using high through -put microarray technology (Peters LJ and 
McKay M, 2001; Russell NS and Begg AC, 2002). To this end, ESTRO has launched 
the GENEPI project (Genetic Pathways for the Prediction of the Effects of Irradiation) 
which ultimately aims to identify and quantify the impact of genetic determinants of 
clinical radiosensitivity and establish powerful predictive assays ( "radiogenomics ") 
for routine clinical use (Baumann M et al., 2003). 
1.4 Molecular Basis of Radiation Sensitivity 
1.4a DNA damage induced by ionising radiation 
Direct and indirect action of radiation 
Ionising radiation interacts with biological material to produce its effects by 
two main mechanisms: direct and indirect actions. When any form of ionising 
radiation is absorbed in biological material, the atoms of the target, eg, DNA may be 
excited or ionised by the x- or gamma -rays. This is known as the direct action of 
radiation. However if the x- or gamma- rays first ionises water within the cell to form 
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free radicals, which then diffuse to and damage the critical targets, this is known as 
the indirect action of radiation (Hall E, 1994). 
Energy deposition events 
The energy deposited by ionising radiation has been categorised into three 
types: spurs, blobs and short tracks (Mozumder A and Magee JL, 1966). A spur is 
about 4 nm in diameter (about twice that of the DNA double -helix), contains less than 
100 eV of energy and involves on average 3 ion pairs. A blob is about 7 nm in 
diameter, contains between 100 and 500 eV of energy and involves about 12 ion pairs. 
About 95% of events from x- or gamma -rays are spurs and 5% are blobs. Put another 
way, in a typical cell volume of 1.5 pl, a dose of 1 Gray will produce 75, 000 spurs 
and 4, 000 blobs. Short tracks involve energy amounts greater than 500 eV. 
Types and yields of the various DNA lesions 
The predominant cellular target responsible for the biological effects of 
radiation is deoxyribose nucleic acid (DNA) (Ward JF, 1986; Iliakis G, 1991; Olive 
PL, 1998). The cell membrane is also damaged during irradiation, initiating signalling 
events that involve the formation of ceramide, and activation of the stress -activated 
protein kinase (SAPK/JNK) cascade (Verheij M et al., 1998). This signalling pathway 
is important in radiation -induced apoptosis (Jonathan EC et al., 1999). 
Within DNA, ionising radiation produces: double- strand breaks, single strand 
breaks, base damage, sugar damage, DNA -DNA crosslinks and DNA -protein 
crosslinks. The number lesions per type of damage produced per cell per Gray is as 
follows (Ward JF, 1988): 
21 
Number /Gy /diploid cell 
Double strand break 40 
Single strand break 500 -1000 
Base damage 1000 -2000 
Sugar damage 800 -1600 
DNA -DNA crosslinks 30 
DNA -protein crosslinks 150 
1.4b DNA double strand breaks are associated most closely with cell lethality 
Singly and locally multiply damaged sites (LMDS) 
When a moiety of DNA is damaged in isolation, John Ward has called this a 
"singly damaged site ". The relative innocence of the single -damage lesion in DNA 
was suggested by experiments involving hydrogen peroxide (Ward JF et al., 1985; 
Hoffmann ME et al., 1984; Bradley MO and Erickson LC, 1981). Hydrogen peroxide 
at 0 °C was found to be proficient at in producing single- strand breaks (SSB) in the 
DNA of Chinese hamster fibroblasts but inefficient at producing double - strand breaks 
(DSB). Cell killing by hydrogen peroxide at 0 °C was however inefficient. JF Ward 
then went on to suggest that ionising radiation, which was a lot more efficient at 
killing cells than hydrogen peroxide, had to produce damage in which more than one 
moiety of DNA in a localised region was damaged. To this region of DNA, he gave 
the term "locally multiply damaged sites" (LMDS). LMDS can be produced either in 
the same strand or in opposite strands. If sufficiently close LMDS are produced in 
opposite strands, then a DSB is formed and this he has hypothesised to be the lethal 
lesion (Ward JF, 1985). Other evidence that point to DSBs as the lethal lesion 
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includes the correlation of chromosome aberration with the induction of DNA DSB. 
Additionally incorporation of radionuclides efficient in producing DSB, eg, 1`5 IdU 
leads to efficient cell killing. 
1.5 Models of radiosensitivity 
Table 1.2 summarises some of the published data on the genetic mutations that 
have been found to date in human syndromes, human and mammalian cell lines and 
animal models (excluding transgenic mice) that are known to be hypersensitive to 
ionising radiation. The mutations involve predominantly two pathways: that involved 
in DNA damage response and repair of DNA DSBs (Table 1.2). This is not surprising 
given that the important biological target for ionising radiation effects is DNA and 
that the type of DNA damage that correlates best with lethality is the DSB. These 
pathways will be reviewed with respect to mammalian systems with mention of 
prokaryotes and other eukaryotic organisms where relevant. Where a protein/protein 
complex has more than one primary function, it will be discussed under the function 
about which most is known. 
1.6 DNA Double- Strand Break Repair 
The two major pathways of double strand break repair are non -homologous 
end joining (NHEJ) and homologous recombination (HR). 
1.6a Homologous Recombination 
Homologous recombination (HR) is the predominant pathway by which DNA 
DSBs are repaired in micro -organisms. This process makes use of the sequence 
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TABLE 1. 2 
Genetic mutations in human syndromes, human and mammalian cell 
lines and animal models associated with hypersensitivity to ionising 
radiation. 
The mutants in complementation groups XRCC1, XRCC2, XRCC3 and XRCC9 are 
predominantly sensitive to alkylating agents and only mildly sensitive to ionising 
radiation while those in groups XRCC4 -8 are extremely sensitive to ionising radiation 
and radiomimetics (Thacker J and Zdzienicka MZ, 2003). Please refer to the text for 
references. 
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Ataxia Telangiectasia ATM DNA damage signalling 
Nijmegen Breakage Syndrome NBSI DNA damage signalling 
Ataxia Telangiectasia Like Disorder hMrell DNA damage signaling 
Human cell -lines 
180 BR (Fibroblast) LIG4 DNA DSB repair: NHEJ 
411 BR (Fibroblast) LIG4 DNA DSB repair: NHEJ 
FB 2303 (Fibroblast) LIG4 DNA DSB repair: NHEJ 
LB 2304 (Lymphoblastoid) LIG4 DNA DSB repair: NHEJ 
M059J (Glioma) DNA -PKcs DNA DSB repair: NHEJ 
Animal Models 
Murine, equine, canine SCID DNA -PKcs DNA DSB repair: NHEJ 
Mammalian cell lines: X -Ray Cross 
Complementing Groups 
XRCC1 XRCCI Base excision repair 
XRCC2 XRCC2 DNA DSB repair: HR 
XRCC3 XRCC3 DNA DSB repair: HR 
XRCC4 XRCC4 DNA DSB repair: NHEJ 
XRCC5 Ku80 DNA DSB repair: NHEJ 
XRCC6 Ku70 DNA DSB repair: NHEJ 
XRCC7 DNA -PKcs DNA DSB repair: NHEJ 
XRCC8 Unknown 
XRCC9 FANCG DNA DSB repair: HR 
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identity between sister chromatids on the same chromosome or the maternal and 
paternal copies of the same chromosomal region for repair damage and hence is of 
high fidelity (Thacker J, 1999). In mammalian cells, HR occurs preferentially between 
sister -chromatids, with homologous chromosomes and sequence repeats on 
heterologous chromosomes used less frequently (Johnson RD and Jasin M, 2000). 
The repair of DSBs by HR is of high fidelity since the process utilizes information on 
a homologous chromosome or sister chromatid. In higher organisms, this process is 
important during the S- and G2- phases of the cell cycle (Hendrickson EA, 1997; 
Takata M et al., 1998; Sonoda E et al., 1998). 
The association of radiation sensitivity with HR defects was initially made in 
the budding yeast, S. cerevisiae. In the late 1960s a number of X -ray sensitive mutants 
were isolated and from these studies, the RAD52 epistasis group of mutants was 
identified (Game JC and Mortimer RK, 1974). 
HR occurs by 3 major mechanisms: gene conversion, break induced 
replication and single- strand annealing (Haber JE, 2000). The classic model for the 
repair of DNA DSBs by HR (Resnick MA, 1976; Szostak JW et al., 1983), also 
known as gene conversion, has the following stages (Figure 1.1): 
Initiation 
Homologous pairing and DNA strand exchange 




Model of Homologous Recombination 
(Modified from Jackson SP, 2002) 
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DSB 
5' to 3' resection: 
Rad50 /Mre11 /NBS1 
QAD52 _ 
4 , 4;1%> 
; RAD52 
Strand invasion: 
RPA, Rad 54, etc 
DNA Pol I 
DNA synthesis 
=13i24 
DNA ligation (ligase 1), 
branch migration, 
H -J resolution 
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Initiation (Presynapsis) 
When DNA DSBs occur, broken DNA ends are recognised, possibly by the RAD 52 
protein. Following this, nucleolytic processing of the DNA ends, probably by the 
Rad50/Mrel l/NBS1 complex, occurs to produce a single stranded 3' overhang. 
Homologous pairing and DNA strand exchange 
Rad51 is assembled onto the ssDNA to form a nucleoprotein filament which is also 
called a presynaptic filament. Rad52 and replication protein A (RPA) aid the 
assembly of the nucleoprotein filament in addition to ancillary eukaryotic -specific 
factors discussed in the following section under Rad51. 
The nucleoprotein filament then searches for homologous duplex DNA and when the 
search is successful, invades the homoduplex DNA and forms a joint molecule 
through strand exchange. This stage is also known as synapsis. 
DNA heteroduplex extension (Postsynapsis) 
The region of DNA heteroduplex is extended by branch migrating the crossover point 
(also known as a Holliday Junction) and DNA synthesis which requires DNA 
polymerases and their accessory factors. In prokaryotes, RuvAB of the RuvABC 
complex promote branch migration. 
Resolution 
The heteroduplex is separated through resolution of the Holiday Junction (HJ) by the 
RuvC protein of the RuvABC complex in E. Coli and completion of DNA repair is by 
DNA ligase I. A complex analogous to the RuvABC complex has been isolated from 
mammalian cells that is capable of branch migration activity and HJ resolution 
(Constantinou A et al., 2001). 
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If repeat sequences are uncovered within the single stranded 3' overhang after 
the initial nucleolytic processing, single - strand annealing (SSA) between the repeated 
sequences may occur instead gene conversion (Helleday T, 2003). The product 
formed by SSA contains deleted sequences and this pathway is thus error prone. 
Table 1.3 (from Thompson LH and Schild D, 1999) summarises the proteins 
known to be involved in HR in humans. Some of these proteins will be further 
discussed with an emphasis on the process as it occurs in eukaryotes. 
Rad51 
Rad51 was first identified in S cerevisiae in 1992 as a homologue of the E coli 
recombination protein Rec A (Shinohara A et al., 1992). Rad51 homologues from 
higher eukaryotes, including human Rad51 were identified in 1993 (Shinohara A et 
al.,1993). Yeast rad51 mutants are defective in DNA DSB repair and in the formation 
of viable spores (Friedberg E, 1995). HsRad51 shares 83% homology with SCRad51 
and 55% homology with E coli Rec A. Rad5lmRna has been found to be significantly 
increased during meiosis, and is also inducible by DNA -damaging agents in mitotic 
cells. In mouse and chicken, there was an interesting tissue specificity of expression: 
with high expression in spleen and thymus (implying a role for V(D)J recombination 
and in the testis and ovary cells, consistent with a major role in meiotic recombination 
(Bezzubova O et al., 1993). No human mutant has yet been identified; the mouse 
knockout is embryonic lethal. 
Human Rad51 has an ATP -dependent DNA binding activity and a DNA - 
dependent ATPase. Its role in HR repair of DNA DSBs is in the search for 
homologous sequences and after finding such sequences, to catalyse strand exchange. 
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TABLE 1.3 
Key Proteins in Homologous Recombination 






Rodent mutant Protein interactions 




p53, c -Abl, XRCC3 
Rad51B 350 14q23-24.2 None Rad51C 
Rad51C 376 17q None XRCC3, Rad51B, 
Rad51D 
Rad51D 328 17q11.2-1.2 None XRCC2, Rad51C 
XRCC2 280 7q36.1 V79 irs 1 Rad51D 
XRCC3 346 14q32.3 CHO irs 1SF HsRad51, Rad51C 
HsRad52 418 12p13.3 Mouse KO viable HsRad51 
HsRad54 747 1p32 Mouse KO viable HsRad51 
HsRad50 1312 5q23-31 None Mrell 
HsMrel l 708 11q21 KO is lethal in mouse HsRad50 
ES cells 
BRCA 1 1863 17q21 Mouse KO embryonic 
lethal 
HsRad51, BASC (see 
text) 




However, unlike RecA, ATP hydrolysis and recombination reaction by Rad51 in vitro 
are very inefficient (Baumann P and West SC, 1998a). Rad51 activities are enhanced 
by interactions with ssDNA binding protein, RPA, Rad52 and Rad55 -57 in S. 
cerevisiae (Shinohara A and Ogawa T, 1999). 
In S. cerevisiae, Rad 52 mutations have the most pronounced recombination 
deficient phenotype (Paques F and Haber JE, 1999). Surprisingly in vertebrate cells, 
Rad52p plays a less central role in that Rad52 deficient mice are viable and not 
sensitive to ionising radiation (Yamaguchi -Iwai et al., 1998; Rijkers T et al., 1998.) 
Ancillary eukaryotic -specific factors either facilitate the activity of the 
primary strand exchange proteins or promote strand transfer themselves. These factors 
include Rad54, Rad59, Rad51B Rad51C, Rad51D, Rad55, Rad 57, Xrcc2 and Xrcc3 
(Cromie GA et al., 2001). S. cerevisiae Rad54 is required for D loop and 
heteroduplex DNA formation. Rad 54 deficient mice are also viable and sensitive to 
ionizing radiation at the embryonic but not at the adult stage (Essers J et al.,1997; 
Essers J et al., 2000). Similarly a rad54 deficient chicken cell line is also sensitive to 
ionizing radiation (Bezzubova O et al., 1997). 
5 Rad51 paralogs have been described in mammalian cells, Rad51 B, Rad51 C, 
Rad51D, XRCC2 and XRCC3, that share less than 50% sequence homology with 
Rad51 (Sonoda E et al., 2001). XRCC2 (Tanbini CE et al., 1997) and XRCC3 (Tebbs 
RS et al., 1995) were identified in rodent cell lines, irsl (Jones NJ et al., 1987) and 
irs1SF (Zdzienicka MZ and Simons JW, 1987) respectively. Their hallmark is 
extreme sensitivity to DNA cross -linking agents such as mitomycin C and they are 
also moderately radiosensitive. Irsl was found to have 100 -fold reduction in HR 
induced by double- strand breaks compared to its parental cell line leading to the 
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conclusion that XRCC2 is involved in HR repair (Johnson RD et al., 1999). The 
disruption of XRCC2 leads to embryonic lethality in mice (Deans B et al., 2000). 
Similarly, in irsl SF, in which XRCC3 is deficient, error -free homology- directed 
repair of DNA DSBs is reduced 25 -fold and restored to wild -type levels through 
XRCC3 expression (Pierce AJ et al.,1999; Brenneman MA et al., 2000). 
BRCA2 
BRCA2 is a tumour suppressor gene mutated in a proportion of breast cancer 
patients with a familial incidence. The 3 418 amino acid human protein has no 
significant homology to any known protein. Brca2-- mouse stem cells are radiation 
hypersensitive (Sharan SK et al., 1997). The role of BRCA2 in homologous 
recombination was initially suspected due to its association with MmRad51 (Sharan 
SK et al., 1997). More recently, evidence has ruled out a role for BRCA2 in non - 
homologous end joining (Patel KJ et al., 1998). 
Hypomorphic BRCA2 mice mutants have been generated and these have 
impairment of HR (Moynahan ME et al., 2001; Tutt 2001). In the former study, 
Rad51 dependent homology directed repair of site -specific double- strand breaks 
which are introduced into a chromosomal substrate by the I -Seel endonuclease, was 
impaired. CAPAN -1, a human pancreatic adenocarcinoma cell line which carries a 
single BRCA2 allele is also severely compromised in HR (Xia F et al., 2001; 
Moynahan ME et al., 2001b) in which there is also impairment of DNA damage - 
induced RAD51 foci formation (Yuan 1999). 
BRCA 2 interacts with Rad51 through 6 of its 8 evolutionarily conserved BRC 
repeat motifs (Wong AKC et al., 1997; Chen PL et al.,1998) and controls Rad51 
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function in 2 ways. The first is in the nuclear localisation of Rad51 which is 
inefficiently transported into the nucleus in certain BRCA2 deficient cells (Davies AA 
et al., 2001). Secondly, BRCA2 interacting with RPA at the DSBs helps load RAD 51 
onto the DNA or to organize the nucleoprotein filament (Yang H et al., 2002). 
BRCA1 
BRCA1 mutations are found in a significant percentage of familial breast and 
especially breast and ovarian cancer kindreds. BRCA1 mutant mouse cells are 
hypersensitive to gamma -irradiation (Shen SX et al., 1998). Brcal deficient mouse 
embryonic cells have impaired repair of chromosomal double- strand breaks by 
homologous recombination and this is accompanied by elevated rates of non - 
homologous end joining (Moynahan ME et al, 1999). 
BRCA1 is an 1863 residue protein whose role in homologous recombination 
was first observed due to its association with Rad51 in mitotic and meiotic cells using 
pulldown assays with cell -free extracts (Scully R et al., 1997). It is now thought that 
the observed interaction between Rad51 and BRCA1 might have been mediated 
through BRCA2 (West SC, 2003) which forms complexes with BRCA1 in vivo (Chen 
J et al., 1998). BRCA1 was later found to co- localise with RAD 50, Mrel 1 and NBS1 
upon irradiation (Zhong Q et al., 1999). This is preceded by the phosphorylation of 
histone H2AX (Paull T et al., 2000) and there is impaired recruitment of BRCA1 to 
these repair foci in H2AX -/- mice (Celeste A et al, 2002) and embryonic stem cells 
(Bassing CH et al., 2002). Paull et al also found that BRCA1 either co- localised with 
RAD 50 or with RAD51 but not both within the same cell. 
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Apart form its role in homologous recombination, BRCA1 is also part of a 
large complex of proteins known as BASC (BRCA1- associated genome surveillance 
complex) that contains ATM, Nbsl- MRE11- RAD50, mismatch proteins MSH2 /6 and 
MLH2 and Bloom's helicase (see 1.8) (Wang Y et al., 2000). Damage associated 
phosphorylation of BRCA1 by multiple kinases precedes formation of repair 
complexes; these kinases include ATM (Cortez D et al.,1999), Chk2 (Lee JS et al., 
2000) and ATR (Tibbetts RS et al., 2000) (See also 1.7b). 
1.6b Non -Homologous End Joining 
During non -homologous end joining (NHEJ) of two DNA ends, no sequence 
homology is required between the two recombining ends. In this process the two ends 
are re- ligated together, sometimes after limited processing at the termini. As such, 
NHEJ is an error prone process with small sequences usually deleted (Khanna KK 
and Jackson SP, 2001). 
The classical theory had been that, in contrast to yeast, mammalian cells 
repaired DNA double -strand breaks predominantly by NHEJ (Roth DB and Wilson 
JH, 1985). However, it is now established that homologous recombination also has a 
crucial role in mammalian cells (Liang F et al., 1998). The predominant process 
appears to be dependent on cell type, stage of development or phase of the cell cycle. 
In G1 /GO phase, the great majority of DSBs are rejoined by NHEJ (Lee SE et al., 
1997; Takata M et al., 1998). 
In mammalian cells, the process of NHEJ involves the DNA -PK heterotrimer 
of proteins, XRCC4/ DNA ligase IV and Artemis (Figure 1.2). The former is made 






























































70/80. When a DNA double -strand break arises as a result of ionising radiation, it is 
first bound by Ku. After binding, Ku recruits DNA -PKcs and activates its kinase 
activity. Prior to ligation, the two DNA ends are held together in physical proximity in 
a process called synapsis (DeFazio LG et al. 2002). During synapsis, the DNA ends 
are processed and Artemis, the most recent component of NHEJ elucidated, is a 
candidate nuclease for this (Moshous D et al., 2001). XRCC4 is then recruited and the 
repair is completed by ligation of the ends, a role ascribed to DNA ligase N (Kan-an 
P, 2000). 
DNA -PK is one of two kinases known to be specifically activated by DNA 
termini, the other being ATM (Hartley KO et al., 1995). It is a serine /threonine kinase 
that is made up of a large catalytic subunit, termed DNA -PKcs (also known as 
PRKDC) and a regulatory factor termed Ku. 
DNA -PKcs is about 460 kDa encoded by a 14 kb mRNA (Hartley KO et al., 
1995). The only region with strong homology to other proteins is the C- terminal 380 
amino acid residues which is highly related to the catalytic domains of the PI 3- kinase 
family that also include ATM, ATR and FRAP. The murine scid mutation is a 
nonsense mutation that results in premature termination of translation within its 
kinase domain (Danska JS et al., 1996). 
The molecular structure of the catalytic subunit, DNA -PKcs suggests it has a 
role as a molecular scaffold whereby short stretches of single- stranded DNA may be 
aligned prior to religation. It has a potential DNA -binding groove and an enclosed 
cavity with three apertures through which single- stranded DNA could pass (Leuther 
KK et al., 1999). The activation of DNA -PKcs is triggered by its interaction with a 
single- stranded DNA region derived from a DSB (Hammarsten O et al., 2000; 
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Martensson S and Hammarsten O, 2002). No in vivo substrates for DNA -PKcs has 
been identified though likely candidates are XRCC4 (Leber R et al., 1998) and 
replication factor A2 (Wang H et al., 2001a). What has been demonstrated is that 
autophosphorylation of DNA -PKcs occurs in vivo in response to ionizing radiation 
and is required for the repairs of DSBs by NHEJ (Chan DW, et al., 2002). 
Information about the role played by DNA -PK in NHEJ and radiation 
sensitivity has come from three main sources: mutant rodent cell lines, spontaneous 
mammalian (rodent, equine and canine) mutants and transgenic mice and a single 
mutant human tumour cell line. 
DNA -PKcs is the product of the murine scid gene (Blunt T et al., 1995; 
Kirchgessner CU et al., 1995). The SCID (severe combined immuno -deficiency) 
mouse was identified in 1983 due to the virtual absence of mature T and B 
lymphocytes from a defect in VDJ recombination (Bosma GC et al., 1983). Later it 
was also found to be profoundly sensitive to ionising radiation and to be defective in 
DNA double- strand break repair (Fulop GM and Phillips RA, 1990; Biedermann KA 
et aí.,1991). The gene was also found to map to the same region as the XRCC7 gene 
(Sipley JD, et al., 1995). The XRCC7 (X -ray cross -complementing) gene 
complements cells which were assigned to the IR7 group of radiosensitive mutant 
rodent cell lines (Zdzienicka MZ, 1995). Reduced DNA -PKcs expression and DNA - 
PK activity is also the underlying mechanism in SCID in Arabian foals (Wiler R et 
al., 1995). The condition was described initially in 1973 in animals which were 
profoundly deficient in B and T lymphocytes and where cells derived from them are 
hypersensitive to ionising radiation. mRNA levels are not diminished suggesting that 
the protein is unstable in equine SCID The latest animal model of spontaneous SCID 
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is that of Jack Russell Terriers. Severe immunodefieciency has again been shown to 
be due to defective V(D)J recombination and DNA -PKcs deficiency. It is also 
interesting that the severity of the phenotype is worst in horses, with canine scid 
intermediate and murine scid the least severe and the degree of severity is inversely 
proportional to the relative DNA -PK activity in expressed in normal fibroblasts 
derived from these three species (Meek K et al., 2001). 
Further understanding of the role of DNA -PKcs has come from characterising 
several independent X -ray sensitive cell -lines which all belong to the XRCC7 group 
and include V -3, irs -20, XR -C1, XR -C2, equine scid, SX -9 and M059J (Zdzienicka 
MZ, 1999). M059J is unique in the list, being the only human cell line with a DNA - 
PK deficiency. Derived from a human glioma, M059J has no detectable protein 
expression (Lees -Miller SP et al, 1995) and low ATM expression (Chan DW et al., 
1998). However the radiation sensitive phenotype was complemented by a fragment 
of human chromosome 8 that contains a copy of DNA -PKcs thus showing that the 
defect causing radiosensitivity in M059J is in the DNA -PKcs gene. (Hoppe BS et al., 
2000).: More recently, a single nucleotide deletion in exon 32 was identified in the 
DNA -PKcs gene which would give rise to a frameshift mutation and could account 
for the biological properties of these cells (Anderson CW et al., 2001). 
The kinase activity of DNA -PKcs is crucial for the function of the protein in 
regards to DNA DSB rejoining (Kurimasa A et al., 1999) and in the SCID mouse, the 
C- terminal domain required for kinase activity is missing (Beamish HJ et al., 2000). 
Substrates phosphorylated in -vitro by DNA -PKcs include XRCC4 (see 
below), WRN (the Werner syndrome protein) and Artemis. Physiological targets of 
the protein continue to remain elusive although auto -phosphorylation of DNA -PKcs 
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has been found at Thr 2609 in vivo in a Ku- dependent manner in response to ionizing 
radiation (Chan DW et al., 2002). In okadaic acid -treated human cells, DNA -PKcs is 
also phosphorylated in vivo at Thr2609, Ser2612, Thr2638 and Thr2647 (Douglas P et 
al., 2002). Auto -phosphorylation inactivates the serine /threonine kinase activity of 
DNA -PK resulting in dissociation of DNA -PKcs from the Ku -DNA complex and is 
thought to be an important regulatory mechanism for the enzyme complex (Chan D 
and Lees -Miller SP, 1996). 
Knockout mice have been generated that are null for DNA -PKcs (Jhappan C et 
aí.,1997; Gao Y et al., 1998a) or ablated for its kinase domain (Taccioloi GE et 
al.,1998). The knockout mice are normal in size with no gross phenotypic 
abnormalities except radiosensitivity and impaired lymphocyte development. 
To date, DNA -PKcs has only been identified in vertebrates, in contrast to Ku 
which has been found in all eukaryotes examined. 
Ku was first identified from the sera of patients with autoimmune diseases 
(Mimori T et al., 1981). It is a highly abundant nonspecific DNA -binding protein 
comprising two subunits of approximately 70 and 83 kD, referred to as Ku70 and 
Ku80 or Ku86 respectively. (Mimori T and Hardin JA, 1986). The cloning of the gene 
encoding Ku80 revealed that it was also the product of the XRCC5 gene which 
complements radiosensitive rodent cell -lines belonging to the 1R5 group (Taccioli GE 
et al., 1994). The gene is located on chromosome 2q33-35. 
The XRCC5 mutants include xrs series, the XR -VB and the sxi series. Ku 
mutants lack DNA end -binding and DNA -PK kinase activities with resulting defects 
in DSB repair and V(D)J recombination. Lack of the Ku80 protein is accompanied by 
absence of Ku 70 protein and DNA -PK activity but DNA -PKcs levels are unaffected 
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(Zdzienieka MZ, 1999). No rodent mutant defective in Ku70 has yet been identified 
nor is there any human cell -line with spontaneous mutations in either subunit. 
Knockout mice for both Ku70 and Ku80 have been generated. Ku70 and Ku80 
knockout mice are very similar in phenotype ( Nussenzweig A et al., 1996; 
Nussenzweig A et aí.,1997; Gu Y et al., 1997; Ouyang H et a1.,1997). Both Ku70 "- 
and Ku804- mice are small in size, weighing 40 -60% of the weight of control 
littermates. They are hypersensitive to ionising radiation and severely T and B 
lymphocyte deficient. In the case of Ku70 -/- (but not Ku80- /-) mice, the majority of 
animals develop T -cell lymphoma (Li GC et al.,1998). 
One of the earliest insights into the role of Ku in NHEJ was provided by the 
discovery that DNA -PK binding to DNA ends was required for kinase activation and 
that this binding was presumably by means of the Ku subunits (Gottlieb TM and 
Jackson SP, 1993). Indeed Ku -DNA complexes visualised by scanning force 
microscopy is consistent with two DNA molecules held together by Ku (Yaneva M et 
al., 1997). The crystal structure of human Ku heterodimer has been determined to be a 
dyad -symmetrical molecule with a preformed ring that encircles duplex DNA (Walker 
JR et al., 2001). Once bound, Ku is postulated to do at least two things: it protects the 
DNA ends from degradation by exonuclease and recruits DNA -PKCS to the site of 
break (Chu G, 1997). The carboxy terminal portion of Ku80 has been found to be 
important for DNA -PKcs activation - the deletion of this region of Chinese hamster 
Ku80 imparts a phenotype similar to DNA -PK deficiency (Singleton BK et a/.,1999). 
Ku also facilitates ligation of DNA ends by aligning the ends (Ramsden DA and 
Gellert M, 1998), recruits the DNA ligase IV -XRCC4 complex to the break and 
stimulates ligation by ligase IV (McElhinny SAN et al., 2000). 
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The latter complex of XRCC4 and DNA ligase IV complete the process of 
NHEJ by literally seeing to the religation of the DNA ends (Karran P, 2000). Xrcc4 
was cloned by functional complementation of the XR -1, a radiosensitive CHO cell 
line (Li Z et a1.,1995). The gene product is a 334 amino acid nuclear protein. XRCC4 
forms an extremely tight complex with DNA ligase IV in mammalian cells (Critchlow 
SE et al.,1997; Grawunder U et al.,1997). Human DNA ligase IV is a 911 amino acid 
protein whose activity in vitro is stimulated by its association with XRCC4. At the 
same time that the association was described, the role of DNA ligase IV as providing 
the end joining activity was supported by the finding that yeast DNA ligase IV 
mediated NHEJ (Wilson TE et al., 1997). 
Further evidence for the participation of the XRCC4 -DNA ligase IV complex 
to participate in the same pathway have come from several observations. DNA -PK 
has been shown to phosphorylate XRCC4 in vitro and Ku has been demonstrated to 
interact with XRCC4 -DNA ligase IV at DNA ends (Chen L et al., 2000). Exposure of 
to ionising radiation resulted in phosphorylation of XRCC4 as evidenced by an 
electrophorectic mobility shift; M059J cells which lack DNA -PKcs did not 
demonstrate a similar shift (MatsumotoY et al., 2000). However the physiological 
significance of XRCC4 phosphorylation by DNA -PK is unknown. XRCC4, with 
mutations of 2 major DNA -PK sites (ser 260 and ser 318) to alanine, was still able to 
complement the radiosensitivity and V(D)J recombination deficiencies in an XRCC4 
negative cell line (XR -1) (Yu Y et al., 2003). 
DNA ligase IV and Artemis are the only NHEJ genes in which mutations have 
been found in human disease. A hypomorphic mutation in DNA ligase IV was 
reported within a highly conserved motif encompassing the active site in a leukaemia 
44 
patient who was radiation hypersensitive (Riballo E et al., 1999). It is significant that 
the individual was developmentally normal and had no evidence of immunodeficiency 
(Plowman PN et al.,1990). Using a fibroblast cell -line established from this individual 
(180BR), genetic evidence for the involvement of DNA ligase IV in the DNA -PK 
dependent pathway of NHEJ in mammalian cells was demonstrated (Wang H et al., 
2001b). Subsequently, 4 patients with features of immunodeficiency and 
developmental growth delay were found to have mutations in DNA ligase IV and cell 
lines from these patients show pronounced radiosensitivity (Table 1.2) (O'Driscoll M 
et a., 2001). 
Mice deficient for XRCC4 or DNA ligase IV are not viable and die during late 
embryonic development as a consequence of neuronal defects (Barnes DE et al., 
1998; Frank KM et 41998; Gao Y et al., 1998). 
A subset of children with severe combined immunodeficiency (SCID) have an 
associated increase in cellular radiosensitivity and the condition is denoted RS -SCID. 
These children have been found to have loss -of- function mutations in Artemis, which 
is located at chromosome 10p (Moshous D et al., 2001). More recently hypomorphic 
mutations associated with low but detectable number of B and T lymphocytes, have 
been described in four patients (Moshous D et al., 2003). The gene codes for a 77 kDa 
protein that belongs to the metallo -ß- lactamase superfamily. Artemis has 3', 5' 
exonuclease activity and together with DNA -PK cleaves 3' and 5' overhangs, as well 
as opening the hairpin intermediates during V(D)J recombination (Ma Y et al., 2002). 
Artemis, like DNA -PKcs has to date been found only in higher species. Artemis - 
deficient mice are remarkably similar to DNA -PKcs deficient mice (Rooney S et al., 
2002). The mice are normal in size, have increase in cellular radiosensitivity and scid. 
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NHEJ likely involves more proteins; requirement for an additional, as yet 
uncharacterised factor, has been identified in a patient with SCID (Dai Y et al., 2003). 
1.7 DNA damage response 
The processes of homologous recombination and non -homologous end joining 
are called into play when cells experience DNA damaging agents such as ionising 
radiation. The mechanism by which cells sense the damage and the signalling 
processes that eventually lead to the assembly of the proteins involved in the repair 
processes are constantly being elucidated in yeast and in higher organisms. Genes that 
are known to be mutated with a radiosensitive phenotype and involved in the DNA 
damage response include S cerevisiae RAD 9, and human ATM, NBS /MRE 11/ RAD 
50 complex. 
1.7a S cerevisiae RAD9 Gene as a paradigm 
It has long been observed that cells treated with DNA -damaging agents, in 
particular ionising radiation, arrest cell cycle progression in the G2 phase of the cell 
cycle (Walters RA et al., 1974; Tobey RA et al.,1975). The RAD 9 mutant of 
Saccharomyces cerevisiae is a radiation sensitive mutant that is also defective in G2 
arrest after treatment with gamma rays. Treatment of the cells with an agent that 
inhibits normal assembly of the mitotic spindle and thereby artificially imposing a 
mitotic delay restores the sensitivity of the rad 9 mutants to wild -type levels (Weinert 
TA and Hartwell LH, 1988). The authors argue that efficient DNA repair can 
therefore occur in rad 9 mutants and the RAD9- dependent response causes arrest of 
cells in G2 until DNA damage is repaired. 
The RAD9 gene encodes a protein with a predicted molecular mass of 148 
kDA. The only phenotype conferred by deletion of the gene in cells unchallenged by 
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DNA -damaging agents is an increased rate of spontaneous chromosome loss (Weinert 
TA and Hartwell LH, 1990). Rad 9 is phosphorylated in response to DNA damage 
and that phosphorylated Rad 9 has a role in modulating protein -protein interactions 
and activating downstream kinases, for example RAD53 (Sun Z et al., (1998). Human 
Rad 9 is a target of ATM (Chen MJ et aí.,2001). 
1.7b ATM (Ataxia- Telangiectasia Mutated) 
The gene mutated in ataxia telangiectasia, ATM, was cloned in 1995 after a 20 
year search (Savitsky K et al., 1995). It is localised on chromosome 11g22 -23. It 
codes for a predominantly nuclear, 370 kDA protein kinase that bears similarity in its 
carboxy -terminal sequence to the catalytic domain of phosphatidylinositol -3 -OH 
kinase (PI(3)K). Current understanding places ATM at the centre of a signalling 
network activated in response to DNA DSBs in mammalian cells (Shiloh Y, 2003) 
(Fig 1.3). The yeast homologues of ATM include MEC] in S. cerevisiae and Rad3 in 
S. pombe. 
The main phenotypic features of AT cells are: 
o chromosomal instability (Kojis et al., 1989), 
o cell -cycle checkpoint defects in G1 /S (Nagasawa H et al., 1985) and 
G2/M (Beamish H and Lavin MF, 1994), 
o as well as S- phase, the latter also known as radioresistant DNA 
synthesis, ie, an inability to arrest DNA synthesis following irradiation 
(Houldsworth J and Lavin M, 1980; Painter RB and Young BR, 1980) 
and 

































































































































Normal cells, on exposure to ionising radiation, respond by having increased 
cellular levels of p53. P53 goes on to activate p21 production and consequently there 
is a halt in the progression from G1 to S phase. It had been observed that AT cells 
showed poor induction of p53 after ionising radiation (Kastan MB et al.,1992). The 
first complete description of an ATM target provided evidence that ATM kinase 
phosphorylates serine 15 and 20 of p53 in response to ionising radiation (Siliciano JD 
et al., 1997). The downstream effects will be discussed in the section below. 
Exposure of cells to ionizing radiation does not change the subcellular 
distribution or the total amount of cellular ATM protein (Watters D et al.,1997; 
Brown K. D et al., 1997). However, pre -existing ATM is rapidly activated by ionizing 
radiation and radiomimetic agents (Banin S et al., 1998; Canman CE et al., 1998; 
Khanna KK et al., 1998). While the upstream events of this activation are not 
completely understood, atomic force micrographs provide compelling evidence that 
ATM binds directly to free DNA ends (Smith GC et al., 1999). More recently, 
evidence has been provided that DNA DSBs trigger widespread activation of ATM 
through changes in chromatin structure (Bakkenist CJ and Kastan MB, 2003). Even a 
few DNA DSBs was sufficient to activate the majority of intracellular ATM, through 
the ionizing radiation induced phosphorylation of the protein at Ser -1981. ATM 
homodimeric or oligomeric complexes, which maintain the protein in an inactive state 
in undamaged cells, then dissociate and activated ATM monomers are released. 
However the signal that links the structurally altered chromatin with Ser -1981 
phosphorylation is still undefined. 
Chk2 is the human homologue of yeast Rad53 and Cdsl, that are required for 
responses to DNA damage and replication blocks in these organisms. It is a 
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serine /threonine kinase which is phosphorylated by ATM at Thr68 in vivo and in 
vitro, and thereby activated, in response to ionizing radiation (Matsuoka S et a1.,2000; 
Melchionna R et al., 2000). The activation of Chk2 kinase leads to the downstream 
phosphorylation of Cdc25C at Ser216 (Matsuoka S et al., 1998; Brown AL et al., 
199.9; Chaturvedi P et al., 1999). In its phosphorylated state, Cdc25C maintains cells 
in G2 arrest. Chk2 also phosphorylates CDC25A (Falck J et al., 2001) which marks it 
for destruction, thus `locking' CDK2- cyclin E kinase in an inactive state, so 
contributing to the G1 -S, intra -S and G2 -M DNA damage checkpoints. 
The intra -S checkpoint was the first to be recognized as deficient in AT 
cells (Painter RB and Young BR, 1980) is now seen as one of the most crucial cellular 
responses to DNA DSBs (Shiloh Y, 2003). The proteins involved in this checkpoint 
that are phosphorylated by ATM include NBS1 (see below), SMC1 (structural 
maintenance of chromosomes 1) (Kim ST et al., 2002; Yazdi PT et al., 2002) and 
FANCD2 (Fanconi Anaemia Complementation Group D) (Taniguchi T et al., 2002) 
in addition to Chk2 already discussed above. This explains why abrogation of ATM 
function results in an impaired S -phase DNA damage response. 
Whether it is the checkpoint deficiencies or a repair defect per se that accounts 
directly for the cellular hypersensitivity to ionising radiation of AT cells continues to 
be controversial. Jeggo et al. argue that there is evidence (Jeggo PA et al.,1998), that 
the hypersensitivity of AT cells to ionising radiation is not due to their checkpoint 
defects but rather to a distinct DNA repair defect. One of the lines of evidence argued 
by the authors is that while p53 defective cell lines also display cell cycle checkpoint 
defects, they are also radioresistant instead of radiosensitive (see below). Also 
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Lehmann et al. describe an AT derived cell line with normal radiation sensitivity but 
also displays radioresistant DNA synthesis (Lehmann AR et al., 1986). 
A closely related related protein is ATR (ATM -Rad3- related). This is also a 
PI3- kinase like protein whose homologues in yeast, Mecl and Rad3 have roles in the 
DNA damage response pathways. ATR plays a role in the later (as opposed to the 
rapid, ATN dependent) response to DSBs (Tibbetts RS et al., 1999) but its main role 
is in the response pathway to UV radiation induced damage, stalled replication forks 
and hypoxia (Heffernan TP et aí.,2002; Hammond EM et al., 2002). ATR mutations 
have thus far not been described in human diseases. 
DOWNSTREAM OF ATM: P53 AND RETINOBLASTOMA PROTEIN 
P53 is a tumour suppressor gene that is mutated in about 50% of human 
cancers and has been described as the guardian of the genome. Germline mutations of 
p53 in humans result in the Li- Fraumeni syndrome in which affected individuals are 
prone to early onset cancer (sarcoma, breast cancer, brain tumours, leukaemia and 
adrenocortical carcinomas). P53 null mice, although developmentally normal, are also 
predisposed to tumourigenesis (Donehower LA et al., 1992). 
Wild type p53 has a pivotal role in many cellular processes including 
regulation of DNA damage -induced cell -cycle checkpoints (Kastan MB et al., 1991), 
apoptosis (Clarke AR et al., 1991) and more recently aging (Tyner SD et al., 2002). 
The p53 protein is also thought to be important in maintaining genetic stability and 
inhibiting blood -vessel formation in tumours by mechanisms that are as yet unclear 
(Vogelstein B et al., 2000). 
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The link between abnormal p53 function and radiation sensitivity comes from 
the finding that cells form the radiosenstitive syndrome, Ataxia Telangiectasia, show 
delayed induction of p53 levels in response to ionising radiation (Kastan MB et al., 
1992). Upon exposure to ionising radiation in normal cells, ATM phosphorylates p53 
preferentially at Ser 15, leading directly to stabilisation of the protein and up- 
regulation of its levels (Siliciano JD et al., 1997; Banin S et al., 1998; Canman CE et 
al., 1998; Khanna KK et al., 1998). In addition, Chk2 kinase is activated and in turn 
stabilises p53 in response to DNA damage by phosphorylating ser20 (Hirao A et al., 
2000). Furthermore, MDM2 is phosphorylate by ATM on Ser 395 and this interferes 
with the ubiquitin- mediated degradation of p53 leading to its accumulation (Khosravi 
R et al., 1999; Maya R et al., 2001). These proteins are still phosphorylated in 
gamma -irradiated AT cells, but with delayed kinetics indicating alternative ATM 
independent pathways p53 induction by ionising radiation. 
The accumulation of p53 allows it to act on its transcriptional targets. In the 
case of G1 arrest, this is chiefly the p21 gene which encodes a cyclin dependent 
kinase inhibitor (el -Deiry WS et al., 1994). Up- regulation of p21 expression inhibits 
cyclin D- and cyclin E- associated kinases (Dulic V et al., 1994). This allows for the 
accumulation of retinoblastoma protein (pRb) in its hypo -phosphorylated state 
resulting in G1 /S arrest. MDM2 is also transcriptionally activated by p53, the former 
then binds to the latter, stimulating ubiquitination and degradation, resulting in a 
negative feedback loop ( Vogelstein B et al., 2000). 
A significant G2 arrest function has been reported for p53 (Agarwal ML et al., 
1995). This is partly mediated through the transcriptional activation of 14 -3- 
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3sigmáwhich sequesters cyclinBl -CDK1 complexes outside the nucleus and helps 
maintain the G2 block (Chan TA et al., 1999; Laronga C et al., 2000). 
In contrast to the relationship between impaired p53 induction and 
radiosensitivity in AT cells, cells from transgenic mice with mutations in p53 show 
increased survival following ionising radiation. (Lee JM and Bernstein A, 1993). 
Similarly, Li- Fraumeni syndrome fibroblasts with p53 mutations demonstrated 
increased resistance to low dose rate ionising radiation (Sproston ARM et al.,1996). 
1.7c NBS1/MRE11 /RAD50 Complex 
The Nijmegen Breakage Syndrome (NBS) was described first in 1981 
(Weemaes CM et al., 1981); it is a rare autosomal condition that afflicts about 70 
families of mainly Eastern European descent. Although the clinical features are 
distinct from AT, the cellular phenotype of cells derived from individuals with NBS 
are virtually identical to AT cells. In 1998 2 laboratories using different 
methodologies independently identified the gene product that is mutated in the 
syndrome: Nibrin or NBS1 (Carney JP et al., 1998; Varon R et al., 1998). NBS1 was 
localized to 8g21where it spans 50kb of genomic DNA and codes for a protein with a 
calculated molecular weight of 85 kDa. 
In 1999, a further piece in the puzzle was filled in when the syndrome Ataxia 
Telangiectasia -Like Disorder (ATLD) was found to be caused by a mutation in 
hMrel 1. (Stewart GS et al., 1999). Like AT and NBS cells, ATLD cells also display 
increased radiation sensitivity, chromosomal instability and radioresistant DNA 
synthesis. hMrell is located at 11g21. It codes for a multi -functional protein of about 
80 kDa with DNA nuclease, strand association and strand -annealing activities. 
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The third member of the complex is Rad50. This is a 150 kDa protein that 
contains nucleotide binding motifs at its amino- and carboxyl -terminal ends. 
In normal cells, Nibrin is constitutively associated with hMrel l and hRad50. 
The Mre- 11/Rad50/Nibrin (M -R -N) complex is rather abundant and for the most part 
uniformly distributed in the nuclei of the cells. When these are exposed to ionising 
radiation, the proteins become associated in large foci, strictly dependent on the prior 
induction of double strand breaks (Nelms BE et al., 1998; Petrini JH et al., 1999). 
These foci are now known as ionising radiation -induced foci (RIIF), being one of 
three distinct foci formed by the Mrel 1 complex (Mirzoeva OK and Petrini JH, 
2001). Importantly the foci are detectable at the earliest time points examined by the 
investigators and dissipate as the double- strand breaks are repaired. In NBS cells, the 
Mrel l and Rad50 are present at normal levels but are cytoplasmic in distribution and 
the IRIF formation are completely abolished. 
Human NBS1 has weak (29 %) homology to yeast Xrs2 protein. The N- 
terminus consists of a fork head associated (FHA) domain and a BRCA1 C- terminus 
(BRCT) domain. Kobayashi et al have shown that the FHA/BRCT domain directly 
binds to histone 7-H2AX and recruits the M -R -N complex to the vicinity of sites of 
DSBs (Kobayasihi K et al., 2002). H2AX is a member of the histone protein H2a 
family. It is phosphorylated within seconds of exposure to ionising radiation, at Ser 
139 in the carboxy- terminal portion (Rogakou EP et al., 1998). This response was 
directly proportional to the amount of DSBs induced. ATM phosphorylates H2AX in- 
vitro and this phosphorylation is severely compromised in atm -/- cells (Burma S et 
al., 2001). Histone 7-H2AX foci are followed by co- localisation with BRCA1 and 
then by either Rad50 or Rad 51 depending on the cell type (Paull T et al., 2000) and 
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one of its postulated roles is the recruitment of repair factors to sites of DNA DSB 
damage (Kobayashi K et al., 2002). 
AT, ATLD and NBS cells also display radioresistant DNA synthesis due to a 
defect in the S -phase checkpoint following ionising radiation. Data by a number of 
independent laboratories show that ATM phosphorylates Nibrin at two or more serine 
residues (Ser 343 was common to all laboratories) in response to ionising radiation. 
This event influences S -phase checkpoint. Cells expressing mutant proteins that 
cannot be phosphorylated by ATM at Ser343 show significantly decreased S -phase 
arrest after ionizing radiation. However conflicting data was obtained with regards 
whether the formation of nibrin/Mre- 11 /Rad50 radiation -induced foci is affected by 
ATM phosphorylation of nibrin. (Lim DS et al., 2000; Gatei M et al., 2000; Zhao S et 
al., 2000; Wu X et al., 2000). 
Mammalian Mrel l is also phosphorylated in response to ionising radiation in 
an ATM dependent manner; in addition, Mrel1 phosphorylation is dependent on 
Nbsl in human cells. (Dong ZW et al., 1999). 
In addition to the role of the M -R -N complex downstream of ATM in the 
DNA damage response pathway as discussed above, recent data also places the 
complex in a role upstream of ATM. Two groups have shown that the M -R -N 
complex is required for ATM activation and the ATM -dependent G2/M checkpoint in 
response to DSBs (Uziel T et al., 2003; Carson CT et al., 2003). 
Mice with null mutations in each of the genes of the complex die early in 
embryogenesis. (Xiao Y and Weaver DT, 1997; Luo G et al., 1999; Zhu J et al., 
2001). 
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Another feature common between AT, ATLD and NBS cells is their 
radiosensitivity. The nature of the molecular defect causing this radiosensitivity in 
NBS and ATLD cells is controversial. Initial expectation that the complex may play a 
role in NHEJ was due to the fact that yeast mutants with defects in Rad50, Mrell and 
Xrs2 (NBS1 is the human functional analogue) are radiosensitive and defective in both 
the homologous recombination and NHEJ. (Zdzieniecka M, 1999). However, recent 
results indicate that Mre- complex mutants can carry out HR as efficiently as wild -type 
cells in most cases. Moreover clear evidence for a role of the complex in NHEJ has 
only been obtained in budding yeast (D' Amours D and Jackson SP, 2002). In 
contrast, Girard PM, et al, found that in noncycling NBS cells, there was a small 
increased fraction of unrejoined double strand breaks and, more significantly, 
increased chromosome breaks 24h after irradiation. Once of the cell lines (347BR) 
showed a nearly normal checkpoint response but marked gamma -ray sensitivity. Their 
conclusion was that the radiosensitivity in NBS cells is attributable to a repair defect 
rather than cell cycle checkpoint defects (Girard P -M et al., 2000). Furthermore 
efficient joining of cohesive -ended DNA fragments in a cell -free assay using HeLa 
cell extracts required an N -M -R complex containing fraction (Huang J and Dynan 
WS, 2002). 
1.8 MISCELLANEOUS GENES ASSOCIATED WITH SENSITIVITY TO 
IONISING RADIATION 
1.8a Genes involved in genetic syndromes 
Fanconi Anaemia (FA) is a rare autosomal recessive syndrome (incidence < 1 
per 100, 000 live births) characterized by congenital abnormalities, bone marrow 
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aplasia and cancer susceptibility (Andrea AD and Grompe M, 2003). There is marked 
sensitivity to DNA cross -linking agents. Although there is a clinical impression of 
radiosensitivity in affected individuals (Marcou Y et al., 2001; Alter BP, 2002), in- 
vitro studies of cellular sensitivity to ionizing radiation have revealed conflicting 
results (Duckworth -Rysiecki G and Taylor AM. 1985; Djuzenova CS et al., 2001). In 
studies which have found in -vitro radiosensitivity, this has been mild (Burnet NG et 
al., 1994) and G2 -phase specific (Bigelow SB et aí.,1979). 
Seven FA related genes have been cloned and designated FANCA, FANCB, 
FANCC, FANCDJ, FANCD2, FANCE, FANCF and FANCG. FANCD2 has been 
identified as BRCA2 (Howlett NG et al., 2002). FA proteins A, C, E, F and G form a 
nuclear complex which, in response to DNA damage, leads to formation of DNA - 
repair foci consisting of BRCA1 and BRCA2/FANCD1 (Garcia -Higuera I et al., 
2001). Interactions with other proteins involved in DNA damage response include the 
phosphorylation of FANCD2 by ATM (Taniguchi T et al., 2002) and the interaction 
of NBS 1 and FANCD2 in the repair of DNA cross -links (Nakanishi K et al., 2002). 
Bloom's Syndrome (BS) is another rare cancer prone syndrome with clinical 
features of proportional dwarfism, sensitivity to sunlight, type II diabetes, sub -/in- 
fertility and frequent infections (Hickson ID, 2003). BS cells are exquisitely sensitive 
to DNA cross -linking agents (Heartlein MW et al., 1987, Kurihara T et al.,1987) and 
sensitive to ionizing radiation during G2 (Aurias A et al., 1985; Kuhn EM, 1980). The 
product of the gene responsible for this disease, BLM, has been identified as a 
member of the RecQ helicase family. Helicases separate the complementary strands 
of nucleic -acid duplexes in an ATP dependent manner with RecQ helicases 
functioning to `repair' damaged replication forks (Hickson ID, 2003). BLM is a 
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phosphorylation target of ATM following gamma -irradiation (Beamish H et a/.,2002) 
and is also found in RAD51 DNA damage foci (Bischof O et aí.,2001; Wu L et al., 
2001). 
1.8b Genes related to pro -fibrotic and inflammatory cytokines 
Cytokines such as Transforming Growth Factor -beta 1 (TGF -ß 1) and 
interleukin -6 (IL -6) have been implicated in predisposition to specific radiation 
fibrosis and pneumonitis respectively (Andreassen CN et al., 2002). TGF -beta 
stimulates differentiation of fibroblasts and production of extra -cellular matrix and 
has been shown to involved in the genesis of radiation fibrosis (Martin M et al., 
2000). Polymorphisms in the promoter region of the gene have been to shown to 
influence the plasma level of TGF -ß 1 (Grainger DJ et al., 1999) and these 
polymorphisms may influence the likelihood of developing radiation fibrosis. IL -6 
and interleukin- lalpha (IL -1a) are pro -inflammatory cytokines that have been 
implicated in the development of radiation pneumonitis; high pre- treatment plasma 
levels were predictive of the development of pneumonitis after thoracic radiation 
(Chen Y et al., 2001) and both IL- lalpha and IL -6 levels were also significantly 




A RETROSPECTIVE CLINICAL REVIEW OF RADIATION MORBIDITY IN 




Radiation therapy has been the main therapeutic modality for carcinoma of the 
uterine cervix presenting in FIGO stages IB to IV, ever since the first report of its use in 
this disease nearly a hundred years ago (Abbe R, 1913). Only in recent times has the 
addition of chemotherapy been shown to be of benefit for select subgroups of patients 
(Thomas GM, 1999; Monaghan J, 1999). Cure rates of 60% for FIGO stage III to 92% 
for FIGO stage I disease have been reported (Lanciano R et al., 1991). High cure rates 
are achievable because high doses can be delivered with a combination of external 
radiotherapy and intracavitary applications; the latter is able to deliver high local doses to 
the tumour with rapid dose fall -off to the surrounding normal tissue due to the inverse 
square law. Radiation technique and dose differ in different parts of the world but in 
general, the primary tumour and the draining pelvic lymph nodes are included in the 
clinical target volume. The dose to the pelvic lymph nodes and to point A have been 
chosen to carefully limit the morbidity to surrounding normal tissue, namely, the rectum, 
bladder, small intestine and vagina wall. Point A, which is where the uterine artery 
crosses the ureter, was chosen as a point of prescription to take into account of the most 
sensitive structures in the high dose part of the target volume (Dobbs J and Barrett A, 
1999). 
However, it is well recognised that there is inter -patient variation in radiation 
sensitivity as borne out by clinical studies showing significant variation between patients 
in normal tissue reactions to radiotherapy (Tucker SL et al., 1992). This inter -individual 
variation is thought to be largely due to genetic differences in cellular sensitivity (Brock 
WA et al., 1995; Burnet NG et al., 1994; Johansen J et al., 1996) and in spite of the 
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delivery of safe dose regimens, an estimated 50/0 of patients are at risk of injury (Busch 
D, 1994). 
The aim of this retrospective study was to assess the incidence of severe late 
morbidity after curative radiotherapy for cervix cancer in a single institution and to 
determine whether a sensitive subgroup as described in the literature could be identified 
in our patient population (Table 2.6). 
PATIENTS AND METHODS 
PATIENTS 
A retrospective review was taken of patients treated with radical radiotherapy for 
carcinoma of the uterine cervix from 1974 to 1988 at Edinburgh Cancer Centre. 
STAGING and TREATMENT 
The staging and radiotherapy treatment techniques for this cohort of patients have 
been described in detail (Gaze MN et al., 1992, Erridge et al., 2002). Briefly, patients 
were staged according to the International Federation of Gynaecology and Obstetrics 
(FIGO) classification. Routine staging investigations included examination under 
anaesthesia, cystoscopy, intravenous urography and chest radiography. Before 1981, 
patients were treated with a `wedge' technique. The whole pelvis was treated with 
anterior and posterior opposed fields with midline shielding, to give a dose of 20 Gy to 
the central pelvis and to point A, and 40 Gy to the pelvic sidewall in 20 fractions over 4 
weeks (Brand MAJ and Kerr GR, 1982). 2 intracavitary caesium (manual afterloading) 
insertions delivered a further dose of 55 Gy to point A. After 1981, external radiotherapy 
was delivered with a three -field brick technique with no midline shield. 40 Gy in 20 
fractions were prescribed (55 Gy in 30 fractions for more advanced disease). This was 
followed by a single intracavitary caesium insertion of 35 Gy to point A (or 27 Gy if the 
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higher external beam dose was delivered). From 1984, the remote afterloading Selectron 
system was used. 
REVIEW OF CASE RECORDS 
A departmental database had been set up to record the sites and severity of 
morbidity according to the Radiation Therapy Oncology Group (RTOG) system (Table 
2.1). From this database, patients who had been recorded to have sustained severe 
(RTOG grade 4 and 5) morbidity 3 months or more after the start of radiotherapy 
treatment, that is, late injury, were identified and their case records reviewed. The mean 
age at diagnosis and distribution of FIGO stage in the cohort who had severe morbidity 
was compared to that in the whole cohort. 
The site /s of severe morbidity and the mean dose at the site of the morbidity were 
determined. The dose at the site of morbidity was calculated from the total of the external 
beam and intracavitary treatment. 
The median time to onset of morbidity for the entire cohort and at each of the 
sites was determined using the Kaplan -Meier method and compared using the log -rank 
test. 
The incidence of morbidity at three dose ranges, <75 Gy, 75 to 85 Gy and >85 Gy at 
point of morbidity was assessed. In choosing these dose ranges, we judged that a dose 75 
Gy to be a dose most therapists would consider safe (Perez CA et al., 1984; Eifel P et 
al., 2004). Where any individual developed more than 1 site of injury, the least dose at 




There were 829 patients treated radically with external beam and intracavitary 
radiotherapy from 1974 to 1988. The median follow -up was 10 years. Their mean age 
(SD) was 54.6 (12.7) years. 96 patients developed 124 episodes of RTOG grade 4 or 5 
morbidity giving a crude complication rate of 11%. The mean age (SD) in this cohort of 
patients was 50.8 (12.7) years and the difference in mean age was statistically significant 
(p <0.01). There was no difference in the FIGO stage distribution in the whole cohort 
compared with the cohort of patients who developed severe late morbidity (table 2.2). 
Distribution of morbidity by site, mean dose and median time to onset 
There were a total of 124 episodes of RTOG grade 4 and 5 morbidity sustained 
by the 96 patients. The most frequent site of injury was the rectum, with 48 episodes of 
injury occurring in this site. This was followed by the bladder, vaginal vault, colon, small 
bowel, rectosigmoid colon and the pubic bone which was the site of only 1 episode of 
severe, late morbidity (table 2.3). 
The rectum was also the most `sensitive' structure; both the rectum and the 
bladder were more `sensitive' than the vaginal wall; the mean dose (SD) delivered at the 
site of injury was 77.8 (20.5) Gy to the rectum, 84.2 (24.2) Gy to the bladder and 95.8 
(6.3) Gy to the vaginal wall (See table 2.4 for p values). The difference between the 
mean dose to the rectum and that to the bladder were not statistically significant 
(p= 0.28). 
The median time to the onset of severe injury was 15 months for all patients 
(figure 2.1). The timing of complications differs according to the site of injury (table 
2.4). Of note, bladder complications develop later than all other sites with a median time 
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to onset of 30 months compared to that of about 9 to 16 months for the other sites 
(p= 0.015). This was also shown in the study by Perez, et al, in which 80% of 
rectosigmoid complications occurred within 30 months of initial therapy, in contrast to 
48 months for urinary complications (Perez CA et al., 1984). 
Radiation dose and incidence of late injury 
29 patients or 3.5% of the 829 patients treated developed injury at doses that were 
less than 75 Gy, 11 (1.3 %) patients at between 75 and 85 Gy and 28 (3.4 %) patients at 
doses greater than 85 Gy (table 2.5). We were unable to ascertain the dose for 28 
patients. 
DISCUSSION 
Radiation oncologists are constantly refining treatment techniques and strategies 
in order to achieve maximal tumour control and cure while minimising radiation induced 
complications. Effective doses used for treating carcinoma of the cervix are 
unfortunately quite close to the tolerance doses of neighbouring organs, namely, the 
rectum and urinary bladder. Strategies developed over the decades to limit the morbidity 
from radiotherapy are many and include the use of multiple fields in the external beam 
component, low dose per fraction, and careful positioning of the intracavitary applicators 
in relation to the rectum and urinary bladder. 
In this retrospective review of a cohort of 829 patients with carcinoma of the 
cervix treated with radical radiotherapy from 1974 -1988, we found a crude prevalence 
of late, severe morbidity (RTOG grade 4 or 5) of 11 %. This is higher than the crude 
prevalence rate of 6.1% found in the recent national audit of patients treated in UK 
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centers in a single year, 1993 (Denton AS et al., 2002). It was otherwise comparable to 
other studies that covered treatment periods similar to that in this study (table 2.6). 
Moreover in our patient population, there is a proportion (about 4 %) of patients who 
experience severe toxicity even at doses less than 75 Gy, which would be deemed safe in 
most institutions (Perez CA et al., 1984; Eifel P et al., 2004). 
There are many patient factors that may contribute to the development of late 
radiation morbidity (Baumann M and Bentzen SM, 2002). These include a history of 
smoking, presence of co- morbid conditions such as diabetes mellitus, prior surgery and 
concurrent chemotherapy. One of the limitations of this retrospective study is that we 
could not analyse the impact of these factors on the complication rates. However an 
analysis of stage distribution, surgery, RT type and chemotherapy in the UK national 
audit did not find a significant influence on complication rates (Denton AS et al., 2002). 
There is increasing evidence that the susceptibility of these individuals to 
radiation injury may be a genetic one (Brock WA et al., 1995; Burnet NG et al., 1994; 
Johansen J et al., 1996). This is well recognised for patients with the rare severely 
radiosensitive syndromes ataxia telangiectasia and Nijmegen Breakage syndrome whose 
cancers are treated with a different modality or radiation schedule. West et al have found 
a spectrum of lymphocyte sensitivities in patients with carcinoma of the cervix, as 
measured by the surviving fraction at 2 Gy (SF2) (West CML et al., 2001). They found 
that lymphocyte SF2 was a highly significant prognostic factor for the probability of 
developing late radiation morbidity. Mathematical modeling studies have suggested that 
as much as 80% of the observed differences in normal tissue morbidity between patients 
prescribed the same course of radiotherapy may be contributed by this individual 
difference in intrinsic radiosensitivity (Turesson I et al., 1996). 
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Although strategies to limit morbidity from radiotherapy continue to be 
developed with increasing sophistication, for example, the use of intensity modulated 
radiotherapy, challenges remain. One such challenge is to identify the -4% of individuals 
that develop severe late morbidity with a standard course of radiotherapy before 
treatment and tailoring treatment regimens accordingly. Elucidating the mechanisms that 
underlie the normal tissue radiosensitivity in these patients would pave the way for the 
development of rapid, robust and clinically applicable assays. 
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Table 2.1 RTOG LATE RADIATION MORBIDITY SCORING SCHEMA* 
o 1 2 3 
Small /large 
intestine 






















































( <150 cc) 
Severe pain or 
tenderness 
Complete arrest 


















* As it pertains to pelvic irradiation 
Note: 
RTOG grade 5 morbidity is defined as death directly related to radiation late effects 
There is no RTOG grading for late morbidity of the vagina and in this site, grade 4 
morbidity was defined as vaginal vault necrosis. 
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Table 2.2 FIGO DISTRIBUTION 
WHOLE 
COHORT ( %) 
PATIENTS WITH SEVERE 
NORMAL TISSUE MORBIDITY ( %) 
NUMBER OF PATIENTS 





















Table 2.3 DISTRIBUTION OF SEVERE MORBIDITY BY SITE 
SITE OF INJURY EPISODES OF RTOG GRADE 4 -5 TOXICITY ( %) 
RECTUM 48 (5.8) 
BLADDER 26 (3.1) 
VAGINAL VAULT 22 (2.7) 
COLON 13 (1.6) 
SMALL BOWEL 10 (1.2) 
RECTOSIGMOID 4 (0.5) 
BONE 1 (0.1) 
TOTAL 124 
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Table 2.4 RADIATION DOSE, TIME TO ONSET AND SITE OF INJURY 
SITE OF INJURY MEAN (SD) DOSE (Gy) MEDIAN TIME (MTHS) 
RECTUM 77.8 (20.5) 12 
BLADDER 84.2 (24.2) 30 
VAGINAL VAULT 95.8 (6.3) 15 
COLON* 10 
SMALL BOWEL* rectum vs bladder p =0.281 12 
RECTOSIGMOID* bladder vs vaginal vault p =0.04 16.5 
BONE* rectum vs vaginal vault p<0.0001 9 
* Dose not recorded for these p =0.015 
sites 
Table 2.5 RADIATION DOSE AND INCIDENCE OF LATE INJURY 
DOSE DELIVERED AT SITE OF INJURY NUMBER OF PATIENTS ( %) 
<75Gy 










Time to development of severe morbidity 
following radical radiotherapy for cervix cancer 
0 24 46 72 96 120 144 168 192 
Time to damage (months) 
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Table 2.6 Severe Late Morbidity After Radical Radiotherapy for Carcinoma 
of the Uterine Cervix 
Radiotherapy Period Scoring No. of Severe Late 
Centre treated system patients Morbidity 
National UK audit- 1993 French- 1558 6.1% crude ; 
53 centres Italian 
glossary 
8 % actuarial 
Mallinckrodt 1959- Similar 811 8% grade 3 
Institute of 1977 to 
Radiology, USA French - 
Italian 
glossary 
MD Anderson, 1960- Similar 1784 9.3 % at 5 
USA 1989 to years 
RTOG 
Aarhus University 1974 - AADK, 442 Actuarial 5 
Hospital, Denmark 1984 Aarhus, year: 
Denmark 28% rectosig. 
13% SI 
10% baldder 





1.3 %grade 4 
Centre de Lutte 1970- French- 642 10 %grade 3 








et al, 2002 
Perez CA et al, 
1984 
Eifel PJ et al, 
1995 
Pedersen D 
et al, 1994 
Rodrigus P 
et al, 1996 
Barillot I et 
al, 2000 
Abbreviations: 
RTOG - Radiotherapy Oncology Group; Rectosig - rectosigmoid; SI - small intestines; 
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CHAPTER 3 
MATERIALS AND METHODS 
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3.1 REAGENTS 
General laboratory reagents were from Sigma, Fisher and BDH or as specified in 
the text. Molecular biology reagents were from Boeringer Mannheim unless otherwise 
specified. Cell culture materials were from Sigma. ATP -gamma 32P was from 
Amersham, the phosphorimager used was by Molecular Dynamics and X -ray film was 
from Kodak. 
3.2 PATIENTS SELECTION 
A departmental database was established in the Department of Oncology in 
Edinburgh in 1974, and now contains data on over 70000 patients. From this registry 
patients treated with curative radiotherapy from 1974 until the time of recruitment were 
identified, who have developed RTOG grade 4 or 5 late radiation injury following 
treatment with standard radiotherapy doses believed to carry an acceptable risk of 
morbidity. We hypothesised that patients developing late injury as a result of impaired 
DNA repair might also be cancer -prone, and accordingly selected patients under the age 
of 50 years for this study. These patients had obviously also to be alive at the time of the 
study. Patients with necrosis rather than fibrosis were selected because we thought a cell - 
death endpoint was more likely to be related to a DNA repair defect than a proliferative 
endpoint such as fibrosis. 
Local Research Ethics Committee approval was obtained for the study and the 
patients provided written informed consent for cell line immortalisation and the 
investigations. Their general practitioners and attending clinical oncologists were also 
informed of their patients' participation in the study. 
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3.3 PATIENT DETAILS 
5 patients who met the above criteria agreed to participate in the study. The 
patients' clinical histories are summarised as follows: 
Cell line LB 0002 was derived from a patient who presented with early onset 
breast cancer at age 38 years and was treated by lumpectomy and adjuvant radiotherapy 
without systemic chemotherapy. 40 Gy in 10 fractions over 25 days were prescribed 
using external beam treatment followed by 42 Gy delivered by low dose -rate (0.46 Gy 
per hour) brachytherapy. She developed skin necrosis 14 years later. She had no 
recurrence 17 years post treatment. 
Cell line LB 0003 was derived from a patient who presented with early onset 
breast cancer at age 40 years and was treated by mastectomy and adjuvant radiotherapy 
without systemic chemotherapy. 45 Gy in 10 fractions over 28 days were prescribed. She 
developed a chest wall necrosis requiring chest wall reconstruction at 17 years, a 
contralateral primary breast cancer after 18 years and a presumed ipsilateral lung cancer 
(from which no confirmatory histology was obtained) 26 years later. 
Cell line LB0004 was derived from a patient who had a FIGO stage IB primary 
squamous cell carcinoma of the cervix diagnosed at age 43 years. She was a smoker with 
no other significant medical history. She was treated with a combination of external 
beam and intracavitary treatment. The dose to point A was 82 Gy. Two years following 
radiotherapy, she developed vesico -vaginal and ileo- vesical fistulae. Both fistulae were 
managed surgically and she remains disease -free 10 years later. 
Cell line LB0005 was derived from a patient who had a FIGO stage IIIB primary 
squamous cell carcinoma of the cervix diagnosed at age 40 years. She was a smoker with 
no other significant medical history. She was treated with a combination of external 
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beam and intracavitary treatment. The dose to point A was 80 Gy. Two years following 
radiotherapy, she developed a recto -vaginal fistula. This was managed surgically and she 
remains disease -free at 15 years post treatment. 
Cell line LB 0006 was derived from a patient who presented with early onset 
breast cancer at age 38 years and was treated by mastectomy and adjuvant radiotherapy 
without systemic chemotherapy. 44 Gy in 10 fractions over 26 days were prescribed 
using external beam treatment. She developed necrosis of the ipsilateral 4 °h and 5 °h ribs 2 
years later. She has had no recurrence 17 years post treatment. 
Cell line LB0001 was derived from a 28 -year old patient with a family history of 
breast cancer, who developed an early and sustained acute radiation reaction, but did not 
require cessation of therapy. She was also treated with systemic chemotherapy. No late 
damage has occurred, 3 years after treatment. 
3.4 LYMPHOCYTE TRANSFORMATION WITH EPSTEIN -BARR VIRUS 
Upon informed consent, twenty ml of venous blood from each patient were 
drawn into tubes containing sodium heparin (Becton Dickinson) and sent by courier to 
the ECACC at Salisbury, Wiltshire within the same day. The lymphocytes were 
extracted and transformed into lymphoblastoid cell lines with Epstein -Barr virus at the 
ECACC and sent back either as a frozen ampoule or a T25 flask of growing culture. 
Briefly the peripheral blood mononuclear cells (PBMCs) were separated by a ficoll 
gradient. 1 x 107 PBMCs were placed with 200 µl of Epstein Barr virus suspension and 
incubated at 37 °C for 1h. Complete RPMI feed medium (see 3.5) was then added to 
achieve a cell concentration of 1 -2 x 106 cells per ml and cyclosporin A added to a final 
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concentration of 1 pg/ml to inactivate the T- lymphocytes. The cell suspension is 
incubated at 37 °C in a 5% CO2 incubator; immortalisation takes about 4 -6 weeks. 
The cell lines were named at the discretion of the ECACC. 
3.5 CELL CULTURE 
Cell -lines were maintained at 5 -8 x 105 cells per ml in feed medium (see below) 
at 37 °C in a humidified incubator gassed with 5% carbon dioxide (CM Godsen et al., 
1986) with change of medium 3 times a week. After two months, cell -lines were 
discarded and fresh stocks were defrosted from liquid nitrogen for experiments. 
Cell -lines were frozen in freezing mix (see below) at a density of 1 x 107 per ml, 
kept at -80 °C overnight before transferring to liquid nitrogen for storage. On defrosting, 
ampoules of cells were removed from liquid nitrogen into a beaker of water at about 
37 °C and the defrosted cells were immediately transferred into 20 ml of feed medium, 




Foetal calf serum 10% 
Oxalacetic acid (0.1M) 0.5% 
Pyruvic acid (0.04M) 0.5% 
L- Glutamine 1.0% 
Mops buffer (1.25M) 1.0% 
Freezing mix 
Dimethyl sulphoxide (DMSO) 8.0% 
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 Foetal calf serum 92.0% 
3.6 CONTROL CELL -LINES 
Control cell lines MACSI, WALES and HAJON were kindly provided by Dr 
Veronica Heynigen, MDC8 by Professor Malcolm Dunlop of the MRC Human Genetics 
unit in Edinburgh and SNC4 from the National Cancer Centre, Singapore. The cells of 
origin of all these cell lines were peripheral B lymphocytes. The former 3 cell lines were 
from patients with ocular abnormalities but no history of cancer while the MDC8 was 
from an unaffected relative of a patient with colorectal cancer. SNC4 was from a normal 
volunteer. BD2630, GM719C and GM1526E are cell lines from individuals with ataxia 
telangiectasia; the former was obtained from the ECACC (European Collection of Cell 
Cultures) and the latter two from NIGMS (National Institute of General Medical 
Sciences). 
3.7 KARYOTYPING OF CELL -LINES 
Cells were sub -cultured one day before the preparation of chromosome spreads 
and fed with medium to the 10m1 mark in T25 flasks. Three flasks were prepared 
altogether. Colcemid (KayroMax at 10µg/ml Gibco Brl) was added to each flask at 
concentration of 1: 100 and incubated for 30, 45 and 60 min respectively at 37 °C in a 
5% CO2 atmosphere. The cells were then spun down at 1200 rpm for 6 min with brake of 
25 %. 7.5 mls of freshly prepared 0.075 M KC1 were added to the cell pellet and this was 
left for 10 min at room temperature. The cells were again spun down as above and the 
KC1 decanted. The cells were then fixed three times in methanol:acetic acid at 3:1 (again 
freshly mixed). After the third fixation, the cells were spotted onto glass slides which had 
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been presoaked and cleaned in 100% alcohol to which a drop of concentrated 
hydrochloric acid was added. 
Upon drying, the slides were sent for Giemsa staining and reading of karotype by 
Ms Marie Robertson and Mrs Cathy Davidson of the MRC Human Genetics Unit, 
Edinburgh. 
3.8 RADIATION 
In preparation for radiation experiments designed to assess cell viability and p53 
induction, the cells were irradiated in cell culture flasks at room temperature with a 
calibrated linear accelerator using 6 MV photons at a dose -rate of 3.2 Gy /min. For 
pulsed -field gel electrophoresis experiments, a Gammacell 40 Exactor with caesium 
sources was used at a dose rate of 1.06Gy /min. 
3.9 VIABILITY ASSAYS 
Cell survival following irradiation was measured using the Promega CellTiter 96 
Aqueous One Solution Cell Proliferation Assay. This is an assay based on the classical 
MTT cell proliferation test. The promega solution contains a tetrazolium compund [3- 
(4,5- dimethylthiazol- 2- yl)- 5-( 3- carboxymethoxyphenyl )- 2- 2(4- sulfophenyl) -2H- 
tetrazolium, inner salt; MTS] and an electron -coupling agent (phenazine ethosulfate; 
PES). The MTS tetrazolium compound is bioreduced by metabolically active cells into a 
coloured formazan product that is soluble in tissue culture medium. The quantity of 
formazan product as measured by the amount of 490nm absorbance is directly 
proportional to the number of living cells in culture. 
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Lymphoblasts were cultured in feed medium and when exponentially growing, 
were irradiated at room temperature in full T25 flasks with a calibrated linear accelerator 
using 6 MV photons at a dose -rate 3.2 Gy per minute. The irradiation was done in the 
full T25 flasks instead of 96 well plates on advice from Dr David Thwaites of the 
Department of Oncology, Western General Hospital, Edinburgh. This was to ensure that 
the doses delivered would be accurate. Since 96 well plates could not be filled 
completely with media, the air in the plates would make the estimation of the dose 
delivered less accurate. Following irradiation, the cells were then plated into 96 well 
plates at concentrations of between 5 x 104 to 2 x 105 cells per ml. After 24, 48, 72, 96 
and 108h, the cells were incubated with the 20 microlitres of the Promega solution per 
well at 37 °C in 5% CO2 atmosphere for 4 hours. The plates were then read at 450 nm in a 
MTX Lab systems Multiskan Elisa plate reader. 
Using the absorbance readings at the various time -points stated, growth curves 
for the cells were constructed. The vertical displacement of growth curves (Price P and 
McMillan TJ, 1990) compared to non -irradiated cells was then used as an estimate of the 
cell survival for the given dose of radiation (see figure 4.2). Two independent irradiation 
experiments were carried out for each cell line with at least two replicates per 
experiment. 
3.10 CRUDE PROTEIN EXTRACT FOR IMMUNOBLOTTING 
Exponentially growing cells were washed twice in PBS before lysis in 
approximately 2 packed cell volumes of 50mM Tris pH 7.5, 1mM EDTA, 10mM DTT, 
0.2% triton X -100 and a protease inhibitor cocktail containing AEBSF, aprotinin, 
bestatin, E -64, leupeptin, and pepstatin A (Sigma). After incubation on ice for 30 
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minutes, the cellular debris was removed by centrifugation at 14000g for 15 minutes. 
The protein concentration of each sample was determined by the method of Bradford 
(Bradford MM, 1976). 
3.11 SDS -POLYACRYLAMIDE GEL ELECTROPHORESIS AND 
IMMUNOBLOTTING 
Aliquots (20 ul) of each sample containing equivalent amounts of protein were 
separated by SDS -PAGE (BioRad mini -protean) on 10% gels except for gels for DNA - 
PKcs and ATM blotting, for which 5% gels were used due to the large size of the 
proteins. Transfer to nitrocellulose membrane (Amersham) was with a semi -dry blotter at 
100v for 1 hour (Owl Separation Systems, HEP -1) except for DNA -PKcs and ATM 
experiments, for which overnight transfer, at 30V, in a wet system (BioRad) was used. 
Ponceau's staining was used to confirm protein loading and transfer. After blocking with 
5% milk, the membranes were probed with antibodies to Ku 70, Ku 80 and DNA -PKcs; 
DNA ligase IV, XRCC4, Rad 51 and ATM (Table3.1). Incubation with primary 
antibody was for 1 hour at room temperature or at 4 °C overnight. Following washing of 
the blots and incubation with the appropriate secondary antibody, detection was 
performed using ECL ( Amersham). Unless otherwise specified, the immunoblots were 
performed at least twice using separate extracts in each case. The list of primary 
antibodies used and their working dilution are shown in Table 3.1. 
3.12 WHOLE CELL EXTRACT 
3.12A Exponentially growing cells were harvested, and whole cell extracts prepared 
according to the technique described by Manley (Manley JL et al., 1983) and widely 
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Table 3.1 
Acrylamide gel concentrations and primary antibodies used for 
immunoblotting experiments 
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Antibody to Code number, source Antibody 
dilution 
Acrylamide 
gel ( %) 
Ku70 AHP 316, Serotec, Oxford, UK 1:4000 10 
Ku80 AHP 317, Serotec, Oxford, UK 1:4000 10 
DNA -PKcs Clone 25 -4, Ab -2, Neomarkers, 1:250 5 
XRCC4 AHP387, Serotec, Oxford, UK 1:2000 10 
DNA ligase IV AHP554, Serotec, Oxford, UK 1;200 10 
Rad51 Ab -1 #PC130, Oncogene 1:1000 10 
Research Products, USA 
ATM (Mutated 
in Ataxia - 
AHP392 1:1000 6 
Telangiectasia) 
P53 Clone DO -1, Ab -6 Neomarkers, USA 1:1000 10 
Retinoblastoma 
protein (pRB) 
Clone IF8, Ab -1, Neomarkers, USA 1:250 8 
Standard acrylamide:bisacrylamide ratio of 29:1 was used except for ATM gels in which 
an acrylamide:bisacrylamide ratio of 100:1 was utilised. 
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used in in vitro DNA repair systems (Wood RD et al., 1988). The procedure was carried 
out at 4 °C. Briefly, 0.8 to 1 L of cells at a density of 0.5 - 1.0 x 106 cells /ml were pelleted 
and washed twice in phosphate- buffered saline. The cell pellet was resuspended in 4 
packed cell volumes of hypotonie lysis buffer (10 mM Tris -HC1 pH 8, 1 mM EDTA, 5 
mM DTT and protease inhibitors) and left on ice for 20 min. The cells were disrupted by 
10 -20 strokes in a Dounce homogeniser, and an additional 4 packed cell volumes of 50 
mM Tris -HC1 pH 8, 10 mM MgC12, 2 mM DTT, 25% sucrose and 50% glycerol added, 
followed by a further one packed cell volume of ammonium sulphate. After stirring for 
30 min, the extract was centrifuged at 41 000 g for 3h at 4 °C (Sorvall TH 641 rotor). The 
supernatant was removed, and 0.33 g/ml ammonium sulphate added with gentle stirring. 
The extract was centrifuged at 10 000 g for 30 min, after which the precipitate was 
recovered and resuspended in buffer containing 25 mM Hepes pH 7.9, 100 mM KC1, 12 
mM MgC12, 1 mM EDTA and 17% glycerol. This was dialysed against 2 changes of the 
same buffer for a total of 6h, centrifuged at 10000g for 10 min, and the supernatant snap 
frozen and stored at -70 °C. 
3.12B Whole cell extracts were also prepared according to Baumann and West 
(Baumann P and West SC, 1998) for use in cell -free plasmid DNA end joining reactions 
(2.17). All procedures were at 0 -4 °C. Briefly, 0.8 to 1 L of cells at a density of 0.5 - 1.0 x 
106 cells /ml were pelleted and washed thrice in ice -cold phosphate- buffered saline and 
once in hypotonie lysis buffer (10 mM Tris -HC1 pH 8.0, 1 mM EDTA and 5 mM DTT). 
Cells were resuspended in 2 vol of hypotonie buffer for 20 min, lysed by 20 strokes in a 
Dounce homogeniser in the presence of protease inhibitors (Sigma mammalian cells 
protease inhibitor cocktail). After 20 min on ice, 0.5 vol of high salt buffer (50 mM Tris- 
HC1 pH 7.5, 1 M KCI, 2 mM EDTA and 2 mM DTT) was added and the extract 
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centrifuged for 3h at 41 000g in a Sorvall TH 641 rotor. The supernatant was dialysed for 
3h against buffer comprising 20 mM Tris -Hcl pH 8.0, 0.1 M KOAc, 20% (v /v) glycerol, 
0.5 mM EDTA and 1 mM DTT, snap frozen and stored at -70 °C 
3.13 DNA -DEPENDENT PROTEIN KINASE ASSAY 
Whole cell extracts prepared as described (3.12A) were assayed for DNA -PK 
activity by measuring the phosphorylation of a biotinylated p53- derived peptide substrate 
(Promega SignaTECT DNA -Dependent Protein Kinase (DNA -PK) Assay System) in the 
presence or absence of calf -thymus DNA (Allalunis -Turner J et al., 1995; Sirzen F et al., 
1999). Briefly, protein extracts were incubated with 
reaction buffer (50mM HEPES KOH, 7.5, 100mM KC1, 10 mM MgC12, 0.2mM 
EGTA, 0.1mM EDTA and 1mM DTT); 
biotinylated p53 derived peptide substrate; 
bovine serum albumin 0.1mg/m1; 
7-[32P] ATP mix (y -[32 P]ATP and 0.1mM ATP) 
in the presence (activated) or absence (control) sonicated cal thymus DNA in TE buffer. 
Reactions were carried out in a total volume of 25 µl for 5 minutes at 30 °C and thereafter 
terminated by the addition of 7.5M guanidine hydrochloride. 10µl of terminated reaction 
was spotted onto squares on a biotin capture membrane which was then washed 
according to the manufacturer's protocol. After the membrane was dried, incorporation 
of 7 -[32 P] into the peptide was analysed with a STORM PhosphorImaging system 
(Molecular Dynamics) using Imagequant software (confirmed by scintillation counting). 
Calculation of DNA -PK activity included a correction for background non -specific 
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kinase activity. The DNA -PK values are based on at least 3 experiments using extracts 
prepared on at least two separate occasions. 
3.14 PULSED -FIELD GEL ELECTROPHORESIS 
For the measurement of post- radiation double -strand break (DSB) repair 
unsynchronised cells were counted, aliquoted (4x105) and irradiated on ice with 30Gy 
using caesium sources (Gammacell 40 Exactor) at a dose rate 1.06Gy /min. Following 
irradiation fresh RPMI was added to each sample. Cells were kept in the incubator at 37° 
C, in 5% CO2. Unirradiated cells and cells at each time point of repair were harvested 
and washed. The pellet was immediately re- suspended in 0.5% Sea Plaque low melting 
temperature agarose (LMP agarose) at 40 °C. The cell -agarose mixture was pipetted into 
pre -warmed 751,11 plug moulds (Bio -Rad) and allowed to set at 4 °C for at least 15 
minutes. To release DNA in situ the cell plugs were transferred to 50m1 tubes containing 
three volumes of ice cold digestion cocktail [1% N- Lauroylsarcosine (Sigma), 0.1 mg/ml 
Proteinase K (Finnzymes), O.1M EDTA, O.O1M Tris -Cl, 0.02M NaC1]. Incubation was 
for lh at 4 °C, 2h at 50 °C followed by incubation in two volumes of the same digestion 
cocktail containing 0.lmg/ml Proteinase K for 18h at 50 °C. Plugs then were washed at 
room temperature in 50 volumes of TE (pH 7.6) with five changes of buffer over period 
of three hours, in two volumes of TE containing 40.ig/ml PMSF (phenylmethylsulphonyl 
fluoride) for 30minutes at 50 °C, in 50 volumes of TE (pH7.6) with three changes of 
buffer and stored in the same solution at 4 °C (Sambrook, J and Russell DW, 2001) 
Cell plugs were cut into samples with volume of approximately 251.11 and loaded 
into the wells of a 0.7% agarose (Seakem Gold agarose, BMA) gel (14cm wide x 12cm 
long x 0.8cm thick) prepared in 0.5 x TBE (45 mM Tris, 1 mM EDTA, 45 mM boric 
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acid, pH 8.5). The yeast chromosome molecular weight marker from Saccharomyces 
cerevisiae (S. cerevisiae) was also added to each gel as control. The wells were then 
sealed with 0.7% LMP agarose. The PFGE unit (Bio -Rad CHEF -DRII) was filled with 2 
L of 0.5 x TBE. The buffer cooling system was controlled at 10 °C. The sample was run 
at 45V (1.7V /cm) with pulse time of 75 min for 40h, followed by 100V, 30 min pulse 
time, for 2h (Kiltie A et al.,1997). 
Following electrophoresis, the gel was placed on a sheet of 3MM paper 
(Whatman), covered with Saran wrap (Komacs) and dried at room temperature for 30min 
followed by 60min at 60 °C using vacuum Gel Dryer (Bio -Rad) (Kiltie AE and Ryan AJ, 
1997). Then 3M paper was removed by soaking the gel in distilled water for 5 -10 min, 
rinsed with double distilled water and placed in 150 ml SYBR Green I (BMA) nucleic 
acid gel stain (1:10000) in 0.5 TBE, pH8.0 at 50 °C for 3h, cooled for at least 10 min on 
ice before analyzing using Syn Gene Gel Documentation System with Syb -100 SYBR 
green filter. Gel images were analyzed with Gene Tools software from Syn Gene. The 
fraction of damage remaining was calculated as the intensity of the lane divided by the 
total intensity of plug plus lane (Eastham AM et al., 2001; Orton C et al., 1997). 
All data were corrected by subtraction of the non -specific migration detected in 
un- irradiated control samples. Three independent experiments were carried out for each 
cell line with two replicates per experiment. 
The PFGE experiments were done by Dr S Korzh working with Dr Loong. 
3.15 p53 INDUCTION 
Exponentially growing cells were irradiated with 2 and 4Gy as described (2.8). 
Cells were returned to the incubator at 37 °C and harvested at the half, 1, 2, 4 and 24h 
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post -irradiation (Khanna KK and Lavin M, 1993) washed twice in PBS and lysed as 
detailed above (2.10). Immunoblotting of extracts of irradiated and control cell samples 
was carried out as described above using an anti -p53 antibody (clone DO -1, 
NeoMarkers, UK) which recognises an epitope in the N- terminus of the protein. p53 
expression was quantified using densitometry (E.A.S.Y Win 32 software from Herolab 
GmbH Laborgeräte), and induction expressed as the ratio of irradiated to control cell 
values. The immunoblots were performed at least twice for each cell line with separate 
irradiation experiments. 
3.16 pRB PHOSPHORYLATION 
Exponentially growing cells flasks were irradiated with 2 and 4Gy as described 
(2.8). Cells were returned to the incubator at 37 °C and harvested at 2h, 4h and 22h post - 
irradiation (Khanna KK et al., 1995). The cell pellet was washed twice in PBS lysed as 
detailed above (2.10). Immunoblotting of extracts of irradiated and control cell samples 
was carried out as described above (2.11). A 8% SDS -PAGE gel was used and the 
separation was at 150v for 120 min, until the 50kDa marker was near the bottom of the 
gel. This was found to give the best resolution between hypo- and hyperphosphorylated 
pRB. Transfer was with a semi -dry blotter for lh 30 min at 300mA. Immunoblotting of 
extracts of irradiated and control cell samples was carried out using an anti -pRB 
antibody (clone IF -8, Ab -1, NeoMarkers, USA) which recognises an epitope in amino 
acid 703 -722 of the protein. The primary antibody was used at a dilution of 1:300 and 
incubation was carried out for 3h at room temperature. The immunoblots were 
performed at least twice for each cell line with separate irradiation experiments. 
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3.17 CELL -FREE DNA END -JOINING 
pUC18 DNA was linearised with Smal, Pstl and BamHl (Boehringer 
Mannheim) to produce DNA with blunt ends, 3' and 5' overhangs respectively. 
Linearised plasmid DNA was gel purified (Qiagen) and quantified. 1 µg of plasmid DNA 
was incubated with 30 - 50 .1g of cell -free extract at 37 °C for 30 minutes. For these 
experiments, whole cell extract produced according to Manley as well as according to 
Baumann and West were utilised. End joining reactions were carried out in 50 mM Tris- 
HC1 pH 7.5, 5 mM DTT, 0.1 mM EDTA, 10 mM MgC12, 2 mM ATP, 2 mM dNTPs, 25 
mM phosphocreatine (Sigma) and 5 units creatininephosphokinase (Sigma) (modified 
from Fairman MP, 1992). Reactions were terminated by incubation with proteinase K 
(2mg/ml) and RNase A (1mg/m1) for another 30 min at 37 °C. After phenol -chloroform 
extraction and ethanol precipitation, re-joined product was run on a 1% agarose gel and 
visualised after staining with ethidium bromide. DNA was quantified using E.A.S.Y Win 




CELL LINE CHARACTERISTICS AND 
SURVIVAL AFTER IONISING RADIATION 
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4.1 LYMPHOBLASTOID CELL LINES 
During the course of receiving curative radiotherapy, up to 5% of individuals 
will be estimated to experience an unexpected, severe late morbidity (Busch D, 
1994) - see chapter 1.2. Treatment and patient related factors including fractionation 
schedule, treatment volume, co- morbid illnesses, concomitant use of other modalities 
such as chemotherapy, can influence the development of radiation morbidity 
(Baumann M and Bentzen SM, 2002). It is also well recognised that 80- 90% of the 
variation in normal tissue reactions cannot be accounted for by the factors listed 
above and is likely due to differences in intrinsic cellular radiosensitvity of 
individuals (Turesson I et al., 1996; Safwat A et al., 2002). Thus to investigate 
whether the episodes of late radionecrosis in our selected patients were related to a 
patient predispostion to normal tissue injury, we established lymphoblastoid cell 
lines (LCL) from peripheral blood lymphocytes. 
6 LCLs were established and used for the studies of cellular radiosensitivity 
and to investigate the abnormalities in the DNA damage response and DSB repair 
pathways. 5 of these cell lines, LB0002 to LB0006 were from patients who 
developed late radiation necrosis following radical radiotherapy. LB0001 was from a 
patient who had an early and sustained acute radiation reaction but no late morbidity. 
Their case histories are detailed in 3.3 
We chose to use LCL for the following reasons. Lymphocytes and 
lymphoblastoid cell lines, from patients with the radiosensitive syndromes ataxia - 
telangiectasia, Nijmegen breakage syndrome and ataxia- telangiectasia -like disorder, 
have been shown to be radiosensitive in vitro (Cole J et al., 1988, West CM et al., 
1995) and to manifest the underlying molecular defects (Carney JP et al., 1998; 
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Varon R et al., 1998; Stewart GS et al., 1999). Obtaining blood is less painful than a 
skin biopsy and therefore more acceptable to patients. Moreover recent publications 
have found that for non -syndromic patients with head and neck and cervix cancers, 
lymphocyte sensitivity to radiation correlates well with late effects (Borgmann K et 
al., 2002; West CML et al., 2001; Hoeller U et al., 2003). 
4.2 CELL LINES GROWTH IN CULTURE 
Once the cell lines were immortalised, they were sent back from the ECACC 
and their growth rates determined. At cell concentrations of 1 -5 x 105 cells per ml of 
medium, whereby cells are in exponential growth, the doubling time of the newly 
established cell lines was between 23 to 35h (Table 4.1 and Figure 4.1); this is 
similar to published doubling times of 24 -36h (Cole J et al., 1988). 
4.3 CELL LINES KARYOTYPE 
The karyotype of all 6 newly- derived cell -lines was examined using Giemsa 
staining of metaphase chromosomal spreads. The chromosomal spreads were 
prepared by the author while Giemsa staining and karyotype analysis were kindly 
performed by Mrs Cathy Davidson and Miss Marie Robertson (MRC Human 
Genetics Unit, Edinburgh, UK). All cell lines were found to be 46, XX. There were 
no translocations or other cytogenetic abnormalities detected (data not shown). 
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Table 4.1 and Figure 4.1 
Cell lines growth rate and growth curves 
Cells were suspended at a concentration of between 1 and 5 x 10' cells /mi medium 
(RPMI 1640, 10% FCS and additives) and incubated at 37 °C in a 5% CO2 
atmosphere. Cultures were maintained in exponential growth by subculturing every 
48 -72h. Regular aliquots were taken and the cell numbers were counted. The 
doubling time for both the control and newly derived cell lines were between 23 and 
35 hours. Results are the average of at least 3 experiments per cell -line. Examples of 
primary growth curves for 4 of the cell lines, namely, control cell line SNC4 and 
newly derived cell lines LB0003, LB0004 and LB0005 are shown in figure 4.1. 
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Cell line Mean Doubling -Time (h) (SE) 
Macsi 23.8 (2.1) 
Wales 28.0 (2.2) 
SNC4 26.3 (2.1) 
LB 0001 33.1 (0.7) 
LB 0002 31.8 (1.2) 
LB 0003 31.2 (1.0) 
LB 0004 31.7 (1.1) 
LB 0005 35.0 (1.1) 
LB 0006 27.3 (2.0) 
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4.3 COMPARISON OF RADIOSENSITIVITY OF NEWLY -DERIVED, 
NORMAL CONTROL AND ATAXIA TELANGIECTASIA 
LYMPHOBLASTOID CELL LINES. 
To determine whether the patients identified with late radiation injury were 
predisposed to this outcome due to an innate increase in cellular radiosensitivity, 
post- radiation viability in the EBV- immortalised lymphoblastoid cell lines was 
assayed, along with a number of positive and negative control lines. A viability assay 
was chosen because of the difficulties of carrying out colony - forming clonogenic 
survival assays with lymphoblastoid cells proliferating in suspension (Harrison M, 
unpublished). A tetrazolium compound (Promega) that is reduced by metabolically 
active cells was used to measure viability (Chapter 3.9). Cells in replicate 96 -well 
plates were assayed for viability on Dl, 2, 3, 5 and 7 post -irradiation. Growth curves 
were constructed and the vertical displacement of growth curves for irradiated cells 
compared to non -irradiated cells was then used as an estimate for cell survival for 
each given dose of radiation (Price P and McMillan TJ, 1990) (Figure 4.2). This is 
necessary due to the dose -dependent lag period after irradiation before regrowth is 
obtained; during the time that irradiated cells take to regrow (especially for the 
higher dose of 2 Gy), the growth rate of non -irradiated cell population would have 
started to plateau. Exponential extrapolation of the growth rate of the non -irradiated 
cells is then used to estimate cell kill (Chapter 3.9). 
The number of proliferating cells after 0, 0.5, 1.0 and 2.0 Gy was determined 
for the cell lines LB 0002, LB0003, LB0004 and LB0006 derived from the patients 
with late radiation injury, the cell line LB0001, derived from an acute over -reacting 
patient, the negative control cell lines Macsi and Wales, and a positive control cell 
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line from an individual with the human radiosensitivity syndrome AT, BD 2630 
(Table 4.2). These experiments showed the viability curves for LB 0002, LB0003, 
LB0004 and to be intermediate between those of the normal controls and an acute 
over -reactor on the one hand, and the AT cell line on the other (Fig. 4.3B -D). 
LB0001 had a viability curve that tended to be higher than the normal controls at the 
lowest dose of 0.5 Gy (Fig 4.3A) but similar SF2. LB0006 had similar viability post - 
irradiation to the normal controls at the doses tested (Fig 4.3E). 
The radiation senstitivities of the cell lines can also be compared to the 
normal and AT cell line using the SF2. This is the proportion of cells remaining 
viable after 2 Gy. The SF2 were 0.3813 for Wales, 0.3818 for Macsi, 0.3505 for 
LB000l and 0.00862 for BD2630. The SF2 for interleukin -2 dependent T- lymphocyte 
cell lines (Cole J et al., 1988) and for normal LCLs (Angele S et a1.,2003) is about 
0.35. The mean SF2 for lymphocytes from 83 patients with cervical carcinoma, as 
determined by a limiting dilution assay, was 0.33 (range 0.069 - 0.65) (West CML et 
al., 2001). 
For the cell lines from the individuals with late radiation necrosis, the SF2 
were 0.2758 for LB0002, 0.2097 for LB0003, 0.1992 for LB0004 and 0.3787 for 
LB0006 (See Figure 4.4). There is a modest increase in cellular radiosensitivity of 
LB0002, LB0003 and LB004 as measures by the SF2. This was statistically 
significant only for LB0003 and LB0004 (Table 4.3). This is in keeping with the 
observation that cellular radiation sensitivity of phenotypically normal patients who 
over -react to radiotherapy can be at or just below the range for normally reacting 
patients (Burnet N and Peacock JH, 2002). 
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Figure 4.2 
Post -irradiation growth curve using a proliferation assay 
The in vitro post- radiation viability for cell line SNC 4 was determined using a 
proliferation assay as described in 3.9. An example of the growth curves obtained 
after each dose of radiation (0, 0.5, 1.0, 1.5 and 2.0 Gy) is shown. The curve for 0 
Gy includes an extrapolation since the cells had reached lag phase at day 5. The 
vertical displacement of growth curves compared to the non- irradiated cells (0 Gy) 














Figure 4.3 and Table 4.2 
In vitro radiation sensitivity of newly- derived lymphoblastoid cell lines. 
The cell line radiation sensitivity is compared against control cell lines (Macsi and 
Wales) and an individual with ataxia -telangiectasia (BD2630). 




D. LB0004 and 
E. LB0006 are from patients with late radiation necrosis. 
Results are from at least 3 experiments with 2 separate irradiation episodes. 
Table 4.2 gives the mean viable fraction and 95% confidence intervals in numerical 
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Cell line Mean Viable Fraction 
after 0.5 Gy 
95% confidence intervals 
Macsi 0.62 0.59 -0.66 
Wales 0.74 0.71 -0.76 
LB0001 0.87 0.83 -0.90 
LB0002 0.57 0.51 -0.62 
LB0003 0.37 0.31 -0.42 
LB0004 0.46 0.42 -0.50 
LB0006 0.78 0.73 -0.83 
BD 2630 0.23 
after 1.0 Gy 
0.21 -0.26 
Macsi 0.59 0.54 -0.64 
Wales 0.56 0.46 -0.57 
LB0001 0.72 0.69 -0.75 
LB0002 0.40 0.33 -0.47 
LB0003 0.28 0.24 -0.31 
LB0004 0.34 0.32 -0.36 
LB0006 0.63 0.57 -0.68 
BD 2630 0.17 
after 2.0 Gy 
0.13 -0.25 
Macsi 0.38 0.35 -0.42 
Wales 0.38 0.36 -0.41 
LB0001 0.35 0.33 -0.38 
LB0002 0.28 0.24 -0.31 
LB0003 0.21 0.18 -0.24 
LB0004 0.20 0.18 -0.21 
LB0006 0.38 0.34 -0.42 
BD 2630 0.086 0.077 -0.095 
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Figure 4.4 
Surviving fraction at 2 Gy (SF2) 
A comparison of the SF2 of lymphoblastoid cell lines from patients with late 
radionecrosis (LB0002- 0006), an individual with increased acute radiation morbidity 
(LB0001), an individual with ataxia telangiectasia (BD2630) and control cell lines 
(Macsi and Wales). A proliferation assay was used to ascertain the SF2. Bars 
represent the mean from at least 3 experiments from 2 separate irradiation episodes. 
















Error Bars show Mean +1 -1.0 SE 
Bars show Means 
B02630 LB0001 LB0002 LB0003 LB0004 
Cell line 
LB0006 Nhcsi Wales 
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Table 4.3 
Mean viable fractions of the newly derived cell lines compared with 
control cell lines 
The mean viable fraction after 0.5, 1.0 and 2.0 Gy ionising radiation is compared 
against control cell lines Macsi and Wales and BD2630, a cell line from an 
individual with ataxia telagiectasia. The p values are obtained using t -test for the 
comparison of means. NS = non -significant at the 0.05 level. 
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LB0001 LB0002 LB0003 LB0004 LB0006 
0.5 Gy 
Macsi NS NS p=0.003 p=0.014 NS 
Wales NS NS p=0.003 p=0.002 NS 
BD2630 NS NS NS NS NS 
1.0 Gy 
Macsi NS NS p=0.001 p=0.001 NS 
Wales NS NS p=0.002 p<0.0001 NS 
BD2630 NS NS NS NS NS 
2.0 Gy 
Macsi NS NS p=0.005 p=0.002 NS 
Wales NS NS p=0.004 p<0.0001 NS 
BD2630 NS NS NS NS NS 
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When fibroblasts from 130 non -syndromic breast cancer patients were 
evaluated for cellular radiosensitivity, the D0.01 (the dose required to reduce the 
surviving fraction too l %) was found to distribute along a normal distribution with 6 
Gy being the mean D0.01. Fibroblasts from severe over -reactors (Burnet N et al., 
1998) were found to have D0.01 of 4.5 Gy (about 20% less than the mean). This was 
in contrast to fibroblasts from extreme over -reactors, which include AT patients and 
a non -syndromic individual form whom 180BR (which has a Lig4 defect) for 
example, the D0.01 for 180BR is 2.39. In the study by Ramsey and Birrell, they too 
found a statistically significant difference in the SF2 for LCLs from non -syndromic 
breast cancer patients manifesting different grades of radiation morbidity. The SF2 
for patients with grade 2 -4 was 0.12 compared with 0.18 for those with grade 0 or 1 
reactions (Ramsay J and Birrell G, 1995); this represents a difference of about 33 %. 
The SF2 for the AT cell line in this study was 0.01. 
Surprisingly, LB0006 had cellular sensitivities no different from the normal 
controls. This would suggest that factors other than cellular sensitivity account for 
the patient's clinical response to radiotherapy (Marcou Y et al., 2001). Interestingly, 
the patient from whom LB0006 was derived had bone necrosis as opposed to the soft 
tissue necrosis that the other patients sustained. This might suggest that severe bone 
reactions from radiation may have different underlying mechanisms than soft tissue 
reactions and that factors other that intrinsic cellular sensitivity are important. 
Despite three attempts, obtaining viability data was not successful for cell 
line LB0005 which was also derived from a patient with late radiation necrosis. This 
was primarily due to the difficulty of maintaining the cell -line in culture in 96 well 
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plates for the period of time it requires (4 to 7 days) to do the viability assays using 
this method. 
In conclusion, 2 of the lymphoblastoid cell lines (LB0003 and LB0004) 
established from patients with late radionecrosis were significantly more sensitive to 
radiation in vitro, compared with control cell lines (Macsi and Wales) as well as with 




INVESTIGATION OF DNA DOUBLE -STRAND BREAK REPAIR 
IN THE NEWLY- DERIVED CELL LINES 
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DNA double- strand breaks are the major lethal cellular events following 
exposure to ionising radiation. A number of different models of double -strand break 
repair have been described (Chapter 1 - Introduction, sections 1.6a and 1.6b). 
Mammalian cells utilise both homologous recombination (HR) and non -homologous 
end joining (NHEJ) to repair DNA DSBs, with the major pathway being NHEJ. The 
predominant process appears to be dependent on cell type, stage of development or phase 
of the cell cycle. In G1 /GO phase, the great majority of DSBs are rejoined by NHEJ (Lee 
SE et al., 1997; Takata M et al., 1998). Homologous recombination in mammals is 
important during the S- and G2- phases of the cell cycle where optimally positioned sister 
chromatids present a perfect template for exchange (Hendrickson EA, 1997; Takata M et 
al., 1998; Sonoda E et al., 1998). 
We hypothesised that patients who develop late necrosis after doses of radiation 
that are tolerated by the majority of individuals may be predisposed by a cellular defect 
in DNA DSB repair. Accordingly we investigated the presence and activity of the key 
NHEJ proteins and of a key component of the HR pathway, Rad51, in our cell -lines 
LB0002- LB0006. We also studied the capacity and kinetics of selected cell -lines to 
repair DNA DSBs by pulsed -field gel electrophoresis. 
5.1 WESTERN BLOT ANALYSIS OF PROTEINS INVOLVED IN DOUBLE - 
STRAND BREAK REPAIR 
The factors involved in NHEJ pathway that have been identified are the Ku -70, 
Ku -80 and the catalytic sub -unit of DNA -PK (these from a heterotrimer DNA -PK); 
XRCC4 and DNA ligase IV and more recently the Artemis protein (section 1.6b). At the 
time of this study, Artemis had not been discovered. Animal models in which 
components of the NHEJ pathway are deficient are radiosensitive. In humans, M059J, a 
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radiosensitive glioma cell line lacks DNA -PKcs expression (Lees- MillernSP et al., 
1995). Extreme radiosensitivity in a number of paediatric patients has now been 
described in association with hypomorphic mutations in DNA ligase IV (O'Driscoll M et 
al., 2001). 
We hypothesised that patients contributing LB0002- LB0006 might have been 
predisposed to their radiation morbidity due to a biochemical abnormality in the NHEJ 
proteins. Accordingly immunoblots were performed to the proteins that were known to 
be involved in the non -homologous end joining (NHEJ) process. In NHEJ the DNA 
dependent protein kinase (DNA -PK) heterotrimer localise to the DNA ends of a DSB. 
Ku70 and Ku80 first bind to DNA ends and in turn recruit DNA -PKcs. The immunoblots 
for each of these sub -units showed that the proteins were present in equal amounts and at 
the expected molecular weights in all the cell lines (Figure 5.1A -C). 
Two other proteins considered important in NHEJ are DNA ligase IV and XRCC4. 
Western blots of DNA ligase IV and XRCC4 show that both proteins are present in all of 
the cell -lines (Figure 5.2). 
Rad51 is a key enzyme involved in HR, an alternative pathway by which 
mammalian cells, especially in S- and G2- phases of the cell cycle, repair DNA DSBs. 
Immunoblotting for rad51 showed that it was also present in equal quantities in all the 
cell lines (Figure 5.3). 
5.2 DNA -PK ACTIVITY 
A radiosensitive CHO cell -line XR2, belonging to the XRCC7 complementation 
group, is known to have normal expression of DNA -PKcs. This is associated with 
reduced kinase activity of the enzyme. More recently, this was attributed to a missense 
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Figure 5.1 
Western blotting for the presence of Ku70, Ku80 and DNA -PKcs 
(A) and (B) 
25 µg of whole cell extracts from control cell lines Macsi and Wales and each of the 
newly derived cell lines LB0001- LB0006 were loaded onto a 10% SDS -polyacrylamide 
gel and the proteins separated by electrophoresis. The proteins were transferred onto 
nitrocellulose membrane and then probed with antibodies to Ku70 and Ku80. 
All the newly derived cell lines showed equal amounts of both Ku80 (A) and Ku70 (B). 
(C) The same procedure was applied except that 100. µg of whole cell extract was 
utilised and separation was on a 5% SDS -polyacrylamide gel. The transferred proteins 
were probed with antibody to DNA -PKcs. All the newly derived cell lines showed equal 
amounts of DNA -PKcs (C). 
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A 
Macsi Wales LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 
B 
75kDa 
4liamsf Ilaumsue tom. tammÌ 
Wales LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 
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C 
250kDa Macsi Wales LB0001 LB0003 LB0004 LB0005 
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Figure 5.2 
Western blotting for the presence of XRCC4 and DNA ligase IV 
30 µg of whole cell extracts from control cell lines Macsi and Wales and each of the 
newly derived cell lines LB0001- LB0006 were loaded onto a 10% SDS- polyacrylamide 
gel and the proteins separated by electrophoresis. The proteins were transferred onto 
nitrocellulose membrane and then probed with antibodies to XRCC4 and DNA ligase. 
All the newly derived cell lines showed equal amounts of both XRCC4 (A) and DNA 
ligase IV (B). The phosphorylated (upper band) and unphosphorylated (lower band) 
forms of XRCC4 were present in all the cell lines. 
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LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 Macsi 105 kDa 
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Figure 5.3 
Western blotting for the presence of Rad51 
30 µg of whole cell extracts from control cell lines Macsi and Wales and each of the 
newly derived cell lines LB0001- LB0006 were loaded onto a 10% SDS- polyacrylamide 
gel and the proteins separated by electrophoresis. The proteins were transferred onto 
nitrocellulose membrane and then probed with antibodies to Rad51. 
All the newly derived cell lines showed equal amounts of Rad51. 
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35 kDa 
Macsi Wales LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 
Immoo OM. WRENr 
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mutation that resulted in an amino acid substitution of glutamic acid for glycine 6 
residues from the C- terminus of the DNA -PKcs protein (Woods T, et al., 2002). 
We hypothesised therefore that LB0002- LB0006 might have decreased DNA -PK 
activity despite normal expression of all three subunits and accordingly DNA -PK activity 
was assayed in the cell lines. To assay for DNA -PK activity, DNA containing strand 
termini and all 3 subunits of the complex are required (Finite NJ, et al., 1995). The 
phosphorylation of the DNA -PK peptide substrate in the presence of calf thymus DNA 
was measured to correct for any background phosphorylation (in the absence of calf 
thymus DNA) by non -specific kinases. 
A statistically significant reduction of DNA -PK activity was observed in two of 
the cell -lines, LB0003 and LB0004 compared to Macsi, Wales, MDC 8. Compared to all 
three control cell lines, LB0004 had a 3 -10 fold and LB0003 a 2.5 -8 fold reduction in 
DNA -PK activity. LB0001, LB0002, LB0005 and LB0006 demonstrated levels of DNA - 
PK activity that were not significantly from the control cell lines (Figure 5.4 and Tables 
5.1A & B). 
As the cellular phenotype of LB0003 and LB0004 are similar to XR -C2, it was 
hypothesised that a missense mutation in the catalytic domain of DNA -PKcs may also be 
found in one or both of these cell -lines. Sequencing for the analogous mutation in the 
catalytic domain of DNA -PKcs in the two cell -lines has been done and neither LB0003 
nor LB0004 contains the mutant sequence (data not shown). Threonines 2637 and 2647 
of DNA -PKcs are autophosphorylation sites that are essential for cellular resistance to 
ionising radiation; substitution of these residues by alanine renders cells radiosensitive 
(Soubeyrand S et al., 2003). Sequencing confirms that both LB0003 and LB0004 contain 
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Figure 5.4 and Tables 5.1A, 5.1B 
DNA -PK activity in the cell lines 
Peptide phosphorylation by cell -free extracts were determined in the presence and 
absence of calf thymus DNA termini. Data are the mean of at least 3 separate 
experiments. Error bars show mean +/- 1 SE. LB0003 and LB0004 showed significantly 
less DNA -PK activity compared to the control cell lines. The ratio of mean DNA -PK 
activity of control cell lines Macsi, Wales and MDC8 to that of the LB0001- LB0006 cell 
lines are shown in table 5.1A. The p values obtained from comparing the mean DNA -PK 




Error Bars show Mean +1 -1.0 SE 
Bars show Means 
L80001 LB0002 LB0003 LB0004 LB0005 L00006 lubcsi MDC8 Wales 
Cell line 
5.1A 
Ratio of DNA -PK Activity 
LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 
Macsi 1.29 2.80 8.24 10.03 6.10 3.06 
Wales 1.32 2.87 8.42 10.25 6.23 3.13 
MDC8 0.40 0.88 2.57 3.13 1.90 0.96 
5.1B 
Comparing Mean DNA-PK Activity 
LB0001 LB0002 LB0003 LB0004 LB0005 LB0006 
Macsi p=0.331 p=0.004 p<0.001 p<0.001 p=0.001 p=0.001 
Wales p=0.525 p=0.084 p=0.021 p=0.019 p=0.054 p=0.061 
MDC8 p=0.187 p=0.812 p=0.015 p=0.001 p=0.309 p=.823 
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threonine residues at 2637 and 2647 (data not shown). At the present time, the 
underlying mechanism for the reduced DNA -PK activity is still unknown. 
5.3 PULSE FIELD ANALYSIS OF DOUBLE STRAND BREAK AND REPAIR 
This work was undertaken following the in -vitro DNA -PK assays and the 
technical work performed by Dr Svitlana Korzh. We expected that cell lines with 
decreased DNA -PK activity would demonstrate impaired DNA DSB repair (Nevaldine B 
et al., 1997; DiBiase SJ et al., 2000) and sought to confirm this in LB0003 and LB0004, 
which were examined for their ability to repair DNA DSBs using pulse field gel 
electrophoresis. Macsi and LB0001 were used as controls. 
Pulse field gel electrophoresis is a sensitive and specific technique that allows for 
the measurement of the initial amount of DNA DSBs induced by agents such as ionising 
radiation. In addition it also allows for the observation of the rate and total amount of 
double -strand break repair. In brief, cells are irradiated and sequential cell aliquots are 
taken at fixed time -points after irradiation. The cells are embedded in agarose plugs and 
subject to incubation in buffers that would lyse the cell membranes. The plugs containing 
the genomic DNA are subject to pulsed field electrophoresis. Genomic DNA is so long 
that it cannot enter into the agarose gel matrix from the wells of the gel. However when 
double -strand breaks have been induced, the DNA fragments are now small enough to 
migrate out of the wells into the gel matrix. The amount of DNA that is in the gel outside 
the well, is expressed as a fraction of the total amount of DNA in the entire lane, that is, 
inside the well and in the gel (fraction of DNA `released'). This is taken to represent the 
quantity of double- strand breaks that have occurred 
With time, the cells repair the DSBs and the DNA regains its initial size and can 
no longer enter the gel. The rate at which the cell repairs DSBs can then be observed by 
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measuring the fraction of DNA released over time after a given dose of ionising 
radiation. At the end of the repair period, the residual quantity of DSBs remaining can 
also be ascertained. 
The initial induction of DSBs was equivalent in the 4 cell -lines across the doses 
tested (Figure 5.5A). Approximately 60% of the DSB that had been observed at 0 min 
were repaired by the control cell -lines by 30 min, whereas only 5% were repaired by 
LB0003 and LB0004 within the same 30 min period (Figure 5.6B and Table 5.2). 
Although this early difference in DSB rejoining had been partly reversed by 4h, the 
number of residual DSB at 24h was higher in LB0003 and LB0004 than Macsi and 
LB0001. In short, the two radiosensitive cell lines with deficient DNA -PK activity do 
appear to exhibit impaired DNA double - strand break repair, particularly in the fast 
component. 
5.4 DNA END JOINING ASSAY 
Genetic studies have identified the proteins involved in non -homologous end 
joining (NHEJ), which is the main repair mechanism for DNA double strand breaks in 
higher eukaryotes. Biochemical approaches such as in -vitro cell -free NHEJ systems 
could address questions that are difficult to answer with genetic studies (Labhart P, 
1999). Questions such as, what is the minimal number of proteins required for the 
joining of specific DNA end structures? Is the involvement of genetically identified 
proteins in NHEJ direct or indirect? What enzymatic activities are present among the 
NHEJ factors and what is their role in NHEJ or in its regulation? 
Since ionising radiation inflicts most of its damage via the production of DNA 
double strand breaks and the main repair mechanism for these are NHEJ, the aim of these 
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Figure 5.5 
DNA double- strand break (DSB) induction as measured by pulsed field 
electrophoresis (PFGE) assays. 
Cells from cell lines Macsi, LB0001, LB0003 and LB0004 were exposed, on ice, to 
doses of ionising radiation as shown. Cells were immediately subject to lysis and then 
PFGE applied to the genomic DNA. Results shown are the mean of at least 3 separate 
samples per cell line. Error bars represent mean +/- 1 SE. Data are corrected by the 
subtraction of non -specific DNA migration detected in unirradiated samples. There was 
no difference in the amount of DNA DSBs induced by a given dose of irradiation (from 

























Figure 5.6 and Table 5.2 
DNA double- strand break (DSB) rejoining as measured by pulsed field 
electrophoresis (PFGE) assays. 
Cells from cell lines Macsi, LB0001, LB0003 and LB0004 were exposed, on ice, to 30 
Gy of ionising radiation and returned to the incubator at 37 °C, 5 %CO2. At the time - 
points shown, aliquots of cells were lysed and the genomic DNA subject to PFGE. 
Results shown are the mean of at least 3 separate samples per cell line. Error bars 
represent mean +/- 1 SE. Data are corrected by the subtraction of non -specific DNA 
migration detected in unirradiated samples. The cell lines with reduced DNA -PK 
activity, LB0003 and LB0004 showed significantly less rejoining of DNA DSBs at 0.5h 





















Mean Fraction of DNA DSB remaining 
LB0001 LB0003 LB0004 
Time after 
IR (H) 
0.5 0.59 (0.54 -0.64) 0.59 (0.54 -0.64) 0.91 (0.87 -0.95) 0.95 (0.91 -0.99) 
1 0.57 (0.53 -0.61) 0.45 (0.38 -0.52) 0.76 (0.67 -0.85) 0.8 (0.76 -0.84) 
2 0.43 (0.4 -0.46) 0.4 (0.35 -0.45) 0.58 (0.52 -0.64) 0.65 (0.58 -0.72) 
3 0.45 (0.43 -0.47) 0.44 (0.39 -0.49) 0.51 (0.5 -0.52) 0.62 (0.6 -0.64) 
4 0.29 (0.26 -0.32) 0.2 (0.18 -0.22) 0.47 (0.39 -0.55) 0.64 (0.6 -0.68) 
24 0.32 (0.3 -0.34) 0.37 (0.34 -0.4) 0.58 (0.57 -0.59) 0.51 (0.48 -0.54) 
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experiments was to develop a robust in -vitro cell -free system dependent on factors 
involved in NHEJ. Such a system could be used to assay cell free extracts from patients 
who are scheduled to receive radiotherapy, for the ability of the former to rejoin DNA 
DSBs by NHEJ. The intention was to subsequently develop the system as a predictive 
biochemical assay for normal tissue intrinsic radiosensitivity. 
In the presence of cell free extracts, from control cell lines (for example, Macsi), 
prepared according to Manley (see chapter 3.12A), linearised pUC18 DNA was observed 
to form linear dimers and occasionally trimers and higher multimers. There was high 
variability of the degree of end joining under the reaction conditions described and the 
rest of the data obtained in these experiments must be considered preliminary only. 
Nevertheless, preincubating the extracts with antibodies to Ku 70, Ku 80, DNA -PKcs 
and DNA ligase IV did not inhibit end joining of the linearised plasmid DNA. There was 
also no inhibition in the presence of 10 and 50 mM LY2940002, a small molecule 
inhibitor of DNA -PKcs kinase activity. 
Experiments using the method of cell -free extract preparation of Baumann and 
West, (Baumann P and West SC, 1998b) were also performed. This was the first 
description (and the only one at the time of this study) of an in -vitro system for NHEJ 
that is dependent on the subunits of DNA -PK and DNA ligase IV. Very little repair 
product was observed using the method of cell free extract preparation described (data 
not shown). However the protein concentration of repeated extracts from different 
control and the newly derived cell lines was substantially below the 15 mg/ml described 
as necessary for joining activity (personal communication, Dr P Baumann). 
One possibility for the failure of our experiments using the Manley extracts, to 
demonstrate dependence of end joining on the NHEJ factors could be related to the 
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reaction conditions used for the end joining per se. We carried out the end joining 
reactions in the presence of 10 mM MgC12 (chapter 3.17) whereas the reaction of 
Baumann and West used 0.5 mM Mg(OAc)2 (Baumann P and West SC, 1998b). That the 
magnesium concentration might be the critical difference is suggested by the findings of 
Wang H et al. They showed that their in -vitro end joining reaction was dependent on 
DNA ligase IV only when performed in the presence of low (0.5 mM) Mg 
concentrations. Pre -incubation of cell free extracts with antibodies to DNA ligase IV had 
no inhibitory effect on end joining when carried out at 10 mM Mg and the conclusion 
was that the contribution of DNA ligase IV to overall in -vitro end joining was small 
(Wang H et al., 2001b). More recently, Huang and Dynan describe an in -vitro DNA 
ligase IV /XRCC4 dependent DNA end - joining system that was carried out at an Mg 
concentration of 1.0 mM (Huang J and Dynan WS, 2002. We would need to repeat our 
assay using Manley extracts at low Mg concentrations to test for dependence on NHEJ 
factors. 
In summary, 2 of our 5 cell lines derived from patients with late radionecrosis, 
LB0003 and LB0004 had abnormalities in DNA DSB repair. They demonstrated reduced 
DNA DSB rejoining associated with reduced in -vitro DNA -PK activity. All three 
subunits of DNA -PK were expressed at normal levels when examined by 
immunoblotting. The possible molecular defect(s) and mechanisms of these findings as 




DNA DAMAGE SIGNAL TRANSDUCTION 
IN THE NEWLY- DERIVED CELL LINES 
The role of DNA damage signal transduction in the radiation hypersensitivity of 
mammalian cells has been best studied in the human radiosensitivity syndromes, ataxia 
Telangiectasia (AT) and the Nijmegen Breakage Syndrome (NBS) [see sections 1.7b 
and 1.7c respectively]. In normal cells, the ATM (AT mutated) protein is rapidly 
activated by ionising radiation and radiomimetic agents leading to p53 phosphorylation 
at serine 15 and 20 (Siliciano JD et al., 1997; Banin S et al., 1998; Canman CE et al., 
1998; Khanna, KK, et al., 1998). The phosphorylation of p53 inhibits the binding of 
MDM2 with p53 and protect p53 from ubiquitination and degradation (Shieh SY et al., 
1997). By promoting the stability of and thus activating p53 in response to ionising 
radiation, ATM induces a G1 /S arrest. The retinoblastoma protein (pRB) functions 
downstream of p53 in the regulation of G1 /S arrest following DNA damage. Following 
p53 activation, cyclin dependent kinases (cyclinA/CDK2, cyclinE /CDK2 and 
cyclinDl /CDK4) are inhibited leading to a loss of phosphrylation of pRB, which results 
in the cell cycle arresting at the G1 /S checkpoint (Dulic V et al., 1994; el -Deiry WS et 
al., 1994). (Figure 6.1). 
Studies attempting to link AT heterozygotes with the development of late 
radiation morbidity have given conflicting results (see section 1.3 and table 1.1). 
Nonetheless we hypothesised that one or more of our patients with late radionecrosis, 
might be heterozygous for an AT mutation. The biochemical components of the targets 
of ATM in the intra -S and G2/M checkpoints were less well characterised at the time of 
this study. Thus to study the functionality of the ATM signalling pathway in LB0002 -6, 
we studied the proteins and processes involved in the ATM dependent G l /S DNA 
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Figure 6.1 
The ATM dependent DNA damage G1 /S checkpoint 
















damage signal transduction pathway (sections 6.2 and 6.3). This was in addition to 
examining the cell lines for presence of the ATM protein (section 6.1). 
Also at the time of this study, NBS 1, mutations of which cause the Nijmegen 
Breakage Syndrome, had just been cloned (Carney JP et al., 1998; Varon R et al., 1998); 
the examination of the NBS1/Mrell/Rad 50 pathway was not included in this study. 
6.1 WESTERN BLOT ANALYSIS OF ATM 
The majority of ATM mutations, in individuals with the radiosensitive syndrome 
ataxia- telangiectasia, are truncating mutations resulting in an unstable and undetectable 
gene product (Gilad S et al., 1996; Telatar M et al., 1996; Lakin ND et al. 1996). We 
thus hypothesised that one or more of the newly derived cell lines LB0002- LB0006 
might be heterozygous for a truncating mutation in ATM. We sought to examine this 
using western blot analysis. Cell line extracts were accordingly probed for the presence 
of the 350 kDa ATM protein. ATM was shown to be present in all the cell lines at the 
correct molecular weight. Therefore none of the cell lines had a truncation mutation in 
ATM. This was not unexpected for LB0006 given that the in -vitro radiation sensitivity 
of the cell line was normal. In particular, LB0005 (see sections 6.2 and 6.3 below) as 
well as the cell lines (LB0003 and LB0004) with reduced DNA -PK activity (see section 
5.2) had normal ATM levels (Figure 6.2). The latter is in contrast to the glioma cell line 
M059J which lacks both DNA -PKcs and ATM expression (Chan DW, et al., 1998). 
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Figure 6.2 
Western blotting for the presence of ATM 
50 µg of whole cell extract from an AT cell line, GM719C, and newly derived cell lines 
LB0003, LB0004 and LB0005 were loaded onto a 6% SDS- polyacrylamide gel (ratio of 
acrylamide to bisacrylamide = 100:1). Following separation by electrophoresis, the 
proteins were transferred onto nitrocellulose membrane and then probed with an 
antibody to ATM. All the newly derived cell lines showed equal amounts of ATM as 
exemplified by the 3 cell lines shown. 
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6.2 POST -IRRADIATION P53 UP- REGULATION BY WESTERN BLOT 
ANALYSIS 
In spite of expressing normal amounts of full length ATM protein, we 
hypothesised that the newly- derived cell lines might have decreased ATM activity due 
to a missense mutation (Stankovic T et al., 1998). Cell lines from AT individuals have 
reduced and delayed p53 up- regulation following ionising radiation (Kastan MB et al., 
1992; Khanna KK and Lavin MF, 1993). To confirm that ATM activity was normal in 
the newly derived cell lines, the up- regulation of p53, a target of ATM following DNA 
damage, was measured after 2 or 4 Gy ionising radiation. Unsynchronised cells were 
irradiated and returned to the incubator at 37 °C, 5% CO2. Aliqouts of cells were 
harvested at 0.5, 1, 2 and 4h post -irradiation and analysed for p53 expression by western 
blot analysis as described in section 3.15. 
Initially p53 was present in all the unirradiated cell lines (data not shown). By 2 
hours post -irradiation with 4 Gy, a 2 to 3 fold up- regulation of p53 was observed in the 
newly derived cell lines, except for LB0005 (Figure 6.3). This degree of p53 up- 
regulation is consistent with previous reports for normal lymphoblastoid cell lines 
(Khanna KK and Lavin MF, 1993; Mirzayans R et al., 1995) indicating normal ATM 
activity in the cell lines apart from LB0005. In particular, both LB0003 and LB0004, the 
two cell lines with reduced DNA -PK activity showed normal kinetics and levels of p53 
up- regulation. This would be in agreement with the observation that p53 up- regulation is 
normal in cells with deficient DNA -PK activity (Burma S et al., 1999; Jimenez GS et 
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Figure 6.4 and Table 6.1 
p53 up- regulation in LB0005 
The time -course of p53 up- regulation by 4 Gy of ionising radiation for LB0005, is 
compared graphically (Figure 6.4) and in a table (Table 6.1) with a normal cell line SNC 
4 and GM719C, a cell line from an individual with ataxia telangiectasia. The means are 
from at least 3 experiments. The error bars (Figure 6.4) show mean +1- 1 SE. The p 
values (Table 6.1) are for the comparison of the means between SNC 4 and LB0005 at 







Cell Line - GM719C 
A LB0005 
SNC4 
Time post - 
irradiation 
Mean Relative Density of p53 bands 
SNC 4 LB0005 GM719C p value 
(comparing SNC 4 versus LB0005) 
Half h 1.58 1.23 0.89 p=0.03 
1h 2.33 1.38 0.77 p=0.001 
2h 2.09 1.51 1.15 p=0.004 
4h 2.60 1.69 1.17 p=0.001 
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Although LB0005 also demonstrated up- regulation of p53 in response to ionising 
radiation, it had significantly reduced levels of p53 post -irradiation with 4 Gy at each of 
the time -points examined (Figure 6.4). The levels of p53 up- regulation at each time - 
point were intermediate between that of the normal control cell line and that of an AT 
cell line GM719C (Table 6.1). These data need further investigation to determine 
whether cell line LB0005 carries a heterozygous missense mutation in or a polymorphic 
variant sequence of ATM (see section 7.2). 
6.3 POST -IRRADIATION RETINOBLATOMA PROTEIN (pRB) 
PHOSPHORYLATION 
pRb and Rb- related proteins have been shown to be checkpoint participants 
downstream of p53 in the p53- mediated G1 arrest in response to DNA damage. (Dulic 
V et al., 1994; el -Deiry WS et al., 1994; Slebos RJC et al, 1994). 
Khanna KK et al found in unirradiated control cells, the ratio of hyper- 
phosphorylated/hypo-phosphorylated pRb was approximately one and that following 
exposure to ionising radiation, there was an accumulation of the hypo -phosphorylated 
(more rapidly migrating) form of pRb. In unirradiated AT cells, the ratio of hyper - 
phosphorylated-to -hypo -phosphorylated Rb was approximately 5:1. Moreover, there was 
either only a small or no increase in the level of hypo -phosphorylated pRb at 2h and 12h 
post -irradiation with 3 Gy (Khanna KK et al., 1995). 
To confirm that normal ATM activity and p53 induction were associated with an 
expected accumulation of hypo -phosphorylated pRb in the newly derived cell lines, 
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immunoblots of cell lysates were performed at 4 and 20h after exposure to 4 Gy. This 
was compared against AT cell line BD 2630. The data was very much in accordance 
with the findings of Khanna et al. In unirradiated BD2630, nearly all the pRb was in the 
hyper -phosphorylated form and there was virtually no conversion to the hypo - 
phosphorylated form upon irradiation (Figure 6.5). 
LB0005 did show accumulation of hypo -phosphorylated pRb after exposure to 
ionising radiation but the degree of accumulation was reduced compared to LB0001 as 
assessed qualitatively (Fig 6.4). In all the other newly derived cell lines, namely 
LB0002, LB0003, LB0004 and LB0006, there was an accumulation of the 
hypophosphorylated pRb upon exposure to ionising radiation (data not shown). Under 
the experimental conditions described, resolution of the two bands representing hyper - 
and hypo -phosphorylated pRb was not sufficient to allow densitometric quantification 
and comparison between the cell lines. 
In summary, examination of components of the ATM dependent G1 /S pathway 
in the cell lines LB0002 -6 from individuals who developed severe late radiation injury 
revealed abnormality in only one of the cell lines, namely, LB0005. LB0005 
demonstrated reduced levels of p53 up- regulation in response to ioinising radiation (Fig 
6.3 and 6.4) even though it expressed normal levels of ATM of the expected molecular 
weight (Fig 6.1). In addition conversion to hypo -phosphorylated pRb occurs in response 
to ionising radiation, implying that G 1/S is not absent. Further elucidation of the G l /S 
and indeed the G2/M and intra -S radiation response in LB0005 is required and future 
experiments are discussed in chapter 7. 
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Figure 6.5 
Phosphorylation status of pRb after exposure to ionising radiation 
determined by immunoblotting. 
Unsynchronized cells were exposed to 4 Gy. 100 µg of whole cell extracts were loaded 
onto a 6% SDS- polyacrylamide gel and the proteins separated by electrophoresis. The 
proteins were transferred onto nitrocellulose membrane and probed with antibody to 
retinoblastoma protein. The more rapidly migrating band is the hypophosphorylated 
form of pRb. Its presence in the irradiated extracts indicates intact Gl /s checkpoint 
following exposure to ionising radiation. Conversion to hypophosphorylated pRb was 
detected 4h and 20h after exposure to ionizing radiation in LB0001 and all the other 
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DISCUSSION 
Severe late radiation injury, either necrosis or fibrosis, is dose -limiting for 
curative radiotherapy, and occurs in about 5% of non -syndromic patients receiving 
this treatment. It has been suggested that these patients may be intrinsically more 
radiosensitive, although they appear to form a continuum with the remaining 95% of 
the normal population (Busch D, 1994; Burnet NG et al., 1992) and that identifying 
these inherently sensitive individuals will allow the delivery of a higher radiation 
dose to other patients, in turn improving their chance of cure (Tucker SL et al., 
1996). Prospective studies of intrinsic radiosensitivity using clonogenic assays have 
shown a correlation of the former with patient survival in patients with cervix (West 
CM et al., 1997) and head and neck cancer (Bjork -Eriksson T et al., 1998) and with 
late tissue morbidity in patients with breast (Loeffler JS et al., 1990), cervix (West 
CML et al., 2001) and other cancers (Alsbeih G et al., 2000). However 2 large 
studies (Russell NS et aí.,1998, Peacock J et al., 2000) have suggested that the 
relationship between intrinsic radiosensitivity and late tissue morbidity is not strong 
enough for accurate prediction (see also Chapter 1.3b). Possible reasons for this 
discrepancy have been discussed in chapter 1.3b. Thus a different approach is 
required and this might include the identification of genetic or biochemical defects 
that predispose individuals to severe normal tissue morbidity. 
Two reports have suggested that DNA repair proficiency might be 
important. Herring and coworkers found a correlation between expression of the 
human AP endonuclease HAP1, determined immunohistochemically in formalin- 
fixed paraffin- embedded tissue, and clonogenic survival after clinically relevant 
doses of radiation in the patients with cervix cancer described above (Herring CJ et 
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al., 1998). Alapetite and colleagues used the alkaline comet assay to investigate 
strand -break rejoining in lymphocytes from 26 patients with severe radiation 
reactions, 22 with normal reactions and 24 healthy donors. All 6 patients with the 
most severe RTOG grade 4 reactions exhibited impaired strand -break rejoining 
(Alapetite C et al., 1999). The controls included patients who had been irradiated 
several years before, suggesting that the impaired rejoining was not a direct 
consequence of the radiotherapy. Severin DM et al sequenced the hHR2J(human 
rad21) gene in 19 radiation -sensitive cancer patients. Rad21 is involved in the repair 
of DNA DSBs in Schizosaccharomyces pombe. In 6 of the 19 patients, a thymidine 
to cytosine transition, which does not result in change in amino acid, was detected at 
position 1440 of the hHR2J open reading frame (T1440C). One patient with a 
particularly severe radiation reaction had a second sequence variant immediately 
adjacent to the first. This was a guanine (G) to adenine (A) transition (G1441A), 
resulting in a change of the amino acid sequence (glycine - -> arginine) in a portion of 
the protein conserved in evolution Severin DM et al., 2001). More recently, 
Andreassen CN et al examined and found positive correlation between clinical 
normal tissue radiosensitivity and single nucleotide polymorphisms in 5 candidate 
genes including XRCC3, a gene important in homologous recombination. 
Taken together, these studies strongly suggest that DNA repair activity might 
influence radiosensitivity in the clinical setting. The predominant lesion responsible 
for lethality is the DSB, and the major repair pathway for its correction in 
mammalian cells is non -homologous end joining (NHEJ). Hence one of our 
hypotheses was that abnormalities in DNA repair, particularly in the NHEJ pathway 
might be associated with the development of severe, late radiation morbidity. At the 
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time we began the study, ataxia -telangiectasia was the only human radiosensitive 
syndrome that had been well characterised biochemically and accordingly we also 
investigated the G1 /S DNA damage signalling pathway orchestrated by the ATM 
protein. 
Before performing the in -vitro work, we first retrospectively analysed a 
defined cohort of patients treated at the Western General Hospital in Edinburgh. 
These were patients who had received radical radiotherapy for carcinoma of the 
cervix between 1974 and 1988. The main aim of the study was to decide if a 
radiation -sensitive subgroup, similar to that published in the literature, could he 
identified in the South East Scottish population. Using a cut -off dose of 75Gy, 
which most centres would consider safe, we found that about 4% of patients 
developed a grade 4 or 5 RTOG late morbidity. Hence it was likely that a radio- 
sensitive subpopulation as described in the literature was also present amongst South 
East Scottish cancer patients. 
We then proceeded to identify these radiation -sensitive patients from a 
departmental database, which had been established in 1974 and now contains data of 
over 70 000 patients. Our first eligibility criteria were patients who had developed 
RTOG 4 (appendix) late radiation injury following treatment with standard 
radiotherapy doses. We hypothesised that patients developing late injury as a result 
of an underlying genetic abnormality in, for example, DNA repair might also be 
cancer -prone, and accordingly selected patients under the age of 50 years for this 
study. We also decided in the first instance to shortlist patients with either breast or 
cervix cancers. Breast cancer patients were selected because of the association of 
breast cancer with carriers of the AT gene (Khanna JNCI, etc). The BRCA1 and 
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BRCA2 genes were also found to be involved in homologous recombination (Scully 
R et al., 1997; Sharan SK et al., 1997). More recently, large genetic association 
studies have implicated implicated rare polymorphic variants of two Rad51 paralogs, 
namely, XRCC2 (R188H) and XRCC3 in breast cancer susceptibility especially in 
younger patients with a positive family history ( Rafii S et al., 2002; Kuschel K et al., 
2002). This further supported our hypothesis that patients with severe radiation 
injury could have a genetic defect that predisposed them to both early onset breast 
cancer as well as the former. 
Radiotherapy (with chemotherapy) is still the radical treatment modality for 
advanced staged cervical cancer. The radiotherapy dose is limited by the tolerance of 
surrounding normal structures especially the small bowel and rectal wall. By 
identifying patients who are predisposed to radiation injury, it is possible that doses 
for the remaining patients with cervical cancer can be escalated, thereby improving 
the local control and cure rates. Thus we studied patients with cervical cancer and 
late radiation injury to try and identify biochemical abnormalities that might be 
developed as predictive assays (see chapter 1.2 and 1.3b). Patients with necrosis 
rather than fibrosis were selected because we thought a cell -death endpoint was more 
likely to be related to a DNA repair defect. Indeed the severe, sometimes fatal 
radiation morbidity, in patients with ataxia -telangiectasia and in the patient from 
whom the DNA ligase IV defective cell line 180BR was derived, is likely to be a 
result of cell death (Gotoff SP et al., 1967; Morgan JL et a., 1968; McFarlin DE et 
al., 1972; Plowman PN et al.,1990). 
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Having identified the patients, we proceeded to establish Epstein -Barr 
immortalised lymphoblastoid cell lines from 5 patients that met the criteria described 
above (LB0002 -6) and 1 patient that had an increased acute skin erythema which 
resolved over time and in whom no late damage has occurred (LB0001). The 
decision to establish lymphoblast as opposed to fibroblast cell lines was based on 
several factors. Two important considerations were firstly, the efficiency of 
immortalisation and subsequent growth to produce sufficient cell numbers for 
biochemical assays using whole cell extracts. For this study all 6 lymphocyte 
samples were successfully immortalised. The second important factor was patient 
acceptability of venepuncture in order to obtain the lymphocytes for immortalisation. 
Moreover EBV- immortalised cell lines are polyclonal and therefore should be 
representative of the B cells of the patients with respect to radiation sensitivity, 
genetic and biochemical studies. The main disadvantage of using lymphoblastoid cell 
lines is that standard clonogenic assays, the gold standard by which in -vitro radiation 
sensitivity is measured, could not be performed. Consequently, there is far less 
published data to compare, for example, the SF2 (surviving fraction at 2 Gy) of these 
newly established cell lines than if they had been fibroblast cell lines. 
After the cell lines were established, we examined the karyotype of the cell 
lines by giemsa staining of metaphase spreads, for evidence of spontaneous 
chromosomal aberrations which would indicate an underlying chromosomal 
instability syndrome, and found LB0001- LB0006 all to be 46 XX. 
A summary of the main in -vitro findings for each of the cell lines is presented 
in the following. 
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7.1 LB0003 and L130004 
LB0003 was derived from an individual with early onset breast cancer at age 
40 years which was treated by mastectomy and adjuvant radiotherapy: 45 Gy in 10 
fractions over 28 days. She developed chest wall necrosis requiring chest wall 
reconstruction 17 years later, a contralateral primary breast cancer after 18 years and 
a presumed ipsilateral lung cancer (from which no confirmatory histology was 
obtained) 26 years later, perhaps indicating a cancer -proneness. The cell line showed 
in -vitro sensitivity to radiation with an SF2 of 0.2097. PFGE data for the cell line 
demonstrated no difference in the amount of initial DNA DSBs induced by a given 
dose of ionising radiation. Instead there was a significant reduction in the proportion 
of DSB repaired by the fast kinetic pathway. For example, at half hour post - 
irradiation with 30 Gy, just 5% of the initial amount of DNA DSBs had been 
rejoined (compared to 60% for the control cell lines). 
Cell line LB0004 was derived from a patient who had a FIGO stage TB 
primary squamous cell carcinoma of the cervix diagnosed at age 43 years. Two years 
following a conventional protocol of radiotherapy, she developed vesico -vaginal and 
ileo- vesical fistulae. The in -vitro findings are similar to LB0003. The cell line 
showed in -vitro sensitivity to radiation with an SF2 of 0.1992. There was a 
significant reduction in the proportion of DSB repaired by the fast kinetic pathway. 
Like LB0003, at half hour post -irradiation with 30 Gy, just 5% of the initial amount 
of DNA DSBs had been rejoined (compared to 60% for the control cell lines). 
Both these cell lines had significantly reduced DNA -PK activity as measured 
in- vitro: LB0003 by 2.5 -8 fold and LB0004 by 3 -10 fold compared to control cell 
lines. In both LB0003 and LB0004, the expression of all three components of the 
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DNA -PK heterotrimer as well as of XRCC4 and DNA ligase IV, by western blot, 
was normal. The G1 /S response to ionising radiation as measured by p53 up- 
regulation was intact and both cell lines expressed ATM. 
Other groups have examined the correlation between DNA -PK activity and 
radiosensitivity using human material. There is conflicting evidence utilising tumour 
cell lines. Three groups have found a very strong correlation between double -strand 
break rejoining, radiosensitivity and DNA -PK activity in 5 lung cancer cell lines 
(Sirzen F et al., 1999) and in 2 squamous cell cancer cell lines (Polischouk AG et al., 
1999), and between radiosensitivity and DNA -PK activity in 14 oesophageal cancer 
cell lines (Zhao HJ et al., 2000). In contrast one group reported no correlation 
between DNA -PK activity and radiosensitivity in 9 glioma cell lines (Allalunis -Turner 
J et al., 1995). This may indicate that other factors are more important in determining 
radiosensitivity in gliomas, which clinically are highly radioresistant. Decreased 
DNA -PK activity was also observed in 6 human cancer cell lines exhibiting low -dose 
radiation hypersensitivity (Vaganay -Juery S et al., 2000). Two studies could not 
relate DNA -PK activity to radiosensitivity when this was assayed in fibroblasts 
(Kasten U et al., 1999; Carlomagno F et al., 1999). In aggregate, these various 
studies suggest that DNA -PK activity may be an important factor affecting 
radiosensitivity in humans, but with cell type -specific variation. 
One group has examined NHEJ enzyme expression, as well as activity, in 
relation to late radiation injury (Carlomagno F et al., 1999). They reported that there 
was no correlation between expression and activity of the NHEJ enzymes DNA - 
PKcs, Ku70, Ku80, XRCC4 and DNA ligase IV, and the homologous recombination 
enzyme rad51 and the risk of developing severe telangiectasia. An early study in this 
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field reported clinical evidence that there were different determinants of specific 
biological endpoints (Bentzen SM et al., 1993). The absence of a relationship 
between DNA repair enzyme activity and clinical response in this series may have 
reflected the choice of a clinical endpoint to which these activities did not contribute, 
and may not apply to other, particularly necrosis -related, endpoints. 
The reduced DNA -PK activity we have observed in the 2 EBV- immortalised 
cell lines does not seem to be an artefact of transformation or of previous 
radiotherapy. Normal levels of DNA -PK activity were seen in the 2 control EBV- 
transformed cell lines (Macsi and Wales) and the other newly derived cell lines 
(LB0001, LB0002, LB0005 and LB0005) we have examined. Four of these were 
derived from patients who had received radiotherapy previously. 
No humans with a DNA -PKcs or Ku null phenotype have been described to 
date. While the two cell lines described here exhibit substantially reduced DNA -PK 
activity, both do have some residual function and express all 3 protein components of 
DNA -PK. It is possible that this reduced level of activity is sufficient for function 
under normal conditions, but insufficient to deal with the extent of DNA repair 
required following radiotherapy. Indeed while transgenic mice null for DNA -PKcs 
are viable, animal models have suggested that with increasing size of the mammalian 
species, the expression of DNA -PK activity in normal fibroblasts increases and the 
SCID phenotype in affected animals becomes correspondingly more severe (Meek K 
et al., 2001). It is possible that a germ -line DNA -PKcs null phenotype is not 
compatible with viability in humans. 
Our limited, preliminary sequencing analysis (Chapter 5.2) did not reveal any 
sequence variation from published databases but we cannot on the current evidence 
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exclude mutations or polymorphisms within the genes encoding one of the 3 DNA - 
PK subunits, affecting either protein -protein interactions, DNA -binding or the kinase 
activity. Indeed, polymorphisms in certain DNA repair genes have been found to 
correlate with the risk of severe normal tissue morbidity (Severin DM et al., 2001; 
Andreassen CN et al., 2003). Future work would involve, in the first instance, 
sequencing to exclude missense mutation of polymorphisms in the DNA -PKcs gene. 
7.2 LB0005 
Cell line LB0005 was derived from a patient who had a FIGO stage IIIB 
primary squamous cell carcinoma of the cervix diagnosed at age 40 years. Two years 
following a conventional protocol of radiotherapy, she developed a recto -vaginal 
fistula. We were unsuccessful with obtaining in -vitro radiation sensitivity data for 
LB0005 using our proliferation assay. The assay was performed in 96 well plates at 
4 -5 days post -irradiation to allow for recovery of exponential growth in the irradiated 
cell populations; after irradiation, LB0005 cells were not able to survive in culture in 
the 96 well plates for that period of time. We plan to use an assay for apoptosis to 
test in -vitro sensitivity of LB0005 to ionising radiation. Apoptosis in lymphoblastoid 
cell lines has been measured at 24 -48h (Takagi M et al., 1998; Crompton NEA et 
al.,1999) post -irradiation and LB0005 should be able to survive for this period in 
culture. 
The in -vitro DNA -PK activity in LB0005 was not significantly different from 
that in normal controls and there was normal expression of all three sub -units of 
DNA -PK and of XRCC4 and DNA ligase IV. 
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LB0005 was the only cell line in the study to demonstrate reduced p53 up- 
regulation in response to ionising radiation. It also expressed normal levels of ATM 
of the expected weight and a degree of conversion to hypophosphorylated pRb after 
ionising radiation exposure indicating that Gl /S arrest post- radiation is not absent. 
Cell cycle progression following ionising radiation needs to be examined using flow 
cytometry to confirm an abnormal G1 /S response that is suggested by the reduced 
p53 up- regulation and to quantify the fraction of cells that do arrest at G1. In addition 
G2/M and S -phase checkpoints post -irradiation need to be examined both using flow 
cytometry and by immunoblotting for phospho -proteins that are phosphorylated in an 
ATM dependent manner. These proteins would include CDC25C which is involved 
in the G2 /M checkpoint and NBS1 which is involved in the intra -S checkpoint 
(Shiloh Y, 2003). 
Certainly if all three checkpoints are found to be compromised in response to 
ionising radiation, then mutations or polymorphisms in ATM that are associated with 
production of full length message and stable protein could still be the underlying 
abnormality in LB0005. Sequencing of ATM gene would then be required. Angele et 
cil reported that LCLs, from radiosensitive breast cancer patients, containing ATM 
polymorphism exhibited a lower p53 induction when compared with normal controls 
(Angele S et al., 2003). Similarly Takagi et al found that ATM -dependent DNA 
damage responses, including serine 15 phosphorylation of p53, was abnormal in 
LCLs with single nucleotide variant ATM from paediatric patients with Hodgkin 
Disease (Takagi M et al., 2004). 
Alternative molecular defect /s could also account for the abnormality in 
LB0005 especially if the flow cytometry and other experiments discussed above 
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reveal that the defect involves the G1 /S checkpoint alone. For example, Dikomey et 
al recently described a molecular mechanism of radiosensitivity in human fibroblasts 
that impaired both DNA DSB rejoining and G1 /S arrest following ionising radiation 
(Dikomey E et al., 2003b). This was not due to defects in DNA -PK and they have yet 
to pin down the underlying genetic or biochemical abnormality; the same 
abnormality may underlie the defect in LB0005. 
7.3 LB0002 and LB0006 
LB0002 was derived from a patient who presented with early onset breast 
cancer at age 38 years and was treated by lumpectomy and adjuvant radiotherapy 
without systemic chemotherapy. She received 40 Gy in 10 fractions over 25 days 
were prescribed using external beam treatment followed by 42 Gy delivered by low 
dose -rate (0.46 Gy per hour) brachytherapy. She developed skin necrosis 14 years 
later. Although this may have arisen from the large doses delivered, the cell line did 
demonstrate in -vitro sensitivity to radiation that was less pronounced than that of 
LB0003 and LB0004 with an SF2 of 0.2758. Apart from an increased in -vitro 
radiation sensitivity, there were no abnormal findings in this study. DNA -PK 
activity was not significantly different from the control cell lines and the expression 
of Ku70, Ku80, DNA -PKcs, XRCC4 and DNA ligase IV were all normal. Future 
work for this cell line could include testing for DNA ligase IV /XRCC4 activity using 
an adenylation assay (Riballo E et al., 1999). 
ATM expression and p53 up- regulation following ionizing radiation 
were both normal. Cell cycle progression following ionising radiation by flow 
cytometry especially for the G2 /M and S -phase blocks need to be investigated since 
this study only focussed on the ATM dependent G1 /S arrest. Finally another 
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potential plan of investigation could be into the role played by both BRCA1, BRCA2 
and rare variants of XRCC2 and XRCC3in this patient with early onset breast cancer 
( Rafíi S et al., 2002; Kuschel K et al., 2002). 
LB0006 was derived from a patient who presented with early onset breast 
cancer at age 38 years and was treated by mastectomy and adjuvant radiotherapy 
(without systemic chemotherapy), receiving 44 Gy in 10 fractions over 26 days. She 
developed necrosis of the ipsilateral 4th and 5th ribs 2 years later. The cell line 
displayed the same level of cellular sensitivity as the controls with an SF2 of 0.3787. 
One reason for this is that factors other than cellular sensitivity may account for the 
rib necrosis sustained by the patient (Marcou Y et al., 2001). No abnormal in -vitro 
findings were found in LB0006 in this study. 
Previous reports of increased clinical radiosensitivity in AT, ATLD, NBS and 
180BR (Plowman PN et al., Badie C et al., 1995) have been associated with extreme, 
and often fatal, radiosensitivity, and in the first 3 with very rare syndromes with 
underlying neurological and immunological abnormalities (Gotoff SP et al., 1967; 
Taalman RD et al., 1983; Stewart GS et al., 1999). The patients from whom we have 
derived these cell lines were clinically normal before radiotherapy, in particular had 
no evidence of neurological or immunological abnormality, other than to have 
developed a cancer at a relatively early age. They have exhibited comparatively 
milder degree of increased radiosensitivity, with radiation injury occurring many 
years after treatment, rather than requiring its cessation. 
As the incidence of cancer continues to rise, the use of ionising radiation will 
continue to increase and so to the need to try and identify patients who are at risk of 
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radiation injury. In contra -distinction to the single gene disorders that cause the 
clinical syndromes described above, it has been postulated that these more typical 
cases of increased clinical radiosensitivity arising in non -syndromic cancer patients 
may be a complex trait (Andreassen CN et al., 2002). If so, then future predictive 
testing may include a battery of tests rather than a single one. In this study, 3 of 5 cell 
lines established from patients with late radionecrosis revealed biochemical 
abnormalities. Although the precise biochemical abnormality has not been 
determined for any of the cell lines in this study, continued investigation should add 
to an understanding of the molecular mechanisms underlying normal tissue 
radiosensitivity. There should be continued establishment and investigation of more 
cell lines along the lines pursued in this work. Then taken with work performed in 
other laboratories and in collaborations such as the GENEPI project by ESTRO, a 
battery of tests may yet be developed for predictive testing. 
160 
References: 
Abadir R and Hakami N. Ataxia Telangiectasia with cancer. An indication for reduced 
radiotherapy and chemotherapy doses. Br. J. Radio!. (1983) 56:343 -345 
Abbe R. The use of radium in malignant disease. Lancet (1913) ii : 524 -527 
Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2 /M and the 
G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. 
Proc. Natl. Acad. Sci. USA. (1995) 92:8493 -8497 
Alapetite C, Thirion P, de la Rochefordiere A, Cosset JM, Moustacchi E. Analysis 
by alkaline comet assay of cancer patients with severe reactions to radiotherapy: 
defective rejoining of radioinduced DNA strand breaks in lymphocytes of breast cancer 
patients. Int. J. Cancer (1999) 83:83 -90 
Allalunis- Turner J, Lintott LG, Barron GM, Day RS, Lees -Miller SP. Lack of 
correlation between DNA -dependent protein kinase activity and tumour cell 
radiosensitivity. Cancer Res. (1995) 55:5200 -5202 
Allalunis- Turner J, Zia PK, Barron GM, Mirzayans R, Day RS 3rd. Radiation - 
induced DNA damage and repair in cells of a radiosensitive human glioma cell line. 
Radiat. Res. (1995a) 144: 288 -293 
Alsbeih G, Malone S, Lochrin C, Girard A, Fertil B, Raasphorst GP. Correlation 
between normal tissue complications and in vitro radiosensitivity of skin fibroblasts 
derived from radiotherapy patients treated for a variety of tumors. Int. J. Radiat. Oncol. 
Biol. Phys . (2000) 46:143 -152 
Alter BP. Radiosensitivity in Fanconi's anemia patients. Radiother. Oncol. (2002) 
62:345 -347 
Anderson CW, Dunn JJ, Freimuth PI, Galloway AM, Allalunis- Turner MJ. 
Frameshift mutation in PRKDC, the gene for DNA -PKcs, in the DNA repair- defective, 
human, glioma- derived cell line M059J. Radiat. Res. (2001) 156:2 -9 
Andrea AD and Grompe M. The Fanconi Anaemia /BRCA pathway. Nat. Rev. Cancer 
(2003) 3:23 -34 
Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions 
after radiotherapy have a genetic basis - where and how to look for it? Radiother. 
Oncol. (2002) 64: 131 -140 
161 
Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue 
radiosensitivity form polymorphisms in candidate genes. Radiother. Oncol. (2003) 
69:127-135 
Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M et al. ATM 
haplotypes and cellular response to DNA damage: association with breast cancer risk 
and clinical radiosensitivity. Cancer Res. (2003) 63:8717 -8725 
Appleby JM, Barber JBP, Levine E, Varlry JM, Taylor AM, Stankovic T et al. 
Absence of mutations in the ATM gene in breast cancer patients with severe responses 
to radiotherapy. Br. J. Cancer (1997) 76:1546 -1549 
Aurias A, Antoine JL, Assathiany R, Odievre M, Dutrillaux B. Radiation sensitivity 
of Bloom's syndrome lymphocytes during S and G2 phases. Cancer Genet. Cytogenet. 
(1985) 16:131 -136 
Badie C, Iliakis G, Foray N, Alsbeih G, Pantellias GE, Okayasu R et al. Defective 
repair of DNA double - strand breaks and chromosome damage in fibroblats from a 
radiosensitive leukaemia patient. Cancer Res. (1995) 55:1232 -1234 
Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular 
autophosphorylation and dimer dissociation. Nature (2003) 421:499 -506 
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L et al. Enhanced 
phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 281:1674- 
1677 
Barber JBP, Burrill W, Spreadborough AR, Levine E, Warren C, Kiltie AE et al. 
Relationship between in vitro chromosomal radiosensitivity of peripheral blood 
lymphocytes and the expression of normal tissue damage following radiotherapy for 
breast cancer. Radiother. Oncol. (2000) 55:179 -186 
Barillot I, Horiot JC, Maingon P, Truc G, Chaplain G, Comte J, et al. Impact on 
treatment outcome and late effects of customized treatment planning in cervix 
carcinomas: baseline results to compare new strategies. Int. J. Radiat. Oncol. Biol. Phy. 
(2000) 48:189 -200 
Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the 
gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr. Biol. (1998) 
8:1395 -1398 
Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, Fleming JC et al. Increased 
ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. 
Proc. Natl. Acad. Sci. USA. (2002) 99:8173 -8178 
162 
Baumann M, Bentzen SM. Clinical manifestations of normal- tissue damage. In Basic 
clinical radiobiology. Editor Steel GG. Arnold 3id Edition (2002) page 105 -119 
Baumann M, Holscher T, Begg AC. Towards genetic prediction of radiation responses: 
ESTRO's GENEPI project. Radiother. Oncol. (2003) 69:121 -125 
Baumann P, West SC. DNA end joining catalyzed by human cell -free extracts. Proc. 
Natl. Acad. Sci. USA. (1998b) 95:14066 -14070 
Baumann P, West SC. Role of the human RAD51 protein in homologous 
recombination and double- stranded -break repair. Trends Biochem. Sci. (1998a) 23:247- 
251 
Beamish H, Lavin MF. Radiosensitivity in ataxia -telangiectasia: anomalies in radiation - 
induced cell cycle delay. Int. J Radiat. Biol. (1994) 65:175 -184 
Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, Peng C et al. Functional link 
between BLM defective in Bloom's syndrome and the ataxia -telangiectasia- mutated 
protein, ATM. J. Biol. Chem. (2002) 277:30515- 30523. 
Bentzen SM. Potential clinical impact of normal tissue intrinsic radiosensitivity testing. 
Radiother. Oncol. (1997) 43:121 -131 
Bentzen SM and Hendry JH. Variability in the radiosensitivity of normal cells and 
tissues. Report from a workshop organised by the European Society for Therapeutic 
Radiology and Oncology in Edinburgh, UK, 19 September 1998. Int. J. Radiat. Biol. 
(1999) 75:513 -517 
Bentzen SM, Overgaard M, Overgaard J. Clinical correlations between late normal 
tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. 
Eur. J. Cancer (1993) 29A:1373 -1376 
Bezzubova O, Shinohara A, Mueller RG, Ogawa H, Buerstedde JM. A chicken 
RAD51 homologue is expressed at high levels in lymphoid and reproductive organs. 
Nucleic Acids Res. (1993) 7:1577 -1580 
Bezzubova O, Silbergleit A, Yamaguchi -Iwai Y, Takeda S, Buerstedde JM. Reduced 
X -ray resistance and homologous recombination frequencies in a RAD54 -/- mutant of 
the chicken DT40 cell line. Cell (1997) 89:185 -193 
Biedermann KA, Sun JR, Giaccia AJ, Tosto LM, Brown JM. scid mutation in mice 
confers hypersensitivity to ionizing radiation and a deficiency in DNA double- strand 
break repair. Proc. Natl. Acad. Sci. USA (1991) 88:1394 -1397 
163 
Bigelow SB, Rary JM, Bender MA. G2 chromosomal radiosensitivity in Fanconi's 
anemia. Mutat. Res. (1979) 63:189 -199 
Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J. Regulation and 
localization of the Bloom syndrome protein in response to DNA damage. J. Cell Biol. 
(2001) 153:367 -380 
Bjork -Eriksson T, West CM, Karlson E, Slevin NJ, Davidson SE, James RD et al. 
The in vitro radiosensitivity of human head and neck cancers. Br. J. Cancer (1998) 
77:2371 -2375 
Blunt T, Finnie NJ, Taccioli GE, Smith GC, Demengeot J, Gottlieb TM et al. 
Defective DNA -dependent protein kinase activity is linked to V(D)J recombination and 
DNA repair defects associated with the murine scid mutation. Cell (1995) 80:813 -823 
Borgmann K, Roper B, El -Awady RA, Brackrock S, Bigalke M, Dork T et al. 
Indicators of late normal tissue response after radiotherapy for head and neck cancer: 
fibroblasts, lymphocytes, genetics, DNA repair and chromosome aberrations. Radiother. 
Oncol. (2002) 64:141 -152 
Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in 
the mouse. Nature (1983) 301:527 -530 
Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein -dye binding. Anal. Biochem. 
(1976) 72:248 -254 
Bradley MO, Erickson LC. Comparison of the effects of hydrogen peroxide and x -ray 
irradiation on toxicity, mutation, and DNA damage /repair in mammalian cells (V -79). 
Biochim Biophys Acta. (1981) 654:135 -141 
Brand MA, Kerr GR. The results of treatment of carcinoma of the uterine cervix using 
a linear vaginal source and 4 MV X rays. Br. J. Radiol. (1982) 55:352 -355 
Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica -Worms H et ah A human Cds 1- 
related kinase that functions downstream of ATM protein in the cellular response to 
DNA damage. Proc. Natl. Acad. Sci. USA. (1999) 96:3745 -3750 
Brenneman Ma, Weiss AE, Nickoloff JA, Chen DJ. XRCC3 is required for efficient 
repair of chromosome breaks by homologous recombination. Mutat. Res. (2000) 459:89- 
97 
Brock WA, Tucker SL, Geara FB, Turesson I, Wike J, Nyman J et al. Fibroblast 
radiosensitivity versus acute and late normal skin responses in patients treated for breast 
cancer. Int. J. Radiat. Oncol. Biol. Phys. (1995) 32: 1371 -1379 
164 
Brock WA and Tucker SL. In vitro radiosensitivity and normal tissue damage. 
Radiother. Oncol.(2000) 55:93 -94 
Brown KD, Ziv Y, Sadanandan SN, Chessa L, Collins FS, Shiloh Y et al. The ataxia - 
telangiectasia gene product, a constitutively expressed nuclear protein that is not up- 
regulated following genome damage. Proc. Natl. Acad. Sci. USA. (1997) 94:1840 -1845 
Burma S, Kurimasa A, Xie G, Taya Y, Araki R, Abe M et al. DNA- dependent 
protein kinase -independent activation of p53 in response to DNA damage. J. Biol. Chem. 
(1999) 274:17139 -17143 
Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone 
I-I2AX in response to DNA double- strand breaks. J. Biol. Chem. (2001) 276:42462- 
42467 
Burnet NG, Nyman J, Turesson I, Wurm R, Yarnold JR, Peacock JH. Improving 
radiotherapy cure rates by predicting normal tissue tolerance from in vitro cellular 
radiation sensitivity. Lancet (1992) 339:1570 -1571 
Burnet NG, Nyman J, Turesson I, Wurm R, Yarnold JR, Peacock JH. The 
relationship between cellular radiation sensitivity and tissue response may provide the 
basis for individualising radiotherapy schedules. Radiother. Oncol. (1994) 33:228 -238 
Burnet NG, Wurm R, Tait DM, Peacock JH. Cellular sensitivity and low dose -rate 
recovery in Fanconi anaemia fibroblasts. Br. J. Radiol. (1994) 67:579 -83 
Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH. Describing patients' 
normal tissue reactions: concerning the possibility of individualising radiotherapy dose 
prescriptions based on potential predictive assays of normal tissue radiosensitivity. Int. J 
Cancer (Fred. Oncol.)(1998) 79:606 -613 
Busch D. Genetic susceptibility to radiation and chemotherapy injury : Diagnosis and 
management. Int. J Radiat. Oncol. Biol. Phys .(1994) 30:997 -1002 
Canman CE, Lim D -S., Cimoprich KA, Taka Y, Tamai K, Sakaguchi K et al. 
Activation of the ATM kinase by ionizing radiatin and phosphorylation of p53. Science 
(1998) 281:1677 -1679 
Carlomagno F, Burnet NG, Turesson I, Nyman J, Peacock JH, Dunning AM et al. 
Comparison of DNA repair protein expression and activities between human fibroblast 
cell lines with different radiosensitivities. Int. J Cancer (2000) 85:845 -849 
165 
Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd et aL The 
hMrel1 /hRad50 protein complex and Nijmegen breakage syndrome: linkage of double - 
strand break repair to the cellular DNA damage response. Cell (1998) 93:477 -486 
Carson CT, Schwartz, Stracker TH, Lilley CE, Lee DW, Weitzman MD. The Mrel l 
complex is required for ATM activation aand the G2 /M checkpoint. EMBO J. (2003) 
20:6610 -6620 
Celeste A, Petersen S, Romanienko PJ, Fernandez -Capetillo, Chen HT, 
Sedelnikova OA et al. Genomic instability in mice lacking histone H2AX. Science 
(2002) 296:922 -927 
Chan DW, Gately DP, Urban S, Galloway AM, Lees -Miller SP, Yen T et al. Lack of 
correlation between ATM protein expression and tumour cell radiosensitivity. Int. J. 
Radiat. Biol. (1998) 74:217 -224 
Chan DW, Chen BPC, Prithivirajsingh S, Kurimasa A, Story MD, Qin J et al. 
Autophosphorylation of the DNA -dependent protein kinase catalytic subunit is required 
for rejoining of DNA double- strand breaks. Genes Dev. (2002) 16:2333 -2338 
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14- 3- 3Sigma is 
required to prevent mitotic catastrophe after DNA damage. Nature (1999) 401:616 -620 
Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR et al. 
Mammalian Chk2 is a downstream effector of the ATM -dependent DNA damage 
checkpoint pathway. Oncogene (1999) 18:4047 -4054 
Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser -20 
mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U 
SA. (1999) 96:13777 -13782 
Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCdsl functions as a DNA 
damage checkpoint in G(1) by stabilizing p53. Genes Dev.(2000)14:278 -288 
Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G et al. Stable 
interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in 
mitotic and meiotic cells. Mol Cell. (1998) 2:317 -328 
Chen L, Trujillo K, Sung P, Tomkinson AE. Interactions of the DNA ligase IV- 
XRCC4 complex with DNA ends and the DNA -dependent protein kinase. J. Biol. Cheat. 
(2000) 275:26196 -26205 
Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in 
BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate 
treatment. Proc. Natl. Acad. Sci. USA. (1998) 95:5287 -5292 
166 
Chu G. Double Strand Break Repair. J. Biol. Chem. (1997) 272:24097 -24100 
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML et al. 
Thymocyte apoptosis induced by p53- dependent and independent pathways. Nature 
(1993) 362:849 -852 
Clarke RA, Goozee GR, Birrell G, Fang ZM, Hasnain H, Lavin M et al. Absence of 
ATM truncations in patients with severe acute radiation reactions. Int. J. Radiat. Oncol. 
Biol. Phys. (1998) 41:1021 -1027 
Constantinou A, Davies AA, West SC. Branch migration and Holliday junction 
resolution catalyzed by activities from mammalian cells. Cell. (2001) 104:259 -268 
Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM- dependent 
phosphorylation of brcal in the DNA damage response to double - strand breaks. Science. 
(1999) 286:1162 -1166 
Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double -strand break repair 
protein XRCC4 interacts with DNA ligase IV. Curr. Biol. (1997) 7:588 -598 
Cromie GA, Connelly JC, Leach DRF. Recombination at double -strand breaks and 
DNA ends: conserved mechanisms from phage to humans. Mol. Cell (2001) 8:1163- 
1174 
Crompton NE, Miralbell R, Rutz HP, Ersoy F, Sanal O, Weltmann D et al. Altered 
apoptotic profiles in irradiated patients with increased toxicity. Int. J. Radiat. Oncol. 
Biol. Phys. (1999) 45:707 -714 
D'Amours D, Jackson SP. The Mrell complex: at the crossroads of DNA repair and 
checkpoint signalling. Nat.Rev.Mol. Cell Biol. (2002) 3:317 -327 
Dai Y, Kysela B, Hanakahi LA, Manolis K, Ribalto E, Stumm M et al. 
Nonhomologous end joining and V(D)J recombination require an additional factor. 
Proc. Natl. Acad. Sci. USA. (2003) 100:2462 -2467 
Danska JS, Holland DP, Mariathasan S, Williams KM, Guidos CJ. Biochemical and 
genetic defects in the DNA -dependent protein kinase in murine scid lymphocytes. Mol. 
Cell Biol. (1996) 16:5507 -5517 
Davies AA, Masson JY, Mcllwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR 
et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. 
Mol. Cell. (2001) 7:273 -282 
Deans B, Griffin CS, Maconochie M, Thacker J. Xrcc2 ie required for genetic 
stability, embryonic neurogenesis and viability in mice. EMBO J. (2000) 6675 -6685 
167 
Denton AS, Bond SJ, Matthews S, Bentzen SM, Maher EJ and the UK Link 
Gynaecology -Oncology Group. National audit of the management and outcome of 
carcinoma of the cervix treated with radiotherapy in 1993. Clin. Oncol. (2002) 12:347- 
353 
DeFazio LG, Stansel RM, Griffith JD, Chu G. Synapsis of DNA ends by DNA - 
dependent protein kinase. EMBO J. (2002) 21(12):3192 -3200 
DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ Jr, Iliakis G. DNA -dependent 
protein kinase stimulates an independently active, nonhomologous, end joining 
apparatus. Cancer Res. (2000) 60:1245 -1253 
Dikomey E, Borgmann K, Peacock J, Jung H. Why recent studies relating normal 
tissue response to individual radiosensitivity might have failed and how new studies 
should be performed. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56:1194 -1200 
Dikomey E, Borgmann K, Brammer I, Kasten -Pistula U. Molecular mechanisms of 
individual radiosensitivity studied in normal diploid human fibroblasts. Toxicology 
(2003b) 193:125-135 
Djuzenova CS, Rothfuss A, Oppitz U, Speit G, Schindler D, Hoehn H, et al. Response 
to X- irradiation of Fanconi anemia homozygous and heterozygous cells assessed by the 
single -cell gel electrophoresis (comet) assay. Lab. Invest. (2001) 81:185 -92. 
Dobbs J and Barrett A. Practical Radiotherapy Planning. Arnold 3rd Edition (1999) 
page 315 -316 
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS 
et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous 
tumours. Nature (1992) 356:215 -221 
Dong Z, Zhong Q, Chen PL. The Nijmegen Breakage Syndrome Protein Is Essential 
for Mrel l Phosphorylation upon DNA Damage. J. Biol. Chem. (1999) 274:19513 - 
19516 
Duckworth- Rysiecki G and Taylor AM. Effects of ionizing radiation on cells from 
Fanconi's anemia patients. Cancer Res. (1985) 45:416 -420 
Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW et al. p53- 
dependent inhibition of cyclin- dependent kinase activities in human fibroblasts during 
radiation -induced G1 arrest. Cell (1994) 76:1013 -1023 
Eastham AM, Atkinson J, West CM. Relationships between clonogenic cell survival, 
DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell 
lines. Int. J. Radiat. Biol. (2001) 77:295 -302 
168 
el -Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J 
et al. WAFT /0P1 is induced in p53- mediated G1 arrest and apoptosis. Cancer Res. 
(1994) 54:1169 -1174 
Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late 
complications in patients treated with radiation therapy for FIGO stage IB carcinoma of 
the uterine cervix. Int. J. Radiat. Oncol. Biol. Phy. (1995) 32:1289 -1300 
Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J et al. Pelvic 
irradiation with concurrent chemotherapy versus pelvic and para -aortic irradiation for 
high -risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 
90 -01. J. Clin. Oncol. (2004) 22:872 -880 
Erridge SC, Kerr GR, Downing D, Duncan W, Price A. The effect of overall 
treatment time on the survival and toxicity of radical radiotherapy for cervical 
carcinoma. Radiother. Oncol. (2002) 63:59 -66 
Essers J, Hendriks RW, Swagemakers SM, Troelstra C, de Wit J, Bootsma D et al. 
Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous 
recombination. Cell (1997) 89:195 -204 
Essers J, van Steeg H, de Wit J, Swagemakers SM, Vermeij M, Hoeijmalers JHJ et 
al. Homologous and non -homologous recombination differentially affect DNA damage 
repair in mice. EMBO J (2000) 19:1703 -1710 
Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM- Chk2- Cdc25A 
checkpoint pathway guards against radioresistant DNA synthesis. Nature (2001) 
410:842 -847 
Xia F, Taghian DG, DeFrank JS, Zeng Z -C, Willers H, Iliakis G et al. Deficeincy of 
human BRCA2 leads to impaired homologous recombination but maintains normal 
nonhomologous end joining Proc. Natl. Acad. Sci. USA. (2001) 98:8644 -8649 
Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP. DNA -dependent protein 
kinase activity is absent in xrs -6 cells: implications for site -specific recombination and 
DNA double- strand break repair. Proc. Natl. Acad. Sci. USA. (1995) 92:320 -324 
Frank KM, Sekiguchi JM, Seidl KJ, Swat W, Rathbun GA, Cheng HL et al. Late 
embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. 
Nature (1998) 396:173 -177 
Fulop GM, Phillips RA. The scid mutation in mice causes a general defect in DNA 
repair. Nature (1990) 347:479 -482 
169 
Friedberg E, Walker G, Siede W. DNA repair and mutagenesis. Blackwell publishing 
(1995) page 559 
Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FA. A targeted DNA - 
PKcs -null mutation reveals DNA -PK- independent function for Ku in V(D)J 
recombination. Immunity (1998a) 9:367 -376 
Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ et al. A critical role for 
DNA end joining proteins in both lymphogenesis and neurogenesis. Cell (1998b) 
95:891 -902 
Game JC and Mortimer RK. A genetic study of X -ray sensitive mutants in yeast. 
Mutat. Res. (1974) 24:281 -292 
Garcia -Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J et al. 
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. 
Cell. (2001) 7:249 -62 
Gatei M, Young D, Cerosaletti KM, Desai -Mehta A, Spring K, Kozlov S et al. ATM - 
dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet. 
(2000) 25:115- 119Nat Genet. 2000 May;25(1):115 -119 
Gaze MN, Kelly CG, Dunlop PR, Redpath AT, Kerr GR, Cowie VJ. Stage IB 
cervical carcinoma: a clinical audit. Br. J. Radiol. (1992) 65:1018 - 1024 
Geara FB, Komaki R, Tucker SL, Travis EL, Cox JD. Factors influencing the 
development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: 
evidence for inherent interindividual variation. Int. J. Radiat. Oncol. Biol. Phys. (1998) 
41:279 -286 
Gilad S, Khosravi R, Shkedy D, Uziel T, Ziv Y Savitsky K et al. Predominance of 
null mutations in ataxia -telangiectasia. Hum. Mol. Genet. (1996) 5:433 -439 
Girard PM, Foray N, Stumm M, Waugh A, Riballo E, Maser RS et al. 
Radiosensitivity in Nijmegen Breakage Syndrome cells is attributable to a repair defect 
and not cell cycle checkpoint defects. Cancer Res. (2000) 60:4881 -4888 
Godsen CM, Davidson C and Robertson M. Human cytogenetics a practical approach. 
Rooney DE and Czepulowski BH (eds). IRL Press: Oxford (1986) pages 31 -54 
Gotoff SP, Amirmokri E, Liebner EJ. Ataxia Telangiectasia: neoplasia, untoward 
response to X- irradiation, and tuberous sclerosis. Am. J. Dis. Child. (1969) 114:617 -625 
Gottlieb TM, Jackson SP. The DNA -dependent protein kinase: requirement for DNA 
ends and association with Ku antigen. Cell (1993) 72:131 -142 
I 70 
Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M et al. Activity of 
DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian 
cells. Nature (1997) 388:492 -495 
Gu Y, Jin S, Gao Y, Weaver DT, Alt FW. Ku70- deficient embryonic stem cells have 
increased ionizing radiosensitivity, defective DNA end -binding activity, and inability to 
support V(D)J recombination. Proc. Natl. Acad. Sci. USA. (1997) 94:8076 -8081 
Hall EJ. Radiobiology for the radiologist. JB Lippincott Company 4th Edition (1994) 
pages 8 -10 
Hall EJ, Schiff PB, Hanks GE, Brenner DJ, Russo J, Chen J et al. A preliminary 
report: frequency of A -T heterozygotes among prostate cancer patients with severe late 
responses to radiation therapy. Cancer J. Sci. Am. (1998) 4:385 -389 
Hammarsten O, DeFazio LG, Chu G. Activation of DNA -dependent Protein Kinase 
by Single -stranded DNA Ends. J. Biol. Chem. (2000) 275:1541 -1550 
Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links 
ATR and p53 through replication arrest. Mol. Cell Biol. (2002) 22:1834 -1843 
Hart RM, Kimler BF, Evans RG, Park CH. Radiotherapeutic management of 
medulloblastoma in a paediatric patient with ataxia telangiectasis. Int. J. Radiat. Oncol. 
Biol. Phys. (1987) 13:1237 -1240 
Hartley KO, Gell D, Smith GCM, Zhang H, Divecha N, Connelly MA et al. DNA - 
dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3- kinase 
and the ataxia telangiectasia gene product. Cell (1995) 82:849 -856 
Heartlein MW, Tsuji H, Latt SA. 5- Bromodeoxyuridine -dependent increase in sister 
chromatid exchange formation in Bloom's syndrome is associated with reduction in 
topoisomerase II activity. Exp. Cell. Res. (1987) 169:245 -254 
Heffernan TP, Simpson DA, Frank AR, Heinloth AN, Paules RS, Cordeiro -Stone M 
et al. An ATR- and Chkl- dependent S checkpoint inhibits replicon initiation following 
UVC- induced DNA damage. Mol. Cell Biol. (2002) 22:8552 -8561 
Helleday T. Pathways for mitotic recombination in mammalian cells. Mutat. Res. 
(2003) 103-115 
Henner WD, Grunbert SM, Hazeltine WA. Sites and structure of gamma radiation - 
induced DNA strand breaks. 'Biol. Chem. (1982) 257:11750 -11754 
171 
Hernandez D, McConville CM, Stacey M, Woods CG, Brown MM, Shutt P et al. A 
family showing no evidence of linkage between ataxia telangiectasia gene and 
chromosome 11g22 -23 Journal of Medical Genetics (1993) 30:135 -140 
Herring CJ, West CM, Wilks DP, Davidson SE, Hunter RD, Berry P et al. Levels 
of the DNA repair enzyme human apurinic /apyrimidinic endonuclease (APE1, APEX, 
Ref -1) are associated with the intrinsic radiosensitivity of cervical cancers. Br. J. Cancer 
(1998) 78:1128 -1133 
Hickson ID. RecQ helicases:caretakers of the genome. Nat. Rev. Cancer (2003). 3: 169- 
178 
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H et al. DNA 
damage- induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 
287:1824 -1827 
Hoeller U, Borgmann K, Bonacker M, Kuhlmey A, Bajrovic A, Jung H et al. 
Individual radiosensitivity measured with lymphocytes may be used to predict the risk of 
fibrosis after radiotherapy for breast cancer. Radiother. Oncol. (2003) 69:137 -144 
Hoffmann ME, Mello -Filho AC, Meneghini R. Correlation between cytotoxic effect of 
hydrogen peroxide and the yield of DNA strand breaks in cells of different species. 
Biochim. Biophys. Acta. (1984) 781:234 -238 
Hoppe BS, Jensen RB, Kirchgessner CU. Complementation of the radiosensitive 
M059J cell line. Radiat. Res. (2000) 153:125 -130 
Houldsworth J, Lavin MF. Effect of ionizing radiation on DNA synthesis in ataxia 
telangiectasia cells. Nucleic Acids Res. (1 980) 8:3709 -3720 
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die -Smulders C et al. 
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 297:606 -609 
Huang J and Dynan WS. Reconstitution of the mammalian DNA double- strand break 
end joining reaction reveals a requirement for an Mrel l /Rad50/NBS1- containing 
fraction. Nucleic Acids Res. (2002) 30:667 -674 
Ianuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in 
female breast cancer patients predict for an increase in radiation -induced late reactions. 
Int. J. Radiat. Oncol. Biol. Phys. (2002) 52:606 -613 
Iliakis G. The role of DNA double strand breaks in ionizing radiation- induced killing of 
eukaryotic cells. Bioessays. (1991) 13:641 -648 
172 
Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells 
exposed to ionizing radiation. Oncogene. (2003) 22:5834 -5847 
Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G et al. Identification of 
germline missense mutations and rare allelic variants in the ATM gene in early -onset 
breast cancer. Genes Chromosomes Cancer. (1999) 26:286 -294 
Jackson SP. Sensing and repairing DNA double- strand breaks. Carcinogenesis (2002) 
23:687 -696 
Jeggo PA, Carr AM, Lehmann AR. Splitting the ATM: distinct repair and checkpoint 
defects in ataxia -telangiectasia. Trends Genet. (1998) 14:312 -316 
Jhappan C, Morse HC 3rd, Fleischmann RD, Gottesman MM, Merlino G. DNA - 
PKcs: a T -cell tumour suppressor encoded at the mouse scid locus. Nat. Genet. (1997) 
17:483 -486 
Jhappan C, Yusufzai TM, Anderson S, Anver MR, Merlino G. The p53 response to 
DNA damage in vivo is independent of DNA dependent protein kinase. Mol. Cell Biol. 
(2000) 20:4075 -4083 
Jimenez GS, Bryntesson F, Torres -Arzayus MI, Priestley A, Beeche M, Saito S et al. 
DNA -dependent protein kinase id not required for the p53- dependent response to DNA 
damage. Nature (1999) 400:81 -83 
Johansen J, Bentzen SM, Overgaard J, Overgaard M. Evidence for a positive 
correlation between in vitro radiosensitivity of normal human skin fibroblasts and the 
occurrence of subcutaneous fibrosis after radiotherapy. Radiother. Oncol. (1994) 
40:101 -109 
Johansen J, Bentzen SM, Overgaard J, Overgaard M. Relationship between the in 
vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, 
telangiectasia and skin erythema after radiotherapy. Radiother. Oncol. (1996) 40: 101- 
109 
Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA 
double- strand breaks by homologous recombination. Nature (1999) 397 -399 
Johnson RD and Jasin M. Sister chromatid gene conversion is a prominent double - 
strand break repair pathway in mammalian cells. EMBO J. (2000) 19:3398 -3407 
Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr. 
Opin. Chem. Biol. (1999) 3:77 -83 
173 
Jones NJ, Cox R, Thacker J. Isolation and cross -sensitivity of X- ray- sensitive mutants 
of V79 -4 hamster cells. Mutat. Res. (1987) 183:279 -286 
Kagan AR. The importance of genetics for the optimization of radiation therapy. Am. J. 
Clin. Oncol. (CCT) (1988) 11:84 -88 
Karran P. DNA double strand break repair in mammalian cells. Cuir. O ¡yin. Genet. 
Del). (2000) 10:144 -150 
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of 
p53 protein in the cellular response to DNA damage. Cancer Res. (1991) 51(23 Pt 
1):6304 -6311 
Kastan MB, Zhan Q, el -Deiry WS, Carrier F, Jacks T, Walsh WV et al. A 
mammalian cell cycle checkpoint pathway utilising p53 and GADD 45 is defective in 
ataxia -telangiectasia. Cell (1992) 71:587 -597 
Kasten U, Plottner N, Johansen J, Overgaard J, Dikomey E. Ku70 /80 gene 
expression and DNA -dependent protein kinase (DNA -PK) activity do not correlate with 
double- strand break (dsb) repair capacity and cellular radiosensitivity in normal human 
fibroblasts. Br. J. Cancer (1999) 79:1037 -1041 
Kearsley JH, Fang ZM, Clarke RA. Clinical radiohypersensitivity screening using 
radiation -induced chromosomal aberrations. Australas. Radiol. (1998) 42:219 -221 
Khanna KK, Lavin M. Ionizing radiation and UV induction of p53 protein by different 
pathways in ataxia -telangiectasia cells. Oncogene (1993) 8:3307 -3312 
Khanna KK, Beamish H, Yan J, Hobson K, Williams R, Dunn I et al. Nature of 
G1 /S cell cycle checkpoint defect in ataxia -telangiectasia. Oncogene (1995) 11:609 -618 
Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K et al. ATM 
associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 
(1998) 20:398 -400 
Khanna KK and Jackson SP. DNA double - strand breaks: signaling, repair and the 
cancer connection. Nat. Genet. (2001) 27:247 -254 
Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM - 
dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA 
damage. Proc. Natl. Acad. Sci. USA. (1999) 96:14973 -14977 
174 
Kiltie A, Orton C, Ryan A, Roberts S, Marples B, Davidson S et al. A correlation 
between residual DNA double- strand breaks and clonogenic measurements of 
radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. Int. J. Radiat. 
Oncol. Biol. Phys. (1997) 39:1137 -1144 
Kiltie AE, Ryan AJ. SYBR Green I staining of pulsed field agarose gels is a sensitive 
and inexpensive way of quantitating DNA double -strand breaks in mammalian cells. 
Nucleic Acids Res. (1997) 25:2945 -2946 
Kim ST, Xu B, Kastan MB. Involvement of the cohesin protein, Smcl, in Atm - 
dependent and independent responses to DNA damage. Genes Dev. (2002) 16:560 -570 
Kirchgessner CU, Patil CK, Evans JW, Cuomo CA, Fried LM, Carter T et al. 
DNA -dependent kinase (p350) as a candidate gene for the murine SCID defect. (1995) 
267:1178 -1183 
Kobayashi J, Tauchi H, Sakamoto S, Nakamura A, Morishima K, Matsuura S et al. 
NBS 1 localizes to gamma -H2AX foci through interaction with the FHA/BRCT domain. 
Curr. Biol. (2002) 12:1846 -1851 
Kojis TL, Schreck RR, Gatti RA, Sparkes RS. Tissue specificity of chromosomal 
rearrangements in ataxia -telangiectasia. Hum. Genet. (1989) 83:347 -352 
Kowalczykowski SC. Initiation of genetic recombination and recombination -dependent 
replication. Trends Biochem. Sci. (2000) 25:156 -165 
Kuhn EM. Effects of X- irradiation in G1 and G2 on Bloom's Syndrome and normal 
chromosomes. Hum. Genet. (1980) 54:335 -341. 
Kurihara T, Inoue M, Tatsumi K. Hypersensitivity of Bloom's syndrome fibroblasts to 
N- ethyl -N- nitrosourea. Mutat. Res. (1987) 184:147 -151 
Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM et al. 
Variants in DNA double - strand break repair genes and breast cancer susceptibility. Hum. 
Mol. Genet. (2002) 11:1399 -1407 
Labhart, P. Nonhomologous DNA end joining in cell -free systems. Eur. J. Biochem. 
(1999) 265:849 -861 
Lakin ND, Weber P, Stankovic T, Rottinghaus ST, Taylor AM, Jackson SP. 
Analysis of the ATM protein in wild -type and ataxia telangiectasia cells. Oncogene. 
(1996) 13:2707 -2716 
175 
Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors 
associated with improved outcome in squamous cell carcinoma of the uterine cervix: a 
final report of the 1973 and 1978 patterns of care studies. Int. J. Radiat. Oncol. Biol. 
Phys. (1991) 20:667 -676 
Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin- dependent kinases 
and 14 -3 -3 sigma negatively regulates cell cycle progression. J. Biol. Chem. (2000) 
275:23106 -23112 
Leber R, Wise TW, Mizuta R, Meek K. The XRCC4 gene product is a target for and 
interacts with the DNA -dependent protein kinase. J. Biol. Chem. (1998) 273: 1794 - 
1801 
Lee JM, Bernstein A. p53 mutations increase resistance to ionising radiation. Proc. 
Natl. Acad. Sci. USA (1993) 90:5742 -5746 
Lee JS, Collins KM, Brown AL, Lee CH, Chung. hCdsl- mediated phosphorylation of 
BRCA1 regulates the DNA damage response. hCdsl- mediated phosphorylation of 
BRCA1 regulates the DNA damage response. Nature. (2000) 404:201 -204 
Lee SE, Mitchell RA, Cheng A, Hendrickson EA. Evidence for DNA -PK- dependent 
and -independent DNA double- strand break repair pathways in mammalian cells as a 
function of the cell cycle. Mol. Cell Biol. (1997) 17:1425 -1433 
Lees -Miller SP, Godbout R, Chan DW, Weinfeld M, Day RS 3rd, Barron GM et al. 
Absence of p350 subunit of DNA -activated protein kinase from a radiosensitive human 
cell line. Science (1995) 267:1183 -1185 
Lehmann AR, Arlett CF, Burke JF, Green MH, James MR, Lowe JE. A derivative 
of an ataxia -telangiectasia (A -T) cell line with normal radiosensitivity but A -T -like 
inhibition of DNA synthesis. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. (1986) 
49:639 -643 
Leuther KK, Hammarsten O, Kornberg RD, Chu G. Structure of DNA -dependent 
protein kinase: implications for its regulation by DNA. EMBO J. (1999) 18:1114 -1123 
Li GC, Ouyang H, Li X, Nagasawa H, Little JB, Chen DJ et al. Ku70: a candidate 
tumor suppressor gene for murine T cell lymphoma. Mol. Cell. (1998) 2:1 -8 
Li Z, Otevrel T, Gao Y, Cheng HL, Seed B, Stamato TD et al. The XRCC4 gene 
encodes a novel protein involved in DNA double- strand break repair and V(D)J 
recombination. Cell (1995) 83:1079 -1089 
176 
Liang F, Han M, Romanienko PJ, Jasin M. Homology- directed repair is a major 
double - strand break repair pathway in mammalian cells. Proc. Natl. Acad. Sci. USA. 
(1998) 95:5172 -5177 
Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH et al. ATM phosphorylates 
p95 /nbsl in an S -phase checkpoint pathway. Nature (2000) 404:613 -617 
Loeffler JS, Harris JR, dahlberg WK, Little JB. In vitro radiosensitivity of human 
diploid fibroblasts derived from women with unusually sensitive clinical responses to 
definitive radiation therapy for breast cancer. Radiat. Res. (1990) 12:227 -231 
Luo G, Yao MS, Bender CF, Mills M, Bladl AR, Bradley A et al. Disruption of 
mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and 
sensitivity to ionizing radiation. Proc. Natl. Acad. Sci. USA. (1999) 96:7376 -7381 
Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing 
by an Artemis /DNA -dependent protein kinase complex in nonhomologous end joining 
and V(D)J recombination. Cell. (2002) 108:781 -94 
MacKay RI, Hendry JH. The modeled benefits of individualizing radiotherapy 
patients' dose using cellular radiosensitivity assays with inherent variability. Radiother. 
Oncol. (1999) 50:67 -75 
Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J et al. Rapid 
destruction of human Cdc25A in response to DNA damage. Science (2000) 288:1425- 
1429 
Manley JL, Fire A, Samuels M, Sharp PA. In Vitro Transcription: Whole Cell Extract. 
Methods Enzymol. (1983) 101: 568 -582 
Martensson S and Hammarsten O. DNA -dependent protein kinase catalytic subunit. 
Structural requirements for kinase activation by DNA ends. J. Biol. Chem. (2002) 
277:3020 - 3029 
Marcou Y, D'Andrea A, Jeggo PA, Plowman PN. Normal cellular radiosensitivity in 
an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiother. 
Oncol. (2001) 60: 75 -79 
Matsumoto Y, Suzuki N, Namba N, Umeda N, Ma XJ, Morita A et al. Cleavage and 
phosphorylation of XRCC4 protein induced by X- irradiation. FEBS Lett. (2000) 478(1- 
2):67-71 
Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the 
Chk2 protein kinase. Science (1998) 282:1893 -1897 
177 
Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. ATM 
phospohorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA (2000) 97:10389- 
10394 
Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O et al. ATM -dependent 
phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes 
Dev. (2001) 15:1067 -1077 
McElhinny SAN, Snowden CM, McCarville J, Ramsden DA. Ku recruits the 
XRCC4- ligase IV complex to DNA ends. Mol. Cell. Biol. (2000) 20:2996 -3003 
McFarlin DE, Strober W, Waldmann TA. Ataxia -telangiectasia. Medicine (1972) 
51:281 -314 
Meek K, Kienker L, Dallas C, Wang W, Dark MJ, Venta PJ et al. SCID in Jack 
Russell terriers: a new animal model of DNA -PKcs deficiency. J. Immunol. (2001) 
167:2142 -2150 
Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for 
radiation -induced phosphorylation and activation of Cdsl. Nat. Cell Biol. (2000) 2:762- 
765 
Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. 
Characterization of a high molecular weight acidic nuclear protein recognized by 
autoantibodies in sera from patients with polymyositis- scleroderma overlap. J. Clin. 
Invest. (1981) 68:611 -620 
Mimori T, Hardin JA. Mechanism of interaction between Ku protein and DNA. J. 
Biol. Chem. (1986) 261:10375 -10379 
Mirzoeva OK, Petrini JH. DNA damage- dependent nuclear dynamics of the Mrell 
complex. Mol. Cell. Biol (2001) 21:281 -288 
Mirzayans R, Famulsld KS, Enns L, Fraser M, Paterson MC. Characterization of the 
signal transduction pathway mediating gamma ray- induced inhibition of DNA synthesis 
in human cells: indirect evidence for involvement of calmodulin but not protein kinase C 
nor p53. Oncogene (1995) 11:1597 -1605 
Monaghan J. Time to add chemotherapy to radiotherapy for cervical cancer. Lancet. 
(1999) 353:1288-1289 
Morgan JL, Holcomb TM, Morrissey RW. Radiation reaction in ataxia telangiectasia. 
Am JDis Child. (1968) 116:557 -8 
178 
Moushous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana -Calvo M, Le Deist 
F et al. Artemis, a novel DNA double -strand break repair /V(D)J recombination protein, 
is mutated in human severe combined immune deficiency. Cell (2001) 105:177 -86 
Moshous D, Pannetier C, de Chasseval R, le Deist F, Cavazzana -Calvo M, Romana 
S et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma 
in patients with hypomorphic mutations in Artemis. J. Clin. Invest. (2003) 111:381 -387 
Moynahan ME, Chiu JW, Koller BH, Jasin M. Brcal controls homology- directed 
DNA repair. Mol Cell. (1999) 4:511 -518 
Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology- directed repair 
of chromosomal breaks. Mol. Cell. (2001) 7:263 -272 
Mozumder A, Magee JL. Model of tracks of ionizing radiations for radical reaction 
mechanisms. Radiat Res. (1966) 28:203 -214 
Nagasawa H, Latt SA, Lalande ME, Little JB. Effects of X- irradiation on cell -cycle 
progression, induction of chromosomal aberrations and cell killing in ataxia 
telangiectasia (AT) fibroblasts. Mutat. Res. (1985) 148:71 -82 
Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M et al. 
Interaction of FANCD2 and NBS 1 in the DNA damage response. Nat. Cell Biol. (2002) 
4:913 -920 
Nelms BE, Maser RS, MacKay JF, Lagálly MG, Petrini JH. In situ visualization of 
DNA double- strand break repair in human fibroblasts. Science (1998) 280:590 -592 
Nevaldine B, Longo JA, Hahn PJ. The scid defect results in much slower repair of 
DNA double- strand breaks but not high levels of residual breaks. Radiat. Res. (1997) 
47:535 -540 
Nussenzweig A, Chen C, da Costa Soares V, Sanchez M, Sokol K, Nussenzweig MC 
et al. Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. 
Nature (1996) 382:551 -555 
Nussenzweig A, Sokol K, Burgman P, Li L, Li GC. Hypersensitivity of Ku80- 
deficient cell lines and mice to DNA damage: the effects of ionizing radiation on growth, 
survival, and development. Proc. Natl. Acad. Sci. USA. (1997) 94:13588 -13593 
Olive PL. The role of DNA single- and double -strand breaks in cell killing by ionizing 
radiation. Radiat Res. (1998) 150:S42 -S51 
179 
Oppitz U, Bernthaler U, Schindler D, Sobeck A, Hoehn H, Platzer M et al. Sequence 
of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue 
radiation side effects. Int. J. Radiat. Oncol. Biol. Phys. (1999) 44:981 -988 
Orton C, Ryan A, Roberts S, Marples B, Davidson S, Hunter R et al. A correlation 
between residual DNA double - strand breaks and clonogenic measurements of 
radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. Int. J. Radiat. 
Oncol. Biol. Phys. (1997) 39:1137 -1144 
Ouyang H, Nussenzweig A, Kurimasa A, Soares VC, Li X, Cordon -Cardo C et al. 
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination 
In vivo. J. Exp. Med. (1997) 186:921 -929 
Painter RB, Young BR. Radiosensitivity in ataxia -telangiectasia: a new explanation. 
Proc. Natl. Acad. Sci. USA. (1980) 77:7315 -7317 
Pagues F, Haber JE. Multiple pathways of recombination induced by double- strand 
breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. (1999) 63:349 -404 
Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ et al. 
Involvement of Brca2 in DNA repair. Mol. Cell. (1998) 1:347 -357 
Paterson MC, Anderson AK, Smith BP, Smith PJ. Enhanced radiosensitivity of 
cultured fibroblasts from ataxia telangiectasia heterozygotes manifested by defective 
colony -forming ability and reduced DNA repair replication after hypoxic gamma - 
irradiation. Cancer Res. (1979) 39:3725 -3734 
Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A 
critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA 
damage. Curr. Biol. (2000) 10:886-895 
Peacock J, Ashton A, Bliss J, Bush C, Eady J, Jackson C et al. Cellular 
radiosensitivity and complication risk after curative radiotherapy. Radiother. Oncol. 
(2000) 55:173 -178 
Pedersen D, Bentzen SM, Overgaard J. Early and late radiotherapy morbidity in 442 
consecutive patients with locally advanced carcinoma of the uterine cervix. Int. J. 
Radiat. Oncol. Biol. Phy. (1994) 29:941 -952 
Perez CA, Breaux S, Bedwinek JM, Madoc -Jones H, Camel HM, Purdy JA, et al. 
Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis 
of complications. Cancer (1984) 54:235 -246 
Peters LJ and McKay M. Predictive assays: will they ever have a role in the clinic? 
Int. J. Radiat. Oncol. Biol. Phys. (2001) 49:501 -504 
180 
Petrini JH. The mammalian Mre11- Rad50 -nbsl protein complex: integration of 
functions in the cellular DNA- damage response. Am. J. Hum. Genet. (1999) 64 :1264- 
1269 
Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology - 
directed repair of DNA damage in mammalian cells. Genes Dcv. 13:2633 -2638 
Plowman PN, Bridges BA, Arlett CF, Hinney A, Kingston JE. An instance of clinical 
radiation morbidity and cellular radiosensitivity, not associated with ataxia - 
telangiectasia. Br. J. Radio!. (1990) 63:624 -628 
Polischouk AG, Cedervall B, Ljungquist S, Flygare J, Hellgren D, Grenman R et al. 
DNA double - strand break repair, DNA -PK, and DNA ligases in two human squamous 
carcinoma cell lines with different radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 
(1999) 43:191 -198 
Price P and McMillan TJ. Use of the tetrazolium assay in measuring the response of 
human tumour cells to ionising radiation. Cancer Res. (1990) 50:1392 -1296 
Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M et al. A potential 
role for the XRCC2 R188H polymorphic site in DNA -damage repair and breast cancer. 
Hum. Mol. Genet. (2002) 11:1433 -1438 
Ramsay J, Birrell G, Lavin M. Testing for mutations of the ataxia telangiectasia gene 
in radiosensitive breast cancer patients. Radiother. Oncol. (1998) 47:125 -128 
Ramsden DA, Gellert M. Ku protein stimulates DNA end joining by mammalian DNA 
ligases: a direct role for Ku in repair of DNA double -strand breaks. EMBO J. (1998) 
17:609 -614 
Resnick MA. The repair of double- strand breaks in DNA: a model involving 
recombination. J. Thereot. Biol. (1976) 59:97 -106 
Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B et al. 
Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curt-. 
Biol. (1999) 9:699 -702 
Rijkers T, Van Den Ouweland J, Morolli B, Rolink AG, Baarends WM, Van Sloun 
PP et al. Targeted inactivation of mouse RAD52 reduces homologous recombination but 
not resistance to ionizing radiation. Mol Cell Biol. (1998) 18:6423 -6429 
Rodrigus P, De Winter K, Leers WH, Kock HCLV. Late radiotherapeutic morbidity 
in patients with carcinoma of the uterine cervix: the application of the French -Italian 
glossary. Radiother. Oncol. (1996) 40: 153 -157 
181 
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double -stranded 
breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. (1998) 
273:5858 -5868 
Rogers PB, Plowman PN, Harris SJ, Arlett CF. Four radiation hypersensitivity cases 
and their implications for clinical radiotherapy. Radiother. Oncol. (2000) 57:143 -154 
Rooney S, Sekiguchi J, Zhu C, Cheng HL, Manis J, Whitlow S et al. Leaky Scid 
phenotype associated with defective V(D)J coding end processing in Artemis -deficient 
mice. Mol Cell. (2002) 10:1379 -90 
Roth DB and Wilson JH. Relative rates of homologous and nonhomologous 
recombination in transfected DNA. Proc. Natl. Acad. Sci. USA (1985) 82:3355 -3359 
Russell NS, Grummels A, Hart AA, Smolders IJ, Borger J, Bartelink H et al. Low 
predictive value of intrinsic fibroblast radiosensitivity for fibrosis development 
following radiotherapy for breast cancer. Int JRadiat Biol. (1998) 73:661 -670 
Russell NS and Begg AC. Editorial radiotherapy and oncology 2002: predictive assays 
for normal tissue damage. Radiother. Oncol. (2002) 64:125 -129 
Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic 
factors explain most of the variation in the expression of skin telangiectasia after 
radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2002) 52:198 -204 
Sambrook, J and Russell DW. Molecular cloning: a laboratory manual. Cold Spring 
Harbor Laboratory Third edition. (2001) Volume 1 pages 5 -64 
Savitsky K, Bar -Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al. A single 
ataxia telangiectasia gene with a product similar to PI -3 kinase. Science (1995) 
268:1749 -1753 
Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, et al. Dynamic 
changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA 
damage. Cell. (1997) 90:425 -435 
Severin DM, Leong T, Cassidy B, Elsaleh H, Peters L, Venter D et al. Novel DNA 
sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int. 
J. Radiat. Oncol. Biol. Phys. (2001) 50:1323 -1331 
Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C et al. Embryonic 
lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. 
Nature (1997) 386:804 -810 
182 
Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N et al. Heterozygosity 
for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy 
complications in breast cancer patients. Br. J. Cancer. (1998) 78:922 -927 
Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L et al. A targeted disruption of 
the murine Brcal gene causes gamma -irradiation hypersensitivity and genetic instability. 
Oncogene (1998) 17:3115 -3124 
Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage- induced phosphorylation of p53 
alleviates inhibition by MDM2. Cell (1997) 91:325 -334 
Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint 
kinases Chkl and Cdsl (Chk2) phosphorylate p53 at multiple DNA damage -inducible 
sites. Genes Dev. (2000) 14:289 -300 
Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. 
Genet. Dev. (2001) 11:71 -77 
Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. 
Cancer (2003) 155 -168 
Shinohara A, Ogawa H and Ogawa T. Rad51 protein involved in repair and 
recombination in S. cerevisiae is a RecA -like protein. Cell (1992) 69:457 -470 
Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K, Ogawa T. Cloning of human, 
mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat. 
Genet. (1993) 4:239 -243 
Shinohara A and Ogawa T:: Rad51 /RecA protein families and the associated proteins 
in eukaryotes. Mutat. Res. (1999) 435:13 -21 
Siliciano JD, Canman CE, Taya T, Sakaguchi K, Appella E, Kastan MB. DNA 
damage induces phosphorylation of the amino terminus of p53 Genes Dev. (1997) 
11:3471 -3481 
Singleton BK, Torres -Arzayus MI, Rottinghaus ST, Taccioli GE, Jeggo PA. The C 
terminus of Ku80 activates the DNA -dependent protein kinase catalytic subunit. Mol. 
Cell Biol. (1999) 19:3267 -3277 
Sipley JD, Menninger JC, Hartley KO, Ward DC, Jackson SP, Anderson CW. Gene 
for the catalytic subunit of the human DNA -activated protein kinase maps to the site of 
the XRCC7 gene on chromosome 8. Proc. Natl. Acad. Sci. USA. (1995) 92:7515 -7519 
183 
Sirzen F, Nilsson A, Zhivotovsky B, Lewensohn R. DNA -dependent protein kinase 
content and activity in lung carcinoma cell lines: correlation with intrinsic 
radiosensitivity. Eur. J. Cancer (1999) 35:111 -116 
Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T et al. p53- 
dependent G1 arrest involves pRB- related proteins and is disrupted by the human 
papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA. (1994) 91:5320 -5324 
Smith GC, Cary RB, Lakin ND, Hann BC, Teo SH, Chen DJ et al. Purification and 
DNA binding properties of the ataxia -telangiectasia gene product ATM. (1999) Proc. 
Natl. Acad. Sci. USA. 96:11134 -11139 
Soubeyrand S, Pope L, Pakuts B, Hache RJ. Threonines 2638/2647 in DNA -PK are 
essential for cellular resistance to ionizing radiation. (2003) Cancer Res. 63:1198 -1201 
Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P et al. ATM 
mutations and phenotypes in ataxia -telangiectasia families in the British Isles: 
expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. 
J. Hum. Genet. (1998) 62:334 -345 
Sproston ARM, Boyle JM, Heighway J, Birch JM, Scott D. Fibroblasts from Li- 
Fraumeni patients are resistant to low dose -rate irradiation. Int. J. Radiat. Biol. (1996) 
70:145 -150 
Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG et al. The 
DNA Double- Strand Break repair Gene hMRE1 1 is Mutated in Individuals with an 
Ataxia -Telangiectasia -like Disorder. Cell (1999) 99: 577 -587 
Sun Z, Hsiao J, Fay DS, Stern DF. Rad53 FHA Domain Associated with 
Phosphorylated Rad9 in the DNA Damage Checkpoint. Science (1998) 281: 272 -274 
Szostak JW Orr -Weaver TL, Rothstein RJ, Stahl FW. The double - strand break repair 
model for recombination. Cell (1983) 33: 25 -35 
Taalman RDFM, Jaspers NGJ, Scheres, de Wit J, Hustinx TWJ. Hypersensitivity to 
ionizing radiation, in vitro, in a new chromosomal breakage disorder, the Nijmegen 
Breakage Syndrome. Mut. Res.(1983) 112:23 -32 
Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot J, Mizuta R et al. Ku80: 
product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. 
Science (1994) 265:1442 -1445 
Taccioli GE, Amatucci AG, Beamish HJ, Gell D, Xiang XII, Torres Arzayus MI et 
al. Targeted disruption of the catalytic subunit of the DNA -PK gene in mice confers 
severe combined immunodeficiency and radiosensitivity. Immunity (1998) 9:355 -366 
184 
Takagi M, Delia D, Chessa L, Iwata S, Shigeta T, Kanke Y, et al. Defective control 
of apoptosis, radiosensitivity, and spindle checkpoint in ataxia telangiectasia. Cancer 
Res. (1998) 58:4923 -4929 
Takagi M, Tsuchida R, Oguchi K, Shigeta T, Nakada S, Shimizu K et al. 
Identification and characterization of polymorphic variations of the ataxia telangiectasia 
mutated (ATM) gene in childhood Hodgkin disease. Blood (2004) 103:283 -290 
Tambini CE, George AM, Rommens JM, Tsui LC, Scherer SW, Thacker J. The 
XRCC2 DNA repair gene: identification of a positional candidate. Genomics (1997) 
41:84 -92 
Taniguchi T, Garcia- Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST et al. 
Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 
(2002) 109:459 -72 
Taylor AMR, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S et al. 
Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 
(1975) 258:427 -429 
Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M et al. 
Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned 
cDNA of the XRCC3 DNA repair gene. Proc. Natl. Acad. Sci. USA (1995) 92:6354 -6358 
Telatar M, Wang Z, Udar N, Liang T, Bernatowska -Matuszkiewicz E, Lavin M et 
al. Ataxia -telangiectasia: mutations in ATM cDNA detected by protein- truncation 
screening. Am. J Hum. Genet. (1996) 59:40 -44 
Thacker J and Zdzienicka MZ. The mammalian XRCC genes: their roles in DNA 
repair and genetic stability. DNA Repair (Amst). (2003) 2:655 -72 
Thomas GM. Improved treatment for cervical cancer -- concurrent chemotherapy and 
radiotherapy. N. Engl. J. Med. (1999) 340:1198 -1200 
Thompson LH and Schild D. The contribution of homologous recombination in 
preserving genome integrity in mammalian cells. Biochimie (1999) 81:87 -105 
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY et 
al. A role for ATR in the DNA damage- induced phosphorylation of p53. Genes Del,. 
(1999) 13:152 -157 
Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ et al. 
Functional interactions between BRCA1 and the checkpoint kinase ATR during 
genotoxic stress. Genes Dev. (2000) 14:2989 -3002 
185 
Tobey RA, Oka MS, Crissman HA. Differential effects of two chemotherapeutic 
agents, streptozotocin and chlorozotocin, on the mammalian cell cycle. Eur. J. Cancer. 
(1975) 11:433 -441 
Tucker SL, Turesson I, Thames HD. Evidence for individual differences in the 
radiosensitivity of human skin. Eur. J. Cancer (1992) 28a:1783 -1791 
Tucker SL, Geara FB, Peters LJ, Brock WA. How much could the radiotherapy dose 
be altered for individual patients based on a predictive assay of normal- tissue 
radiosensitivity? Radiother. Oncol. (1996) 38:103 -113 
Turesson I, Nyman J, Holmberg E, Oden A. Prognostic factors for acute and late skin 
reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. (1996) 36:1065 -1075 
Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G et al. Mutation in Brca2 
stimulates error -prone homology- directed repair of DNA double- strand breaks occurring 
between repeated sequences. EMBO J. (2001) 20:4704 -4716 
Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H et al. 
p53 mutant mice that display early ageing- associated phenotypes. Nature (2002) 415:45- 
53 
Unger T, Juven- Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G et al. 
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO 
J. (1999) 18:1805 -1814 
Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of 
the MRN complex for ATM activation by DNA damage. EMBO J. (2003) 22:5612 -5621 
Vaganay -Juery S, Muller C, Marangoni E, Abdulkarim B, Deutsch E, Lambin P et 
ah Decreased DNA -PK activity in human cancer cells exhibiting hypersensitivity to 
low -dose irradiation. Br. J. Cancer (2000) 83:514 -518 
Van Gent DC, Hoeijmakers JHJ and Kanaar R. Chromosomal stability and the DNA 
double- stranded break connection. Nat. Rev. Genet. (2001) 2:196 -206 
Varon R, Vissinger C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K et al. 
Nibrin, a novel DNA double- strand break repair protein, is mutated in Nijmegen 
breakage syndrome. Cell (1998) 93:467 -476 
Verheij M, Ruiter GA, Zerp SF, van Blitterswijk WJ, Fuks Z, Haimovitz- Friedman 
A et ah The role of the stress -activated protein kinase (SAPK/JNK) signaling pathway in 
radiation -induced apoptosis. Radiother. Oncol. (1998) 47:225 -232 
186 
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature (2000) 408: 307- 
310 
Walker JR, Corpina RA, Goldberg J. Structure of the Ku heterodimer bound to DNA 
and its implications for double - strand break repair. (2001) Nature 412:607 -614 
Walters RA, Gurley LR, Tobey RA, Enger MD, Ratliff RL. Effects of X- irradiation 
on DNA precursor metabolism and deoxyribonucleoside triphosphate pools in Chinese 
hamster cells. Radiat. Res. (1974) 60:173 -201 
Wang H, Guan J, Wang H, Perrault AR, Wang Y and Iliakis G. Replication protein 
A2 phosphorylation after DNA damage by the coordinated action of ataxia 
telangiectasia- mutated and DNA -dependent protein kinase. Cancer Res. (2001a) 
61:8554 -8563 
Wang H, Zeng ZC, Perrault AR, Cheng X, Qin W, Iliakis G. Genetic evidence for 
the involvement of DNA ligase IV in the DNA -PK- dependent pathway of non - 
homologous end joining in mammalian cells. Nucleic Acids Res. (200 lb) 29:1653 -1660 
Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of 
BRCA1- associated proteins involved in the recognition and repair of aberrant DNA 
structures. Genes Dev. (2000) 14:927 -939 
Ward JF, Blakely WF, Joner EI. Mammalian cells are not killed by DNA single - 
strand breaks caused by hydroxyl radicals from hydrogen peroxide. Radiat Res. (1985) 
103:383 -92 
Ward JF. Biochemistry of DNA lesions. Radiat. Res. Suppl. (1985) 8:5103 -11 
Ward JF. Mechanisms of DNA repair and their potential modification for radiotherapy. 
Int. J. Radiat. Oncol. Biol. Phys. (1986) 12:1027 -1032 
Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, 
mechanisms of formation, and reparability. Prog. Nucleic Acid Res.Mol. Biol. (1988) 
35:95 -125 
Watters D, Khanna KK, Beamish H, Birrell G, Spring K, Kedar P et al. Cellular 
localisation of the ataxia -telangiectasia (ATM) gene product and discrimination between 
mutated and normal forms. Oncogene (1997) 14:1911 -1921 
Weemaes CM, Hustinx TW, Scheres JM, van Munster PJ, Bakkeren JA, Taalman 
RD. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta 
Paediatr. Scand. (1981) 70:557 -564 
187 
Weinert TA, Hartwell LH. The RAD9 gene controls the cell cycle response to DNA 
damage in Saccharomyces cerevisiae. Science (1988) 241:317 -322 
Weinert TA, Hartwell LH. Characterization of RAD9 of Saccharomyces cerevisiae and 
evidence that its function acts posttranslationally in cell cycle arrest after DNA damage. 
Mol. Cell Biol. (1990) 10:6554 -6564 
Weissberg JB, Huang DD, Swift M. Radiosensitivity of normal tissues in ataxia - 
telangiectasia heterozygotes. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:1133 -1136 
West CM, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic 
radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma 
of the cervix. Br. J. Cancer (1997) 76:1184 -1190 
West CML, Davidson SE, Elyan SAG, Valentine H, Roberts SA, R Swindell et al. 
Lymphocyte radiosensitvity is a significant prognostic factor for morbidity in carcinoma 
of the cervix. Int. J. Radiat. On col. Biol. Phys. (2001) 51:10 -15 
West SC. Molecular view of recombination proteins and their control. Nat. Rev. Mol. 
Cell Biol. (2003) 4:1 -11 
Wiler R, Leber R, Moore BB, VanDyk LF, Perryman LE, Meek K. Equine severe 
combined immunodeficiency: a defect in V(D)J recombination and DNA -dependent 
protein kinase activity. Proc. Natl. Acad. Sci. USA. (1995) 92:11485 -11489 
Wilson TE, Grawunder U, Lieber MR. Yeast DNA ligase IV mediates non - 
homologous DNA end joining. Nature (1997) 388:495 -498 
Wong AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with 
the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene 
BRCA2. J. Biol. Chem. (1997) 272:31941-31944 
Wood RD, Robins P, Lindahl T. Complementaion of the xeroderma pigmentosum 
DNA repair defect in cell -free extracts. Cell (1988) 53:97 -106 
Woods T, Wang W, Convery E, Errami A, Zdzienicka MZ, Meek K. A single amino 
acid substitution in DNA -PKcs explains the novel phenotype of the CHO mutant, XR- 
C2. Nucleic Acids Res. (2002) 30:5120 -5128 
Wu L, Davies SL, Levitt NC, Hickson ID. Potential role for the BLM helicase in 
recombinational repair via a conserved interaction with RAD51. J. Biol. Chem. (2001) 
276:19375 -19381 
188 
Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O'Neill TB et al. 
ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA 
damage response. Nature (2000) 405:477 -482 
Xiao Y, Weaver DT. Conditional gene targeted deletion by Cre recombinase 
demonstrates the requirement for the double- strand break repair Mrel l protein in murine 
embryonic stem cells. Nucleic Acids Res. (1997) 25:2985 -2991 
Yamaguchi -Iwai Y, Sonoda E, Buerstedde JM, Bezzubova O, Morrison C, Takata 
M et al.. Homologous recombination, but not DNA repair, is reduced in vertebrate cells 
deficient in RAD52. Mol Cell Biol. (1998) 18:6430 -6435 
Yaneva M, Kowalewski T, Lieber MR. Interaction of DNA -dependent protein kinase 
with DNA and with Ku: biochemical and atomic -force microscopy studies. EMBO J. 
(1997) 16:5098 -5112 
Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH et al. BRCA2 
function in DNA binding and recombination from a BRCA2 -DSS 1 -ssDNA structure. 
Science (2002) 297:1837 -1848 
Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, Qin J. SMC 1 is a downstream effector 
in the ATM/NBS1 branch of the human S -phase checkpoint. Genes Del). (2002) 16:571- 
582 
Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for 
ionizing radiation -induced assembly of Rad51 complex in vivo. Cancer Res. (1999) 
59:3547 -3551 
Yu Y, Wang W, Ding Q, Ye R, Chen D, Merkte D et al. DNA -PK phosphorylation 
sites in XRCC4 are not required for survival after radiation or for V(D)J recombination. 
DNA Repair (Amst). (2003) 2:1239 -1252 
Zdzienicka MZ and Simons JW. Mutagen- sensitive cell lines are obtained with a high 
frequency in V79 Chinese hamster cells. Mutat. Res. (1987) 178:235 -244 
Zdzienicka MZ. Mammalian mutants defective in the response to ionizing radiation - 
induced DNA damage. Mutat Res. (1995) 336:203 -213 
Zdzienicka MZ. Mammalian X- ray- sensitive mutants which are defective in non - 
homologous (illegitimate) DNA double- strand break repair. Biochimie (1999) 81:107- 
116 
Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K et al. DNA -dependent 
protein kinase activity correlates with Ku70 expression and radiation sensitivity in 
esophageal cancer cell lines. Clin. Cancer Res. (2000) 6:1073 -1078 
189 
Zhao S, Weng YC, Yuan SS, Lin YT, Hsu HC, Lin SC et al. Functional link between 
ataxia -telangiectasia and Nijmegen breakage syndrome gene products. Nature. (2000) 
405:473 -477 
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J et al. Association of BRCA 1 
with the hRad50 -hMrel l -p95 complex and the DNA damage response. Science (1999) 
285:747 -750 
Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen 
breakage syndrome gene NBS 1 leads to early embryonic lethality in mice. Curr. Biol. 




RTOG LATE RADIATION MORBIDITY SCORING SCHEMA* 
(www.rtog.org/members/toxicity/late.html) 

























None Slight atrophy 
Pigmentation 
change 
Some hair loss 


















































( <150 cc) 
Severe pain or 
tenderness 
Complete arrest 










































& ST changes 
Sinus 
tachycardia > 
110 (at rest) 













Normal heart size 
Persistent 
abnormal T wave 































*as applicable to breast and pelvic irradiation. 
Note: RTOG grade 5 morbidity is defined as death directly related to radiation late 
effects 
There is no RTOG grading for late morbidity of the vagina and in this site, grade 4 
morbidity was defined as vaginal vault necrosis. 
193 
 
Oncogene (2004) 23, 5562 -5566 
© 2004 Nature Publishing Group All rights reserved 0950 -9232/04 $30.00 
www.nature.com/onc 
Reduced DNA- dependent protein kinase activity in two cell lines derived 
from adult cancer patients with late radionecrosis 
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Epstein -Barr virus- immortalized lymphoblastoid cell lines 
were derived from five patients with late radionecrosis. 
Two of these cell lines exhibited postradiation viability 
levels intermediate between normal cell lines and that 
from an individual with ataxia telangiectasia. Compared 
with controls, these two cell lines exhibited impaired 
ability to rejoin DNA double- strand breaks on pulsed -field 
gel electrophoresis and 6-10 -fold reduced DNA -dependent 
protein kinase (DNA -PK) activity in vitro in cell -free 
extracts. Immunoblotting showed normal levels of Ku70, 
Ku80 and XRCC4 and the presence of DNA -PKcs in both 
cell lines. These findings suggest that DNA -PK might be 
an important factor affecting the predisposition of radio- 
therapy patients to late radionecrosis. 
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Keywords: DNA -dependent protein kinase; radiation 
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The cancerocidal effect of radiotherapy is dependent on 
delivered dose. This is limited by normal tissue 
tolerance. However, at radiation dose -schedules well 
tolerated by most individuals, some patients develop late 
radionecrosis. The factors accounting for these inter - 
individual differences are unknown (Safwat et al., 2002). 
Four human radiosensitivity syndromes are related to 
defective DNA repair: ataxia telangiectasia (AT) (Tay- 
lor et al., 1975), Nijmegen breakage syndrome (NBS) 
(Taalman et al., 1983), ataxia telangiectasia -like disease 
(ATLD) (Stewart et al., 1999) and DNA ligase IV 
deficiency (O'Driscoll et al., 2001). All are rare auto - 
somal recessive conditions. Affected individuals have 
often been children with severe, sometimes fatal, toxicity 
from conventional radiotherapy. 
Most patients with late radionecrosis are adults with 
no preradiation phenotype. They may be intrinsically 
more radiosensitive, but form a continuum with the 
`normal' population. Identifying these sensitive indivi- 
duals may allow a higher radiation dose to be delivered 
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to other patients, with improved chance of cure (Tucker 
et al., 1996). Studies of intrinsic radiosensitivity have 
shown a correlation with patient survival (West et al., 
1997; Bjork -Eriksson et al., 1998) and late tissue 
morbidity (West et al., 1998; Alsbeih et al., 2000). They 
have not identified the underlying biochemical mechan- 
isms. Two reports have suggested the importance of 
DNA repair proficiency. Herring et al. (1998) found a 
correlation between HAP1 expression and clonogenic 
survival after clinically relevant doses of radiotherapy. 
Alapetite et al. (1999) observed impaired strand -break 
rejoining in lymphocytes from six patients with RTOG 
grade 4 reactions. The control patients included 
individuals who had been irradiated several years 
previously, indicating the impaired rejoining was not 
consequent upon radiotherapy. 
Taken together, these studies suggest that DNA 
repair activity affects clinical radiosensitivity. The 
predominant ionizing radiation -induced lethal DNA 
lesion is the double- strand break (DSB) (Iliakis, 1991). 
Its major repair pathway is nonhomologous end - joining 
(NHEJ). To explore the role of DNA repair in adult 
cancer patients with late radionecrosis, we derived cell 
lines from five patients with RTOG grade 4 late 
radionecrosis. We hypothesized that patients developing 
radionecrosis due to impaired DNA repair might be 
cancer- prone, and selected patients under age 50 years. 
Patients with necrosis but not fibrosis were selected 
because a cell -death end point was thought to be more 
likely related to impaired DNA repair than a prolif- 
erative end point such as fibrosis. Local Research Ethics 
Committee approval was obtained and patients pro- 
vided written informed consent. 
Initially, we investigated the expression and activity of 
enzymes involved in NHEJ in the five cell lines. We 
report two cell lines that exhibit reduced post- radiation 
viability, impaired DSB rejoining and reduced DNA - 
dependent protein kinase (DNA -PK) activity in vitro. 
Cell line LB0003 was derived from a patient who 
presented with breast cancer at 40 years of age, treated 
by mastectomy and adjuvant radiotherapy. She devel- 
oped chest wall necrosis requiring reconstruction after 17 
years, contralateral primary breast cancer after 18 years 
and a presumed ipsilateral lung cancer 26 years later. 
Cell line LB0004 was derived from a patient with 
FIGO stage Ib squamous cell cervix carcinoma at 43 
years of age, treated with external beam and intracavi- 
Table 1 
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Clinical characteristics Origin Transformed at 
LB0001 Breast cancer patient, age 29 years; 
severe acute radiation reaction 
Edinburgh Cancer Centre ECACC, Salisbury, UK 
Macsi Patient with ocular abnormality; 
no cancer 
Professor Veronica van Heynigen, 
MRC HGU 
MRC Human Genetics Unit, Edinburgh, 
UK 
Wales Patient with ocular abnormality; 
no cancer 
Professor Veronica van Heynigen, 
MRC HGU 
MRC Human Genetics Unit. Edinburgh. 
UK 
BD 2630 Individual with AT ECACC, Salisbury, UK ECACC, Salisbury, UK 
tary radiotherapy. After 2 years, she developed vesi- 
covaginal and ileovesical fistulae. Both fistulae were 
managed surgically and she remains disease -free 10 
years later. Control cell lines used were all immortalized 
with Epstein -Barr virus (EBV) (Table 1). 
LB0003 and LB0004 exhibit moderately increased 
radiosensitivity 
To determine whether these patients were predisposed to 
radionecrosis by increased cellular radiosensitivity, we 
assayed postradiation viability in LB0003, LB0004, 
positive and negative control cell lines. We chose a 
viability assay because of the difficulty associated with 
colony- forming clonogenic survival assays with lympho- 
blastoid cells in suspension. The number of proliferating 
cells after 0, 0.5, 1.0 and 2.0 Gy was determined for the 
cell lines LB0003 and LB0004, derived from patients 
with late radionecrosis, and for LB0001, Macsi, Wales 
and BD 2630. The postradiation viability curves for 
LB0003 and LB0004 were intermediate between those of 
the normal controls and the acute over -reactor 
(LB0001), and the AT cell line (Figure 1). After 2 Gy, 
the proportion of cells remaining viable was 38.1% for 
Wales, 38.2% for Macsi, 35.1% for LB0001, 21.0% for 
LB0003, 19.9% for LB0004 and 8.6% for BD2630. 
Postradiation DSB repair is reduced in LB0003 and 
LB0004 
To ascertain whether this reduced postradiation viability 
was due to impaired DNA repair, we investigated the 
induction and rejoining of DNA DSBs using PFGE. 
Unsynchronized cell cultures were used. Initial DSB 
induction by 30 Gy ionizing radiation was similar in 
LB0001, LB0003, LB0004 and Macsi (data not shown). 
Significantly fewer DSBs were repaired by LB0003 and 
LB0004 than by Macsi and LB0001 (Figure 2). Almost 
half (42.9% for LB0001 and 43.7% for Macsi) of DSB 
observed at 0 min were repaired in 30 min by the control 
cell lines, whereas only 8.6 and 5.4% were repaired by 
LB0003 and LB0004. In general, DSB rejoining was 
complete by 4 h, with normal controls restituting 72- 
81 % of damage and the LB0003 and LB0004 only 35- 
53%. Even after 24h, this difference persisted. This 
suggests that the two cell lines from individuals with late 
radionecrosis exhibit impaired DSB repair. The reduc- 
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Figure 1 Postradiation viability of cell lines. Data are shown for 
cell lines Macsi (_.._) Wales (_.._) LB0001 ( - - -) LB0003 
(....) and LB0004 (_._) and BD2630 () from an individual 
with AT. EBV -immortalized lymphoblastoid cells were established 
by standard techniques (Godsen et al., 1986). Control lympho- 
blastoid cell lines ( Macsi and Wales) from individuals with 
abnormal ocular development, but no history of cancer. were 
donated by Professor Veronica van Heyningen. BD 2630 was 
obtained from the European Collection of Cell Cultures (Salisbury. 
UK). Cells were grown in RPMI 1640 medium (Gibco BRL) with 
10% FCS, 2 mm L- glutamine, penicillin and streptomycin. Ex- 
ponentially growing cells were irradiated at 20 °C with a 6 MV 
linear accelerator at 3.2Gy /min. Cells were plated in triplicate at 
densities of 5 x 10' -5 x 10' cells /ml and incubated at 37 -C. A 
colorimetric proliferation assay using a compound (3-(4,5 - 
dimethylthiazol-2-yl)-5-(3- carboxymethoxypheny l) -2 -(4- sulfophe- 
nyl)- 2H- tetrazolium, inner salt; MTS) reduced by metabolically 
active cells was used to determine viable cells (Promega Cell Titer 
96 System). Similar assays have been shown to correlate well with 
clonogenic assays in estimating radiosensitivity (Price and McMil- 
lan, 1990). On days 1, 2, 3, 4 and 5 postirradiation, 2011 MTS was 
added to each well and incubated for 4h. Optical density (OD) 
measurements were made at 450 nm, and triplicate data averaged 
after correction for background absorbance. Surviving fractions 
were estimated by dividing the mean OD of the irradiated sample 
wells by that of the nonirradiated sample wells from the day 5 assay 
results, at which time cell lines had returned to exponential growth 
following radiation -induced cell cycle delay, and before contact 
inhibition of cell growth within the wells develops. However. 
unirradiated cells had often ceased exponential growth by day 4. 
and control data were extrapolated to day 5 to allow calculation of 
the surviving fraction. This approach has been necessary when 
using the MTT proliferation assay (Price and McMillan, 1990) 
2.0 
tion in DSB repaired by the fast kinetic pathway is in 
keeping with previous studies of DSB -rejoining kinetics 
in DNA -PKcs- deficient cell lines (Allalunis- Turner et al., 
1995b; DiBiase et al., 2000). 
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Figure 2 Kinetics of repair of DNA damage measured by PFGE 
assay. Unsynchronized cells from cell lines Macsi ( -O -), LB0001 
( L ), LB0003 ( -V -) and LB0004 ( -D) were counted, aliquoted 
(4 x IO') and irradiated on ice with 30 Gy using a caesium source 
(Gammacell 40 Exactor) at I.06Gy /min. Following irradiation, 
cells were incubated with fresh RPMI in 5% CO, at 37'C. 
Unirradiated cells and cells at each time point were harvested and 
washed. Each pellet was immediately resuspended in 0.5% Sea 
Plaque low melting temperature agarose at 38'C. The mixture was 
pipetted into prewarmed 75Eá plug moulds (Bio -Rad) and allowed 
to set at 4'C. Cell plugs were transferred to 50 ml tubes containing 
three volumes of ice cold digestion cocktail (1% N- Iauroylsarcosine 
(Sigma), 0.1 mg /ml Proteinase K (Sigma), 0.1 M EDTA, 0.01 M 
"iris -HCI, 0.02 M NaCI) and incubated for 1 h at 4`C, 2 h at 50 C 
and in two volumes of the digestion cocktail containing 0.1 mg /m1 
Proteinase K for 18 h at 50''C. Plugs were washed at room 
temperature in 50 volumes of Tris -EDTA (pH 7.6) with five 
changes of buffer over 3 h, in two volumes of Tris -EDTA (pH 7.6) 
containing 40µg /m1 phenylmethylsulphonylfluoride for 30 min at 
50"C, and in 50 volumes of Tris -EDTA (pH 7.6) with three changes 
of buffer and stored in the same solution at 4 °C. Cell plugs were cut 
into 25 µl samples and loaded into the wells of a 0.7% agarose 
(Seakem Gold agarose, BMA) gel prepared in 0.5 x TBE (45 mM 
Tris, I mM EDTA, 45 mM boric acid, pH 8.5). A reference 
Sacchcavrnmces cerevisiae chromosome molecular weight marker 
was added to each gel. The wells were sealed with 0.7% LMP 
agarose. The PFGE unit (Bio -Rad CHEF -DRII) was filled with 21 
of 0.5 x TBE. The sample (at I O'C) was run at 45 V (1.7 V /cm) with 
a pulse time of 75 min for 40 h, followed by 100 V, 30 min pulse 
time, for 2 h. Following electrophoresis, the gel was dried, rinsed 
with double distilled water and placed in 150 ml SYBR Green I 
(BMA) (I : 10000) in 0.5 TBE pH 8.0 at 50'C for 3 h, cooled for 
10 min on ice and analysed using a SynGene Gel Documentation 
System with a Syb -100 SYBR grrcn filter. Gel images were 
analysed using the Gene Tt,o!F. c'ftware (SynGene). The residual 
damage fraction was calculet_,i as the ratio of the intensity of the 
material entering the gel lane to the total intensity of plug plus this 
material. All data were corrected by subtraction of the nonspecific 
migration detected in unirradiated control samples. The DSB 
remaining at a given time of postirradiation cell incubation was 
normalized to the incidence of DSB at time zero set at 100 %. Three 
independent experiments were carried out for each cell line with 
two replicates per experiment 
DNA -PK crctivitt' is reduced in cell -flee extracts from 
LB0003 and LB0004 
The DNA -PK complex plays a key role in NHEJ. We 
hypothesized that DNA -PK kinase activity might be one 
of the determining factors in DSB repair, and a 
surrogate for the major repair activity in these experi- 
ments, where the majority of cells were in GI or early 
S phase. We assayed DNA -PK activity in the cell lines 
LB0003 and LB0004 from patients with late morbidity, 
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Figure 3 DNA -PK activity in cell lines. Exponentially growing 
cells from the cell lines Macsi, Wales, LB0001, LB0003 and LB0004 
were harvested, and whole -cell extracts prepared (Manley et at., 
1983). Briefly, 0.8 -1 I of cells at a density of 0.5 -1.0 x 106 cells /ml 
were pelleted and washed. The pellet was resuspended in four 
packed cell volumes (PCV) hypotonie lysis buffer (10 mM Tris -HCI 
pH 8, 1 mM EDTA, 5 mM DTT and protease inhibitors) and left on 
ice for 20 min. The cells were disrupted in a Dounce homogenizer, 
and an additional 4 PCV 50 mM Tris -HCI pH8, 10 mM MgCl2, 
2mM DTT, 25% sucrose and 50% glycerol added, followed by one 
PCV ammonium sulphate. After 30 min, the extract was centri- 
fuged at 38 000 r.p.m. for 3 h at 4 °C. The supernatant was removed, 
and 0.33 g /ml ammonium sulphate added. The extract was 
centrifuged at 10000g for 30 min, and the precipitate recovered 
and resuspended in buffer containing 25 mM HEPES pH 7.9, 
100 mM KCI, 12 mM MgCl,, 1 mM EDTA and 17% glycerol. This 
was dialysed against two changes of the same buffer for 6 h, 
centrifuged at 10 000g for 10 min, and the supernatant snap frozen 
and stored at -70-C. DNA -PK activity was assayed by measuring 
the phosphorylation of a biotinylated p53- derived peptide substrate 
(Promega SignaTECT DNA -Dependent Protein Kinase (DNA - 
PK) Assay System) by cell extracts in the presence or absence of 
calf -thymus DNA. Incorporation of ÿ- [''-P] into the peptide was 
analysed with a phosphorimager (confirmed by scintillation 
counting) and DNA -PK activity calculated with a correction for 
background kinase activity. Results were based on at least three 
experiments using extracts prepared on at least two separate 
occasions 
LB0001 from an acute over -reactor, and Macsi and 
Wales from individuals without cancer. To assay DNA - 
PK activity, DNA containing termini and all three 
complex subunits are required. Phosphorylation of a 
DNA -PK peptide substrate was measured in the 
presence of calf thymus DNA and corrected for back- 
ground phosphorylation (in the absence of calf thymus 
DNA) by nonspecific kinases. We observed a 6-10 -fold 
reduction in DNA -PK activity in the cell lines LB0003 
and LB0004 compared to LB0001, Macsi and Wales 
(P<0.0001 for LB0003 and LB0004 vs Macsi; 
P <0.0005 for LB0003 and LB0004 vs Wales; and 
P <0.002 for LB0003 and LB0004 vs LB0001) (Figure 3). 
To confirm that other DNA damage and signalling 
pathways, including ATM which may also be stimulated 
by DNA strand breaks were intact (and hence the 
reduction in protein kinase activity in the presence of 
DNA ends was due to reduced DNA -PK activity), we 
measured the levels of p53 after 4 Gy ionizing radiation 
to confirm that normal upregulation of the protein 
occurred after radiation of these cell lines. This was 
normal in all cell lines tested, indicating normal ATM 
activity in these cell lines (data not shown). 
A correlation between DSB rejoining, radiosensitivity 
and DNA -PK activity has been reported in lung cancer 
(Sirzen et al., 1999) and squamous cell cancer cell lines 
(Polischouk et al,, 1999), and between radiosensitivity 
and DNA -PK activity in oesophageal cancer cell lines 
(Zhao et al., 2000). In contrast, one group reported no 
correlation between DNA -PK activity and radiosensi- 
tivity in glioma cell lines (Allalunis- Turner et al., 1995a). 
This may indicate that other factors have more effect on 
radiosensitivity in gliomas, which are highly radio - 
resistant. 
The reduced DNA -PK activity we observed in EBV- 
immortalized cell lines does not seem to be an artefact of 
transformation or of previous radiotherapy. Normal 
levels of activity were seen in all the control EBV- 
transformed cell lines, one of which (LB0001) was 
derived from a patient who had received radiotherapy 
over 2 years previously. This strongly suggests that the 
association of reduced DNA -PK activity with reduced 
postradiation viability in these cell lines is a reflection of 
an underlying DNA repair deficiency in vivo, and may 
have contributed to the injury in these patients. Another 
group has used EBV- transformed cells to investigate 
radiosensitivity, and has also shown an association 
between increased cellular radiosensitivity and the risk 
of late injury (Alapetite et al., 1999). 
All DNA -PK subunits are present in cell free extracts 
from LB0003 and LB0004 
The residual DNA -PK activity observed in the cell lines 
LB0003 and LB0004 suggested that these cell lines were 
unlikely to be totally deficient in DNA -PKcs, Ku70 or 
Ku80. To confirm this, we performed immunoblots 
against these proteins in the cell lines with reduced 
DNA -PK activity, LB0003 and LB0004, and controls 
(LB0001, Macsi and Wales). We could not detect a 
significant difference in the level of Ku 80 and 70 
proteins among any of the cell lines (Figure 4a and b). 
DNA -PKcs was present in both the cell lines with 
reduced activity and the control cell lines (Figure 4c). 
Conclusion 
No humans with a DNA -PKcs or Ku null phenotype 
have been described. While the two cell lines described 
here exhibit substantially reduced DNA -PK activity, 
both have some residual function and express all three 
protein components of DNA -PK. It is possible that this 
reduced level of activity is sufficient for function under 
normal conditions, but insufficient to deal with the 
extent of DNA repair required following radiotherapy. 
Mutations described in transgenic mice and cell lines 
have shown protein truncations in one of the DNA -PK 
components, impaired protein -to- protein interactions 
between the DNA -PK subunits and reduced kinase 
activity. Our data exclude the former possibility, since 
we have observed normal size product of all three 
proteins in immunoblots. However, we cannot, on the 
current evidence, exclude mutations within the genes 
DNA -PK activity and radiation injury 
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Figure 4 (a -c) Immunoblot of subunits of DNA -PK in indicated 
cell lines. Exponentially growing cells from cell lines Macsi. Wales, 
LB0001, LB0003 and LB0004, were lysed in 50mM Tris pH 7.5, 
I mm EDTA, 10mM DTT, 0.2% Triton X -100 and a protease 
inhibitor cocktail (Sigma). Aliquots (20µl) of each sample contain- 
ing equivalent amounts of protein were separated by SDS -PAGE. 
Following transfer to nitrocellulose membrane ( Amersham), 
Ponceau's staining was used to confirm protein loading and 
transfer. After blocking with 5% milk, the membranes were probed 
with (a) anti -Ku80 (Serotec AHP318), (h) anti -Ku 70 (Serotec 
AHP316) and (c) anti -DNA -PKcs (Ab -2, Neomarkers, raised 
against the N- terminus of the protein). Detection was performed 
using ECL ( Amersham). The immunoblots were performed at least 
twice using separate extracts in each case. The marker was from 
Amersham (RPN 800) 
encoding one of the three DNA -PK subunits, affecting 
either protein- protein interactions, DNA -binding or the 
kinase activity itself, or in genes encoding other 
unidentified proteins, which interact with or post - 
translationally modify one of the subunits of DNA - 
PK. One cell line in the XRCC7 complementation group 
(XR -C2) has been described with normal levels of DNA - 
PKcs, but no detectable kinase activity. This cell line 
exhibited significantly increased radiosensitivity and 
impaired DSB repair. Sequence analysis of the PRKDC 
gene in XR -C2 demonstrated a point mutation produ- 
cing a single amino -acid substitution six residues from 
the C- terminus of the DNA -PKcs protein (Woods et al., 
2002), but sequencing of the cell lines reported here has 
not shown a similar mutation. 
This is the first report of a biochemical abnormality in 
cell lines derived from patients with late radionecrosis at 
conventional doses; that this occurs in two of the five 
patients investigated in a pathway so central to recovery 
from radiation damage in human cells raises the 
possibility that mild deficiencies in the dominant path- 
way of DSB repair, perhaps related to single nucleotide 
Oncogene 
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polymorphisms in the DNA -PK genes, might be a 
common cause of late radionecrosis. 
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